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Endometrial carcinoma
Endometrial carcinoma is the most common gynecological malignancy in the western 
world, and with a current incidence of 16/100.000 in the Netherlands it affects around 
2000 women each year, most of them postmenopausal.1, 2 Known risk factors for developing 
an endometrial carcinoma are exo- and endogenous estrogen exposure, diabetes, early 
menarche, nulliparity, late menopause, old age and tamoxifen use.3-8 The incidence of 
endometrial carcinomas is increasing, predominantly as a result of increases in both life 
expectancy and the prevalence of a high Body Mass Index.7, 9 As a result, the prevalence of 
endometrial carcinomas in the United States  is already as high as 24/100.000.10 Endometrial 
carcinomas are traditionally divided into endometrioid and non-endometrioid carcinomas, 
based on histology.11 Endometrioid carcinomas are assumed to arise from hyperplastic 
endometrium under the influence of unopposed estrogen stimulation, and generally have a 
favorable prognosis. Non-endometrioid carcinomas on the other hand, which have serous 
or clear cell histology, are assumed to arise from atrophic endometrium, and have a worse 
outcome.11 The majority of the endometrial carcinomas has endometrioid histology, and 
presents at an early stage with postmenopausal blood loss.2, 12 Overall, the prognosis of 
endometrial carcinomas is therefore favorable, yet annually around 500 women still die of 
this disease in the Netherlands.1
When endometrial pathology is suspected, the endometrium is visualized using a transvaginal 
ultrasound, and a subsequent endometrial biopsy is advised when the endometrium is 
measured to be ≥ 4mm thick.2, 12-15 The primary treatment is based on the clinical stage, 
the histological type, and the tumor grade, and is most often surgical.2, 12, 16 In patients with 
a clinical stage I, low or intermediate grade endometrioid carcinoma a hysterectomy and 
a bilateral salpingo-oophorectomy are recommended.16 Studies have shown that in these 
patients there is no benefit from a routine systematic lymphadenectomy.17-19 In contrast, 
because high grade endometrioid, and non-endometrioid carcinomas have a substantial risk 
of lymph node metastasis, surgical staging is indicated for these carcinomas.2, 20-25 Based on 
the FIGO stage (Table 1), the presence of non-endometrioid or high grade endometrioid 
histology, the depth of myometrial invasion, the presence of lymphovascular space invasion, 
and the age of the patient adjuvant radiotherapy to prevent a locoregional recurrence is 
recommended in the Netherlands.2, 11, 16, 24-35 
Vaginal brachytherapy is preferred for low and low-intermediate risk endometrial 
carcinomas, whereas external beam radiotherapy is required for high-intermediate and high 
risk carcinomas.26-28 Although some studies have shown that chemotherapy might reduce 
the risk of distant spread in selected cases, there is no international consensus about the 
use of chemotherapy yet.36 FIGO stage IV disease is rare, and management of these cases is 
not yet standardized.2, 16
Endometrial carcinoma types 
Endometrioid and non-endometrioid carcinomas were shown to be different on 
immunohistochemical and genetic levels.11, 37-49 Endometrioid carcinomas are characterized 
by expression of the estrogen receptor (ER) and progesterone receptor (PR), microsatellite 
instability, and PTEN, KRAS, PIK3CA, and CTNNB1 mutations.37-46 In contrast, non-
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endometrioid carcinomas are characterized by TP53 mutati ons, reduced E-cadherin 
expression, and ERBB2 amplifi cati ons.45, 47-49
However, there is a growing evidence that the traditi onal dualisti c model is too rigid.50, 51 On 
a histological level, classifi cati on of endometrial carcinomas in one of the two subgroups 
can be challenging, as some present with a mix of endometrioid and non-endometrioid 
histology, and a mixed molecular profi le.52, 53 Additi onally, based on the current concept of 
endometrial carcinogenesis, the endometrium next to endometrioid carcinomas is expected 
to be hyperplasti c. Interesti ngly, in a recent study atrophic endometrium was found next 
to 20% of the endometrioid carcinomas.54 These carcinomas were shown to have a worse 
prognosis than endometrioid carcinomas with adjacent hyperplasti c endometrium, and 
might represent a third type, but the molecular profi le of these carcinomas has not yet 
been studied. 
More recently, studies have shown that geneti c profi ling can be used to identi fy non-
endometrioid carcinomas which were misdiagnosed as endometrioid carcinomas, and to 
identi fy aggressive endometrioid carcinomas wrongly identi fi ed as low risk endometrioid 
carcinomas.55, 56 One study has classifi ed endometrial carcinomas purely based on their 
genomic profi les, and identi fi ed four subgroups: a hypermutated and an ultramuted group, 
and a copy-number low and a copy-number high group.57 The ultramutated and copy-
number low groups contained mainly endometrioid carcinomas, the copy-number high 
group contained non-endometrioid and high grade endometrioid carcinomas, and the 
hypermutated group contained high grade endometrioid carcinomas as well.
Currently, litt le is known about the combined value of histological and molecular markers 
in improving the classifi cati on of endometrial carcinomas. Development of an endometrial 
carcinoma classifi cati on model which includes both histological and molecular characteristi cs 
of the carcinoma could improve endometrial carcinoma management in daily clinical 
practi ce.50, 51, 58, 59
Carcinogenesis of endometrial carcinomas
Based on histological and molecular diff erences between the two types, endometrioid 
and non-endometrioid carcinomas are assumed to follow diff erent carcinogenic pathways. 
Endometrioid carcinomas are assumed to arise from hyperplasti c endometrium. Normal 
postmenopausal endometrium is supposed to be inacti ve and atrophic, but can become 
hyperplasti c under the infl uence of unopposed estrogen sti mulati on.60, 61 Hyperplasia can 
have either a simple or a complex architecture, and is considered to be atypical if nuclear 
enlargement with dispersed or clumped chromati n is present.62 Studies have shown that 
there is a substanti al risk of either a coexistent endometrial carcinoma or progression to an 
invasive carcinoma if endometrial hyperplasia with nuclear atypia is present.62-65 
Figure 1. The molecular regulators of endometrial carcinogenesis
Table 1. The Internati onal Federati on for Gynecology and Obstetrics (FIGO) classifi cati on of 
endometrial carcinomas
Stage Disease spread
IA Confi ned to corpus uteri, <50% myometrial invasion
IB Confi ned to corpus uteri, ≥50% myometrial invasion
II Confi ned to uterus, cervical stroma invasion
IIIA Involvement of the serosa and/or adnexa
IIIB Involvement of the parametrial ti ssue and/or vagina
IIIC1 Involvement of the pelvic nodes
IIIC2 Involvement of the para-aorti c nodes (with or without the pelvic nodes)
IVA Invasion of the bladder and/or bowel mucosa
IVB Distant metastases
RAS
RAF
MEK
ERK
PI3K
mTOR
AKT
PTEN
MDM2
p53
β-catenin
E-cadherinRTK
p16
p21
ER
estrogen
Proliferation
Cell cycle arrest
Angiogenesis
Invasion Apoptosis
114    
CHAPTER 1   Introduction and thesis outline
 15
On a molecular level, endometrioid carcinogenesis is assumed to be driven predominantly 
by the PI3K/Akt, MAPK/ERK and Wnt pathways, which have been summarized in Figure 1.66 
Mutations of the PTEN gene, a negative regulator of the PI3K/Akt pathway, and activation 
of the Wnt pathway, associated with unopposed estrogen stimulation and loss of PR, are 
believed to be early events, already present in atypical hyperplasia, whereas KRAS and PIK3CA 
mutations play a role in malignant transformation of endometrial hyperplasia.39, 40, 67-73 The 
carcinogenesis of non-endometrioid carcinomas is believed to be independent of estrogen 
stimulation and these carcinomas are assumed to originate from atrophic endometrium 
under the influence of TP53 mutations, loss of E-cadherin, and ERBB2 amplification, 
although a minority might in fact be dedifferentiated endometrioid carcinomas.45, 47-49, 52 In 
addition, it has not been clarified yet whether the components of endometrial carcinomas 
with mixed histology and mixed molecular profiles follow separate carcinogenic pathways, 
or whether one component originates from the other component.52, 53
Our knowledge about the carcinogenesis is based on the traditional dualistic model and 
the molecular differences between the two subtypes, and is therefore challenged by 
recent studies showing that there are probably more subtypes.52-57, 74 Unfortunately, these 
studies only analyzed endometrial hyperplasia, and it is unknown whether these additional 
subgroups follow different carcinogenic pathways.55-57 It is also uncertain whether atypical 
hyperplasia is the true premalignancy of endometrioid carcinomas, as studies analyzing the 
risk of a coexistent endometrial carcinoma or progression to an invasive carcinoma show 
confecting results.63-65, 75 Moreover, the prevalence of atypical hyperplasia was recently 
shown to be higher than expected, which implies that the risk of a coexistent carcinoma or 
progression is lower than currently assumed.76 
Molecular analysis of benign, assumed premalignant, and malignant endometrium, as 
well as endometrium next to endometrial carcinomas would help us further understand 
endometrial carcinogenesis. 
Progression of endometrial carcinomas
Although most endometrial carcinomas have a favorable prognosis, a minority presents 
either in an advanced stage or with recurrent disease.2, 12 These carcinomas cause the 
majority of the disease related mortality, and it is therefore essential to identify them as soon 
as possible.29, 30, 51, 77 Endometrial carcinoma can spread hematogenous, lymphogenous, and 
intra-abdominal, and the symptoms can vary, depending on the location of the metastases.78 
In ovarian carcinomas, different molecular profiles have been associated with the type 
of spread, but so far this has not been studied in endometrial carcinomas.79 It has been 
shown that abdominopelvic metastases generally have the same genetic profiles as the 
primary tumor.80 This would suggest that it could indeed be possible to identify molecular 
markers which predict the presence of metastases. However, a specific mutation as a cause 
of endometrial carcinoma metastasis was not identified, and it has been suggested that 
either a great diversity of genetic events, or a combination of intergenetic, epigenetic, and 
environmental effects contribute to the metastatic process.80
Endothelial-mesenchymal transition (EMT) is assumed to play a pivotal role in endometrial 
carcinoma progression and metastatis.66, 81, 82 During EMT, the carcinoma cells lose basal 
apical polarity and become spindle shaped instead, with weakening of cell-cell junctions; 
as a result the cells become more mobile and have an increased infiltrative capacity.66 On a 
molecular level, the cells show decreased expression of ER, PR, and loss of epithelial markers 
like E-cadherin, and increased expression of mesenchymal markers and β-catenin.66, 81, 82 The 
PI3K/Akt, MAPK/ERK, and Wnt pathways, which play a role in endometrial carcinogenesis, 
are involved in EMT as well.66 Transforming growth factor beta (TGF-β) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) signaling play a role in EMT.66 The 
process is mainly controlled by the transcription factors TWIST, and members of the SNAIL, 
SLUG, and ZEB1 protein families.66 
However, knowledge about the molecular characteristics of endometrial carcinoma 
progression have not yet led to markers which can be used to identify endometrial 
carcinomas that are prone to metastasize, and to predict the pattern of spread.83, 84 Studies 
that compared the molecular profiles of primary carcinomas and recurrences reported 
differences in the expression of ER, PR, stathmin and p-mTOR, and a relationship between 
loss of ER and PR, and the presence of lymph node metastases has also been described.85-87 
Additional research is needed to improve the identification of endometrial carcinoma 
progression.
Prognostic markers
At the moment, most prognostic models include the tumor histology, differentiation grade, 
percentage of myometrial invasion, presence of lymphovascular space invasion, and the age 
of the patient.2 However, a substantial number of the carcinomas which are considered to 
be low risk will recur, whereas a substantial number of the carcinomas which are considered 
high risk will not.16, 50 To improve prognostic models we need to reevaluate existing markers, 
discover and validate new molecular markers, and study the combined value of existing and 
new markers. 
Several improvements to the currently used histological markers have already been 
proposed. In the currently used guidelines, lymphovascular space invasion plays a role 
in advising adjuvant radiotherapy to prevent locoregional recurrences, whereas it has 
shown to a strong marker of distant spread.16, 88-91 Moreover, several alternatives to the 
currently used method of measuring myometrial invasion have been described.92-98 Further 
studies on the prognostic value and therapeutic consequences of myometrial invasion 
and lymphovascular space invasion could improve the individualization of endometrial 
carcinoma management.16, 99
In addition to histological risk factors, several immunohistochemical and genetic markers 
have been described. The most extensively studied markers of poor prognosis are 
immunohistochemical loss of ER and PR, which was associated with lymph node metastases 
and disease recurrences.85-87 Especially loss of PR, a strong tumor suppressor, seems to be a 
valuable prognostic marker.100 More recently the L1 cell adhesion molecule (L1CAM) might 
be a strong prognostic marker in endometrial carcinomas as well.59, 101-104 Other promising 
immunohistochemical markers of poor prognosis are increased expression of p53, MIB1, 
β-catenin, p21, p16, and stathmin, and reduced expression of E-cadherin.24, 45, 105-114 
Studies focusing on the prognostic value of genetic markers found that activity of the PI3K/Akt 
pathway predicted aggressive behavior in low risk cases, and that genetic profiles could be 
used to identify non-endometrioid carcinomas which were falsely classified as endometrioid 
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carcinomas.55, 56 Based on the genetic profiles, The Cancer Genome Atlas Research network 
described four distinct genetic subgroups, which had a different prognosis as well.57 
However, the value of these new markers in addition to the currently used prognostic 
models is not well known, and as a result these markers are currently only used to support 
the histological diagnosis.58, 59, 115, 116 Further analysis of the combined value of molecular and 
histological markers is necessary before these new findings can be translated to daily clinical 
practice.
Aims of the thesis
Currently, the management of endometrial carcinomas is completely based on histological 
identification of high risk carcinomas. There is a growing amount of evidence that this is too 
rigid, and as a result, a substantial number of assumed low risk carcinomas will recur, and of 
the assumed high risk cases will not.16, 50
In order to improve endometrial carcinoma survival the identification of high risk carcinomas 
should be improved, both by improving prognostic markers already in use, and by integrating 
new molecular markers in the prognostic models. These new markers can be identified by 
studying the molecular characteristics of the carcinogenesis and progression of endometrial 
carcinomas. Subsequently, the value of these markers in a prognostic model, and their 
relation to other prognostic markers, should be tested and validated in large clinical cohorts, 
to translate these findings to daily clinical practice. The aims of this thesis therefore were 
to study:
-The molecular characteristics of endometrial carcinoma carcinogenesis and progression
-The value of and improvements to the currently used markers
-The prognostic value of molecular markers in the management of endometrial 
carcinomas
Outline of the thesis
In Chapter 2, the immunohistochemical and genetic profiles of endometrioid carcinomas 
next to atrophic endometrium , endometrioid carcinomas next to hyperplastic endometrium, 
and non-endometrioid carcinomas are analyzed. 
In Chapter 3, the genetic characteristics of complex and simple hyperplasia with and without 
atypia, endometrioid carcinomas with adjacent hyperplastic or atrophic endometrium, the 
adjacent endometrium itself, and non-endometrioid carcinomas.
In Chapter 4, the immunohistochemical profiles of endometrial carcinomas without metastases, 
with intra-abdominal, and with distant metastases, as well as the corresponding metastases are 
analyzed.
In  Chapter 5, the disease outcome of early stage endometrioid carcinomas with lymphovascular 
space invasion is analyzed.
In Chapter 6, the interobserver variability of measuring myometrial invasion using three 
different methods is analyzed. 
In Chapter 7, the prognostic value of L1CAM expression in a large cohort of endometrial 
carcinomas from the European Network for Individualized Treatment of Endometrial Cancer 
is analyzed.
In Chapter 8, the combined prognostic value of loss of the estrogen and progesterone 
receptors, and expression of L1CAM is analyzed.
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Abstract
Background
Endometrial carcinomas are divided into type I endometrioid endometrial carcinomas 
(EECs), thought to arise from hyperplastic endometrium, and type II nonendometrioid 
endometrial carcinomas, thought to arise from atrophic endometrium. However, a minority 
(20%) of EECs have atrophic background endometrium, which was shown to be a marker of 
a worse prognosis. This study compares the immunohistochemical and genetic profiles of 
this possible third type to that of the known two types.
Materials and Methods
43 patients with grade 1 EEC and hyperplastic background endometrium (type I), 43 patients 
with grade 1 EEC and atrophic background endometrium (type III) and 21 patients with 
serous carcinoma (type II) were included (n=107). Tissue microarrays of tumor samples were 
immunohistochemically stained for PTEN, L1CAM, ER, PR, p53, MLH1, PMS2, β-catenin, 
E-cadherin and MIB1. The BRAF, KRAS, and PIK3CA genes were analyzed for mutations.
Results
A significantly higher expression of ER and PR, and a lower expression of L1CAM, p53 and 
MLH1 were found in type I and III compared to type II carcinomas. Expression of E-cadherin 
was significantly reduced in type III compared to type I carcinomas. Mutation analysis 
showed significantly less mutations of KRAS in type III compared to type I and II carcinomas 
(p<0.01).
Conclusion
There appear to be slight immunohistochemical and genetic differences between EEC with 
hyperplastic and atrophic background endometrium. Carcinogenesis of EEC in atrophic 
endometrium seems to be characterized by loss of E-cadherin and a lack of KRAS mutations. 
As expected, endometrioid and serous carcinomas were immunohistoschemically different. 
Introduction
Cancer of the uterine corpus is the most common gynecologic malignancy among women 
in the developed world. In 2012, it affected 47,130 women and caused the death of 8,010 
women in the US.1
It is generally accepted that endometrial carcinomas (ECs) can be divided into two 
subtypes.2 Type I endometrial carcinoma is the most common subtype. It affects women 
at a median age of 60 years and has a good prognosis. These tumors are usually related to 
unopposed estrogen stimulation and show endometrioid histology, arising from hyperplastic 
endometrium. In contrast, the less common type II carcinomas affect older women and 
have a poor prognosis. These tumors are not related to unopposed estrogen stimulation 
and are characterized by clear cell or serous histology, arising from atrophic endometrium.3-5 
Distinct carcinogenic pathways have been described in each subtype. Type I carcinomas are 
characterized by microsatellite instability and alterations of the PTEN, KRAS, PIK3CA and 
CTNNB1 genes, whereas type II carcinomas are often aneuploid and show over expression 
of p53 and Her2/neu.6-9 
However, some tumors do not fit within this dualistic model. In a recent study we reviewed 
slides from 527 patients with grade 1 endometrioid endometrial carcinomas and found 
that 17% of these carcinomas had atrophic background endometrium.10 Furthermore, 
the presence of atrophic background endometrium adjacent to endometrioid carcinomas 
was associated with several predictors of poor survival, and an independent predictor of 
reduced progression free survival in endometrioid endometrial carcinomas. Moreover, 
recent studies looking at the molecular basis of endometrial carcinomas also show that this 
dualistic model is too simplistic and propose to categorize them based on their molecular 
profile.11-13 These studies show that within the two groups as defined by the dualistic model, 
it is able to distinguish certain groups solely based on their molecular pattern. It might be 
possible that endometrioid endometrial carcinomas with atrophic background endometrium 
have a different molecular and therefore immunohistochemical pattern when compared to 
endometrioid endometrial carcinomas with hyperplastic background endometrium.
The aim of the present study was to analyze the hypothesis that endometrioid endometrial 
carcinomas with a background of atrophic endometrium arise through different 
carcinogenic pathways than type I and II endometrial carcinomas. Therefore, the expression 
of several immunohistochemical markers and the presence of distinct genetic mutations 
in endometrioid endometrial carcinoma with a background of atrophic endometrium was 
compared to those of type I and II carcinomas. 
Materials and Methods
Patients
For this study, patients with endometrial carcinoma from two cohorts, who were at least 
treated with a hysterectomy and bilateral salpingo-oophorectomy and who did not have a 
personal history of malignancy, were evaluated for inclusion. The first cohort is comprised 
of patients treated for grade 1 endometrioid endometrial carcinoma at the Radboud 
university medical center (Radboudumc) and the Canisius-Wilhelmina Hospital in Nijmegen, 
the Netherlands, between January 1999 and December 2009, and at the Mayo Clinic in 
Rochester, Minnesota, US, between January 2002 and December 2008.10 The second cohort 
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is comprised of patients with uterine serous carcinoma treated at the Radboud university 
medical center and the Canisius-Wilhelmina Hospital, Nijmegen between January 1999 and 
December 2009.14, 15
Slides of the primary carcinoma and background endometrium from the cohort of patients 
with grade 1 endometrioid endometrial carcinoma were reviewed with special attention to 
the nature of the background endometrium by experienced pathologists (JB, SB, or DV) who 
were unaware of the original pathology results and clinical outcome. In the case of doubt or 
discrepancy with the original pathology report a second review was performed by another 
pathologist and consensus was reached. Background endometrium was categorized as 
simple hyperplasia, simple atypical hyperplasia, complex hyperplasia, complex atypical 
hyperplasia, disordered proliferative, atrophic, and normal proliferative as previously 
described.5, 10, 16 Some cases had to be excluded because the tumor covered the entire cavity 
of the uterus and there was no background endometrium to be evaluated.
All patients with grade I endometrioid endometrial carcinoma and a background of pure 
(100%) atrophic endometrium (abbreviated to type III) as well as a similar amount of 
patients with grade I endometrioid endometrial carcinoma and a background of hyperplastic 
endometrium (type I) were included. Subsequently, all patients from the uterine serous 
carcinoma (type II) cohort of whom uterine tissue could be retrieved from the archive were 
included. This cohort consisted of carcinomas with both pure and mixed serous histology. 
It has been previously described that only about half of the serous carcinomas have pure 
serous histology.17 
Tissue microarray and immunohistochemistry
Tissue microarrays were created from the primary carcinoma.18 Two representative areas 
of the carcinoma were selected on hematoxylin and eosin-stained slides. For the type II 
cases, areas with pure serous histology were selected. Two cylinders with a diameter of 2 
mm were punched out of every donor block from the selected areas, and mounted into a 
recipient paraffin block using the Tissue-Tek Quick-Ray (Sakura Finetek, Torrance, CA, US) 
manual tissue microarrayer. 
The tissue microarrays were cut in 4 μm slides and immunohistochemically stained. Several 
markers were selected to be stained, based on the difference in their expression in type I 
and type II endometrial carcinoma.6-9, 19, 20 An overview of the antibodies and dilutions used 
as well as the area of the cell which was evaluated when scoring is shown in Table 1.
Immunohistochemical analysis of PTEN, L1CAM, ER, PR, p53, MLH1, PMS2, β-catenin, 
E-cadherin and MIB1 expression was performed according to the local protocols. These 
markers were chosen because previous literature has shown that their expression is 
different in type I and II EC.8, 9, 20 In short, formalin fixed paraffin sections were stained with 
the primary antibody following EDTA antigen retrieval, blocking of endogenous background 
with Peroxidase Blocking Reagent and protein blocking using horse serum. Subsequently, 
a secondary antibody was added and visualization was performed with Vectastain and 
3,3’-Diaminobenzidine (Zymed lab. California, US) as a substrate. Staining was enhanced 
in CuSO
4
 and slides were counterstained with Mayer’s hamatoxylin. Finally, slides were 
dehydrated and mounted. 
Table 1. Antibodies and dilutions used in this study, as well as the areas of the cell used for scoring
 Antibody Dilution Company Area scored
PTEN inactivation 6H2.1 1:100 Dakoa Cytoplasm/nucleus
L1CAM UJ127 1:100 Thermo Scientificb Membrane
ER expression SP1 1:80 Thermo Scientific Nucleus
PR expression PgR 636 1:250 Dako Nucleus
P53 mutations DO-7 1:400 Thermo Scientific Nucleus
Loss of MLH1 G168-15 1:50 BDc Nucleus
Loss of PMS2 A16-4 1:100 BD Nucleus
β-catenin alteration 14/Beta-Catenin 1:100 BD Membrane
E-cadherin alteration SPM471 1:300 Thermo Scientific Membrane
High proliferation rate MIB1 1:100 Thermo Scientific Nucleus
Tumor samples were given a score ranging from 0 to 9 by two independent evaluators (YG, 
and AT.) which was the product of the percentage of cells stained (0 = 0%, 1 = 1-10%, 2 = 
11-50% and 3 = 51-100%) and intensity of staining (0 = none, 1 = weak, 2 = moderate and 3 = 
strong).21 The evaluators were unaware whether the tissue cylinders were from type I, type 
II or type III carcinomas. Samples with too little tissue to assess or samples not containing 
any malignant tissue were not included in the calculations. In case of a large discrepancy 
between the scores of the two evaluators (i.e. a difference in percentage or intensity score 
> 2 or disagreement on the presence of malignant tissue) a third independent reviewer (JB), 
who was unaware of the score given by the first evaluators, scored the sample as well. 
The final score per case (range 0 to 9) was calculated by adding all scores given to the 
two tissue samples and dividing them by the number of scores in the sum (which varied 
depending on the presence of tumor tissue in the sample and the need for a third review). 
The final semiquantitative score was used for analysis of PTEN, ER and PR according to the 
literature as well as for β-catenin and E-cadherin, because there is no consensus as to which 
scoring system should be used.22, 23 L1CAM was considered positive when there was staining 
seen in at least 10% of the malignant cells.24 Cases with a final score ≥ 4 concerning p53 
were considered to be positive while those with a score < 4 were negative.25 MLH1 and 
PMS2 were considered lost when there was no scoring at all, according to the international 
guidelines. Finally, MIB1 staining was considered positive at every intensity and categorized 
as 1-10%, 11-50% and 51-100% cells positive. 
Mutation analysis
Slides with at least 10% representative tumor tissue were selected for DNA isolation. For 
the cases from the Mayo Clinic, the two TMA tumor biopsies were used instead. DNA 
was isolated with TET-lysis buffer (10 mmol/L Tris-HCl, pH 8.5; 1 mmol/L EDTA, pH 8; 
0.1% Tween-20) containing 5% Chelex-100 (Bio-Rad, Hercules, CA). Protein digestion was 
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performed by adding proteinase K to each sample and incubati on at 56°C for 48 h. Next, 
Protein K was inacti vated at 95°C for 10 min. The samples were centrifuged for 10 min 
at 14.000 rpm (RT) and the DNA concentrati on of the supernatant was measured using 
the Quant-iT picogreen dsDNA assay kit (Invitrogen, Carlsbad, CA, U.S.) before storage at 
4°C. For the detecti on of mutati ons, DNA was amplifi ed for exons of the KRAS, BRAF and 
PIK3CA genes using earlier published PCR primers.26 The amplifi ed exons were assessed for 
mutati ons at 22 nucleoti de positi ons by single nucleoti de probe extension assays using a 
SNaPshot Multi plex kit (Applied Biosystems, Foster City, CA) as described previously.26, 27
Stati sti cal analysis
The diff erences between the immunohistochemical marker scores of the three endometrial 
carcinoma subtypes were calculated using the Mann Whitney test, the χ2 test and the Fisher 
exact test. Diff erences between the amount of cases with geneti c mutati ons per subtype 
were calculated using the χ2 test and Fisher exact test. As a measure for tumor heterogeneity 
the correlati on between the scores given to the two biopsies per tumor was calculated 
using the Pearson correlati on coeffi  cient. This test was also used to calculate the correlati on 
between diff erent markers. Diff erences were considered to be stati sti cally signifi cant at a 
p-value ≤ 0.05. SPSS version 20 (SPSS IBM, New York, NY, U.S.) stati sti cal soft ware was used 
for analysis of the data.
Ethical approval
No ethical approval was needed for this study, which was performed according to the 
Code for Proper Secondary Use of Human Tissue (Dutch Federati on of Biomedical Scienti fi c 
Societi es, www.federa.org).
Results
Pati ents
Of the 527 pati ents with grade 1 endometrioid endometrial carcinoma evaluated, 
background endometrium was hyperplasti c in 387 (73%) and atrophic in 88 (17%). The 
background endometrium was normal premenopausal, proliferati ve in 27 (5%) pati ents 
and could not be assessed due to the size of the tumor in 25 (5%) pati ents. Pure atrophy 
was found in 43 (48.9%) of the 88 pati ents with atrophic background endometrium. Out of 
the 387 pati ents with hyperplasti c background endometrium, 43 (11.1%) were randomly 
selected as controls. From the cohort of pati ents with uterine serous carcinoma, all pati ent 
data as well as ti ssue was present in 21 cases (out of 47 meeti ng the inclusion criteria), 14 
(66.7%) of which had pure serous histology, which is slightly higher than that in the general 
populati on of pati ents with uterine serous carcinoma.17 In total, 107 cases were included for 
immunohistochemical and mutati on analyses. 
Immunohistochemistry
 Aft er initi al evaluati on of 2140 ti ssue samples, additi onal review because of discrepancy 
between the evaluators’ scores was necessary for 107 samples (44 type I, 19 type II and 
44 type III). This was equally divided among all markers. Three type III cases were excluded 
from the analysis because both tumor samples contained too litt le representati ve ti ssue 
or because they did not contain malignant ti ssue (one ER case, one MLH1 case and one 
MIB1 case). The fi nal marker scores per type of endometrial carcinoma and the diff erences 
between the scores are shown in Figure 1.
Figure 1. The diff erent marker scores per type of endometrial carcinoma. P-values of the Mann Whitney test (for 
the boxplots) and χ2 test (for the other graphs) comparing the individual types are shown.
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The correlati on between the scores given to the two biopsies from the same tumor as a 
measurement of tumor heterogeneity is shown per marker in Table 2, categorized as high (r 
between 0.7 and 0.9), moderate (r between 0.4 and 0.7) and weak (r between 0.1 and 0.4), 
according to Dancey and Reidy.28 It was moderate to high for most markers, only the scores 
for β-catenin were not correlated (r = -0.01, p=0.92)
Table 2. Marker heterogeneity, depicted as the strength of the correlati on (according to Dancey and 
Reidy) between the score of the two biopsies per marker
Strong Moderate Weak
PTEN (r*=0.72, p†<0.01) L1CAM (r=0.44, p<0.01) β-catenin (r=-0.01, p=0.92)
ER (r=0.80, p<0.01) p53 (r=0.55, p<0.01)
PR (r=0.78, p<0.01) PMS2 (r=0.48, p<0.01)
MLH1 (r=0.78, p<0.01) E-cadherin r=0.56, p<0.01)
MIB1 (r=0.60, p<0.01)
* Pearson’s correlati on coeffi  cient; † P-value for Pearson’s correlati on coeffi  cient
There was a strong positi ve correlati on between the presence of PMS2 and MLH1 (r = 0.78, 
p < 0.01) as well as between the presence of ER and PR (r = 0.70, p < 0.01). L1CAM positi vity 
had a slightly negati ve correlati on with ER (r = -0.33, p < 0.01) and PR (r = -0.42, p < 0.01).
When looking at the diff erences between the subtypes it can be seen that in both type 
I and III EC expression of ER and PR was signifi cantly higher than that in type II EC, while 
expression of L1CAM, p53 and MLH1 was signifi cantly lower in type I and III EC than that in 
type II EC. Expression of E-cadherin and MIB1 was signifi cantly lower in type III EC compared 
to type I and II EC. Examples of E-cadherin and MIB1 staining in type I and III carcinomas are 
shown in Figure 2.
Figure 2. Examples of E-cadherin (A) and MIB1 (B) expression in type I (left ) and type III (right) endometrial 
carcinomas. 
Mutati on analysis
A representati ve part of the tumor could be retrieved for every case and DNA yield was 
adequate for every sample when assessed by spectral photometry. Mutati on analysis of the 
PIK3CA gene was successful in all cases, of the BRAF gene in all but one type I case and the 
KRAS gene in all but two type I, one type II and two type III cases. The distributi on of wild type 
and mutated genes per type as well as the diff erences between types is shown in Table 3. 
Table 3. Results of the mutati on analysis per type of endometrial carcinoma
 Type I Type II Type III p (I-II)a p (I-III)a p (II-III)a
BRAF    
 
- 
 
 
 -
 
 
 -
 
Wild type 42 (97.7%) 21 (100%) 43 (100%)
Mutated - - -
Unknown 1 (2.3%) - -
KRAS    
 
0.58 
 
 
 <0.01
 
 
<0.01 
 
Wild type 26 (60.5%) 14 (66.7%) 40 (93%)
Mutated 15 (34.9%) 6 (28.6%) 1 (2.3%)
Unknown 2 (4.7%) 1 (4.8%) 2 (4.7%)
PIK3CA    
0.48 1.00
 
 0.28
 
Wild type 37 (86%) 16 (76.2%) 38 (88.4%)
Mutated 6 (14%) 5 (23.8%) 5 (11.6%)
Unknown - - -
aP-value for the Fisher exact test
The only signifi cant diff erence was found with the KRAS gene, which was mutated in 15/43 
(37.2%) of the type I and 6/21 (23.8%) of the type II carcinomas, compared to only 1/43 
(2.3%) of the type III carcinomas. In the type I carcinomas eight of the mutati ons were 
located on codon 12, fi ve on codon 13, one on codon 19 and one on codon 61 and in the 
type II carcinomas three mutati ons were located on codon 12 and two on codon 13. The 
mutati on in the type III carcinoma was located on codon 19.
The BRAF gene was not mutated in any of the cases, while the PIK3CA was mutated more 
oft en in type II EC (23.8%) than in type I (14%) and III (11.6%) EC, but these diff erences were 
not signifi cant.
Discussion
This study compared the immunohistochemical and geneti c profi les of endometrioid 
endometrial carcinomas with hyperplasti c background endometrium (type I) to those 
with atrophic background endometrium (hypotheti cal type III). While they were quite 
comparable, endometrioid carcinomas with atrophic background endometrium showed 
reduced expression of E-cadherin and less KRAS mutati ons compared to endometrioid 
carcinomas with hyperplasti c background endometrium. The endometrioid carcinomas 
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were also compared to those with serous histology (type II), which had a different 
immunohistochemical profile as expected.
Immunohistochemical profile
The immunohistochemical differences between type I and II endometrial carcinoma in this 
study are in line with previous literature. As expected, ER and PR expression were significantly 
higher in type I carcinomas, while L1CAM, p53 and MLH1 were significantly higher in type 
II carcinomas. Moreover, while the differences in PMS2, E-cadherin, β-catenin and MIB1 
expression were not significant, the observed trends were according to the findings in 
previous literature on these markers. Interestingly, PTEN expression was found to be lowest 
in serous carcinomas, while previous studies have shown loss of PTEN in endometrioid 
carcinomas.8, 9, 20 
It was hypothesized that type III carcinomas would have a distinct immunohistochemical 
profile. For most markers, there was no difference in expression between type I and III. 
However, expression of E-cadherin and MIB1 were significantly reduced in type III compared 
to type I carcinomas. 
Loss of E-cadherin has been described in both endometrioid and non-endometrioid 
carcinomas, while expression levels were found to be normal in hyperplastic endometrium.29-32 
In epithelial cells, E-cadherin is the major molecule of the cadherin family, which is essential 
for tight cell-cell connections.33 Reduced expression of E-cadherin was associated with 
lymph node metastasis, deep myometrial invasion, tumor dedifferentiation and advanced 
disease stage.29-32 Loss of E-cadherin is likely to be responsible, at least partially, for the 
fact that type III carcinomas are associated with lymph node metastasis, deep myometrial 
invasion and advanced disease stage as well.10 Moreover, while increased expression of 
MIB1, a proliferation marker associated with aggressive tumors, might seem more likely in 
type III carcinomas, we found the opposite to be true. However, this finding is in line with 
the conclusions from a recent publication showing the prognostic value of E-cadherin over 
proliferation markers.34
As expected, staining was slightly heterogeneous for most markers. Only β-catenin staining 
showed very strong heterogeneity, the reason for which is unknown. Finally, a strong 
correlation between the presence of ER and PR as well as MLH1 and PMS2 was shown, which 
is in line with the literature.22, 35 A negative correlation between the presence of L1CAM and 
the loss of ER and PR was also shown, though weaker than previously described.20 
Genetic profile
In line with previously published data, BRAF mutations were found in none of the cases.36 
PIK3CA mutations are associated with invasive growth and poor prognosis and were most 
frequently found in type II carcinomas, in accordance with previous findings.37-40 
Mutation analysis of KRAS, which have been described in 30% of the type I, but only 10% of 
the type II carcinomas showed several interesting results.9 In type I carcinomas we observed 
a slightly higher amount of KRAS mutations than previously reported, which might be 
explained by the fact that most studies only look at codon 12 mutations, while we looked 
at mutations at codons 12, 13, 61 and 19. Most of the KRAS mutations that we found were 
located on codons 12, 13 and 61, which are the most likely locations of KRAS mutations 
according to the literature.41 Only in one type II and in the only mutated type III case was 
the mutation on codon 19, an infrequent location of mutations in some tumors that has not 
been described in endometrial carcinomas before.42 Codon 19 mutations of KRAS have been 
suggested to alter the treatment response of colorectal carcinomas.42 However, this does 
not explain the high amount of KRAS mutations that we observed in type II carcinomas. This 
finding might be explained by the fact that we chose to include representative type II cases, 
some of which had a minor component of non-serous histology.17 The KRAS mutations in 
three of the six type II cases might have been present in minor areas with endometrioid 
histology instead of those with serous histology.43 The discrepancy between previously 
published results and the amount of mutations that we observed in type II carcinomas was 
much larger. Finally, the amount of mutations in the KRAS gene in this study was significantly 
lower in type III compared to type I and II carcinomas. 
KRAS mutations have been found to be an early event in the carcinogenesis of endometrioid 
endometrial carcinomas, present not only in endometrioid carcinoma, but endometrial 
hyperplasia as well.43, 44 These findings support the lack of KRAS mutations in endometrioid 
carcinomas arising from atrophic endometrium.
 Our findings in type III carcinomas of loss of E-cadherin with a lack of KRAS mutations are 
reported in several other studies. Up-regulation of E-cadherin expression by KRAS mutations 
was demonstrated in one study, while another describes expression of Zeb1, a transcription 
factor repressing E-cadherin expression, in tumor cell lines that grow independent of KRAS 
mutations.45, 46 These findings might suggest that loss of E-cadherin is an early event of 
carcinogenesis of type III carcinomas because there is a lack of KRAS mutations. 
Implications for the classifications of endometrial carcinomas
In 1983 endometrial carcinomas were subdivided into two distinct morphological subgroups 
and this division has played a distinct role in the management of endometrial carcinomas ever 
since.2 This morphological subdivision has proven to be very useful and in more recent years 
was also shown to be present on the immunohistochemical and genetic levels.8, 9 However, 
recent immunohistochemical and genetic studies have also shown that a subdivision into 
two groups is too simplistic.11-13 Moreover, even on a morphological level there is reason to 
believe that this subdivision into type I carcinomas arising from hyperplastic endometrium 
and type II carcinomas arising from atrophic endometrium is incomplete. Studies from our 
group have not only shown that 17% of the endometrioid carcinomas have in fact atrophic 
background endometrium – and a worse prognosis – but that the background endometrium 
of 9.3% of the pure and 34.7% of the mixed serous carcinomas was in fact hyperplastic.10, 15
The results of the current study, show additional value of immunohistochemistry and 
genetics next to morphology, which is in line with other recent studies. While studies by 
McConechy et al. and The Cancer Genome Atlas have shown that type I and II carcinomas 
both have a distinct genetic profile, they also show the existence of more subgroups 
based on the genetic profile.11, 12 McConechy et al. describe the use of genetics to aid in 
distinguishing cases with a worse prognosis which are hard to distinguish morphologically, 
for example grade 3 endometrioid carcinomas and serous carcinomas.12 Interestingly, while 
the TCGA publication only looked at the overlap between their four genetic subtypes and 
the two morphological subtypes, they do describe two groups with a low number of KRAS 
mutations, which have a bad to intermediate prognosis.11
Based on our findings as well as the growing amount of literature describing alternative 
subdivisions of endometrial carcinomas, we believe that it is important to take a closer 
look at overlap between newly found immunohistochemical and genetic profiles. It is, for 
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example, unknown whether serous carcinomas with hyperplastic background endometrium 
have distinct immunohistochemical and genetic profiles. Future research should focus on 
combining morphology, immunohistochemistry and mutation analyses in a way which can 
be used to identify patients with a worse prognosis more accurately, as proposed by Chiang 
et al.47 
Strengths and weaknesses of the study
This study is the first to analyze the immunohistochemical and genetic profiles of 
endometrioid endometrial carcinomas with atrophic background endometrium. A large 
set of immunohistochemical markers and genes was analyzed to give a clear view of the 
similarities and differences between the different endometrial tumor types. While many 
recent publications have shown that there are more than two types of endometrial 
carcinoma based on their molecular profile, this study shows that this is also true on an 
immunohistochemical level. It also shows that there is a significant heterogeneity within 
tumors, making a clear subdivision difficult.
A weakness of the study may be the fact that DNA was extracted for mutation analysis from 
whole slides instead of selected tumor tissue. However, while this might be responsible for 
the high mutation rate we found in type II carcinomas, it does not interfere with answering 
the question whether there is a difference between type I and III carcinomas. If anything, 
it highlights more clearly that very few KRAS mutations are found in type III carcinomas 
as well as the surrounding tissue. Lastly, it might have been better to match the patient 
characteristics of the patients with Type I and III carcinomas, because it is possible that the 
latter have a higher age and a lower BMI compared to the former, possibly influencing the 
carcinogenesis.
Conclusion
In conclusion, on the immunohistochemical and genetic levels, endometrioid carcinomas 
arising from atrophic background endometrium were shown to be quite comparable to 
endometrioid carcinomas arising from hyperplastic background endometrium. However, 
while KRAS mutations are an early event in carcinogenesis of endometrioid endometrial 
carcinoma in hyperplastic endometrium, these mutations were rarely seen in endometrioid 
carcinomas with atrophic background endometrium. Instead, carcinogenesis of these 
carcinomas seems to be characterized by loss of E-cadherin, which is uncommon in 
endometrioid carcinomas arising from hyperplastic endometrium. Immunohistochemical 
and genetic profiling might aid in distinguishing these cases which were previously shown 
to have a worse prognosis.
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Abstract
Background
Endometrial carcinomas are histologically classified as endometrioid, assumed to originate 
from hyperplastic endometrium, or non-endometrioid carcinomas, assumed to originate 
from atrophic endometrium. However, both on a histological and a molecular level there are 
indications that there are more carcinoma types and carcinogenetic pathways. This study 
aims to analyze endometrial carcinogenesis on a molecular level.
Materials and Methods
The presence of known KRAS, PIK3CA, AKT1, CTNNB1, BRAF, EGFR and NRAS mutations 
was studied in proliferative, atrophic and hyperplastic endometrium, endometrioid and 
serous carcinomas, and the endometrium next to these carcinomas, using single molecule 
Molecular Inversion Probes.
Results
Mutations were found in 9 (15%) of the 62 non atypical, and in 6 (18%) of the 34 atypical 
hyperplasia cases. In comparison, mutations were found in 1 (3%) of the simple, and 8 (30%) 
of the 27 complex hyperplasia cases. In 12/22 (55%) endometrioid carcinomas a mutation 
was found. The KRAS gene was most often mutated in carcinomas next to hyperplastic 
endometrium, whereas PIK3CA and CTNNB1 mutations were found in endometrioid 
carcinomas with adjacent atrophic endometrium.
Conclusion
Complex hyperplasia rather than atypical hyperplasia appears to be the most important 
lesion in the carcinogenesis of endometrioid carcinomas, and KRAS, PIK3CA, and CTNNB1 
mutations appear to play an important role in this process. Carcinogenesis of endometrioid 
carcinomas next to hyperplasia seems to be different to that of those next to atrophia. 
The value of these findings in managing endometrial hyperplasia and carcinoma should be 
studied.
Introduction
Endometrial cancer is the most common gynecological malignancy in the developed 
world, and its incidence is rising.1 Traditionally, endometrial carcinomas are divided into 
those with endometrioid and those with non-endometrioid histology, which were shown 
to have different molecular profiles as well. Endometrioid carcinomas are characterized 
by a heterogeneous molecular profile of mutations in PTEN, KRAS, CTNNB1, and PIK3CA, 
whereas TP53 mutations are most common in non-endometrioid carcinomas.2-4 
Endometrioid and non-endometrioid carcinomas are assumed to follow different 
carcinogenic pathways as well. Normal postmenopausal endometrium is atrophic, but can 
become hyperplastic, mainly as a result of unopposed estrogen stimulation.5 Endometrial 
hyperplasia can be categorized based on both the presence of simple or complex architecture, 
and the absence or presence of atypical nuclei.6 It is assumed that endometrioid carcinomas 
originate mainly from hyperplasia with atypia, and the World Health Organisation (WHO) 
therefore advises to categorize hyperplasia as either non-atypical or atypical, and to perform 
a hysterectomy when atypia is present.7-9 Non-endometrioid carcinomas on the other hand 
are assumed to originate from atrophic endometrium.10 On a molecular level, PTEN and 
KRAS mutations are assumed to be early events in endometrioid carcinogenesis, already 
present in endometrial hyperplasia, whereas PIK3CA mutations appear related to invasive 
transformation.11-13 In serous carcinomas, TP53 mutations were shown play an important 
role, but other non-endometrioid carcinomas have more heterogeneous molecular 
profiles.2, 3, 14 Moreover, it has been suggested that some non-endometrioid carcinomas are 
in fact dedifferentiated endometrioid carcinomas, as they have both non-endometrioid and 
endometrioid molecular characteristics.2, 3
In a recent study analyzing the endometrium of asymptomatic postmenopausal women, 
who were expected to have atrophic endometrium, a high prevalence of endometrial 
hyperplasia, including hyperplasia with atypical nuclei was found.15 In addition, although 
endometrioid carcinomas are assumed to originate in endometrial hyperplasia, the 
endometrium next to these carcinomas is atrophic in around 20% of the cases, and these 
cases were shown to have a worse prognosis.16 Moreover, studies categorizing endometrial 
carcinomas based on their molecular profiles have concluded that there are most likely 
more than two subgroups.17, 18
These recent findings challenge the dualistic nature of endometrial carcinogenesis, and 
the fact that a large proportion of the atypical endometrial hyperplasia will progress into a 
carcinoma. It is therefore
important to analyze the molecular characteristics of endometrial carcinogenesis in relation 
to these recent findings. This information is not only valuable for the clinical management 
of endometrial carcinomas, but for the management of endometrial hyperplasia as well. 
Materials and Methods
Cases
This study included a benign (proliferative and atrophic endometrium), a premalignant 
(hyperplastic endometrium), and a malignant (endometrioid carcinomas and serous 
carcinomas) cohort. The latter cohort also included the endometrium adjacent to the 
carcinomas. 
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- Benign: Patients who underwent a hysterectomy for uterovaginal prolapse at the 
Radboud university medical center Nijmegen between July 2011 and October 2012, and 
the Elisabeth-TweeSteden Hospital Tilburg between February 2012 and October 2012. 
The endometrium was sampled according to the Sectioning and Extensively Examining 
the Endometrium (SEE-End) protocol.15
- Premalignant: Patients who underwent a hysterectomy, and were subsequently 
diagnosed with endometrial hyperplasia, at the Radboud university medical center 
Nijmegen from 2002 till 2012. Patients from the SEE-End cohort were excluded.
- Malignant and adjacent endometrium: Patients treated for either grade 1 endometrioid 
carcinomas or serous carcinomas at the Radboud university medical center or Canisius-
Wilhelmina hospital in Nijmegen from 1999 till 2009.16, 19
Hematoxylin and eosin stained endometrial slides were reviewed by a gynecological 
pathologist (JB) with respect to the diagnosis, and representative areas were marked. 
Atrophic endometrium was defined as shallow endometrium with a thin basal layer and 
with a few tubular glands lined by inactive endometrium.7 Proliferative endometrium was 
defined as glandular proliferation, but no hyperplasia based on the gland:stroma ratio in 
postmenopausal women, and as widely spread, sometimes tortuous, tubular glands showing 
mitotic activity and abundant stroma in premenopausal women.7 Hyperplasia was defined 
as glandular proliferation with an increased gland:stroma ratio of 3:1, and was classified as 
simple or complex according to the (old) World Health Organization criteria.6 Atypia was 
defined as enlarged, rounded, polymorphic nuclei with loss of polarity, prominent nucleoli, 
chromatin clumping and an increased nucleus to cytoplasm ratio.6 Both the carcinoma and 
adjacent tissue were marked in the carcinoma groups. Cases with no or insufficient tissue 
were excluded.
DNA isolation
The previously marked representative areas were separated by either macro- or laser 
microdissection from respectively 20µm or 10µm thick section from corresponding formalin-
fixed, paraffin embedded tissue. For laser micro dissection, slides were mounted on poly 
ethylene napthalate (PEN) membrane slides (Leica Microsystems, Buffalo Grove, IL, US), 
pretreated with ultraviolet light, and visualized with hematoxylin.
The separated tissue was digested overnight at 56°C in TET-lysisbuffer (10mM Tris/HCL 
pH8.5, 1mM EDTA pH8.0, 0.01% Tween-20) with 5% Chelex-100 (Bio-Rad, Hercules, CA) and 
0.2% proteinase K. Subsequently, proteinase K was inactivated at 95°C for ten minutes, and 
the supernatant was transferred after centrifugation into a clean tube. DNA concentration 
was determined using the Qubit Broad Range Kit (Thermo Fisher Scientific, Waltham, MA, 
US). 
smMIP design and library preparation
The samples were analyzed using single molecule Molecular Inversion Probes (smMIPs). Both 
the design of the smMIPs and the preparation of the library were performed as previously 
described (Eijkelenboom A. et al. (in press). Reliable Next Generation Sequencing of FFPE 
tissue using single molecule tags. J Mol Diagn).20 In short, a panel of smMIPs, targeting both 
strands of hotspots listed in Supplementary Table 1 in a tiled manner, was designed. The 
smMIP probes contained extension and ligation probe arms (together 40bp long), and these 
arms were separated by an 112bp gap. These genes were chosen because they have been 
previously described to play a role in the PI3K/AKT, MAP/ERK and Wnt pathways, which 
play a role in the development of endometrial carcinomas, and because mutations of all of 
these genes have been previously described in endometrial carcinomas.12, 21-33 A common 
backbone sequence was inserted between the targeting arms and eight nucleotides were 
inserted between the backbone and ligation probe. The smMIP probes were produced by 
Integrated DNA Technologies (Leuven, Belgium) were mixed and phosphorylated with 1ul 
of T4 polynucleotide kinase (M0201, New England Biolabs, Ipswich, MA, US) per 25ul of 
100uM smMIPs and ATP-containing T4 DNA ligase buffer (B0202, New England Biolabs, 
Ipswich, MA, US). The molecular ratio between genomic DNA and smMIPs was set to 1:3200 
for every individual smMIP, and genomic DNA input was expected to be 100 ng. 
A capture mix was made by adding the phosphorylated smMIP-pool, 1 unit of Ampligase DNA 
ligase (A0110K, Epibio, Madison, WA, US) with Ampligase Buffer (A1905B, Epibio, Madison, 
WA, US), 3.2 units of Hemo Klentaq (M0332, New England Biolabs, Ipswich, MA, US) and 
8 µmol of dNTPs (28-4065-20/-12/-22/-32, GE Healthcare, Hoevelaken, the Netherlands) 
to 20 µl of sample containing genomic DNA. After denaturation at 95°C for 10 minutes, 
the mix was incubated for probe hybridization, extension and ligation at 60°C for 18 hours 
and cooled prior to exonuclease treatment. Exonuclease I (10 units M0293, New England 
Biolabs, Ipswich, MA, US) and III (50 units, M0206, New England Biolabs, Ipswich, MA, US) 
and Ampligase Buffer were added to the capture volume, adding up to a total of 27 µl, and 
incubated for 45 minutes at 37°C followed by inactivation at 95°C for 2 minutes. A total of 
20 µl of the exonuclease treated capture was used for PCR in a total volume of 50µl with 
a common forward primer, bar-coded reverse primers, and iProof high fidelity master mix 
(1725310, Bio-Rad. Veenendaal, the Netherlands). The resulting PCR products were pooled 
prior to purification with 0.8x volume of Agencourt Ampure XP Beads (A63881, Beckman 
Coulter, Woerden, the Netherlands).
Sequencing and analysis
Sequencing of libraries diluted to a concentration of 1.2 pM was performed using a 
NextSeq500 device (Illumina, San Diego, CA, US) and the 300 cycles Mid Output sequencing 
kit, resulting in 2x150bp paired-end reads. The Bcl files were converted to fastq files, and 
bar-coded reads were demultiplexed. Duplicate reads were used to assemble consensus 
reads using Sequence Pilot software (JSI Medical Systems, Costa Mesa, CA, US) with the 
following settings: Tags active: yes; R1 tag length: 8; R2 tag length: 0; Min abs. cov. cons.: 1; 
Min per. cov. cons.: 50%; Ignore cons. read thresh.: 30%; Ignore N tags: yes; Ignore low Qs 
tags: yes. The following settings were used for variant calling using Sequence Pilot: Required 
Coverage / Min abs. cov.: 20 combined; Mutations / Min abs. cov.: 5 combined; Min % cov.: 
1% per dir. Mutations in well sequenced parts of the DNA, which had an allele frequency of 
at least >5% in benign and >10% in malignant samples, and which were previously described 
in the Catalogue of Somatic Mutations in Cancer (COSMIC, cancer.sanger.ac.uk/cosmic) 
were considered to be clinically relevant. 
Ethical approval
No ethical approval was needed for this study, which was performed according to the 
Code for Proper Secondary Use of Human Tissue (Dutch Federation of Biomedical Scientific 
Societies, www.federa.org).
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Results
Cases
DNA isolation, PCR and sequencing were performed for a total of 179 samples, and were 
successful in 137 (77%), as shown in Table 1 per subgroup. The number of cases with mutations 
per subgroup, and the number of successfully analyzed genes and mutations per gene are 
shown in Table 2 and 3. Of the 41 pairs of endometrial carcinoma and adjacent endometrium, 
analysis was unsuccessful for seven complete pairs, eight endometrial carcinomas, and four 
adjacent endometrium carcinoma samples, leaving 22 pairs to be analyzed. Hyperplastic 
and atrophic endometrium next to the endometrioid carcinomas, both eleven cases, are 
shown separately. The endometrium next to the serous carcinomas was heterogeneous, 
with four cases with pure atrophy, two with pure endometrial hyperplasia, and two with a 
mix of atrophic and hyperplastic endometrium. Due to the small numbers these cases are 
not shown separately in the tables. The location and allele frequency of all mutations found 
are shown in Supplementary Table 2.
Table 1. Percentage of the included samples which was successfully analyzed (number of samples 
successfully analyzed/total number of samples analyzed)
Study group % Successful
Proliferative endometrium 64% (7/11)
Atrophia 60% (12/20)
Simple hyperplasia 100% (19/19)
Simple atypical hyperplasia 94% (16/17)
Complex hyperplasia 90% (9/10)
Complex atypical hyperplasia 90% (18/20)
Atrophia next to EEC* 73% (11/15)
Hyperplasia next to EEC 60% (9/15)
EEC  next to atrophia 73% (11/15)
EEC next to hyperplasia 73% (11/15)
Endometrium next to USC 55% (6/11)
Serous carcinoma 73% (8/11)
Total 77% (130/168)
Table 2. The percentage of endometrial hyperplasia cases and subgroups with mutations, as well as 
the prevalence of specific mutations in these groups. The absolute number of cases with (specific) 
mutations relative to the number of cases successfully analyzed are shown between brackets.
Mutated KRAS PIK3CA AKT EGFR
Total 15% (9/62) 5% (3/49) 7% (4/58) 3% (2/62) 2% (1/60)
Not atypical 11% (3/28) 0% (-/21) 8% (2/25) 0% (-/28) 4% (1/27)
Atypical 18% (6/34) 11% (3/28) 6% (2/33) 6% (2/34) 0% (-/33)
Simple 3% (1/35) 0% (-/22) 0% (-/32) 0% (-/35) 3% (1/33)
Complex 30% (8/27) 11% (3/27) 15% (4/26) 7% (2/27) 0% (-/27)
SHa 5% (1/19) 0% (-/12) 0% (-/17) 0% (-/19) 6% (1/18)
SAHb 0% (-/16) 0% (-/10) 0% (-/15) 0% (-/16) 0% (-/15)
CHc 22% (2/9) 0% (-/9) 25% (2/8) 0% (-/9) 0% (-/9)
CAHd 33% (6/18) 17% (3/18) 11% (2/18) 11% (2/18) 0% (-/18)
aSimple hyperplasia without atypia, bSimple atypical hyperplasia, cComplex hyperplasia without atypia, 
dComplex atypical hyperplasia
Table 3. The percentage of carcinoma cases and adjacent tissue cases with mutations, as well as 
the prevalence of specific mutations in these groups. The absolute number of cases with (specific) 
mutations relative to the number of cases successfully analyzed are shown between brackets.
Mutated KRAS PIK3CA AKT CTNNB1 BRAF NRAS
Next to EECa 10% (2/20) 7% (1/15) 6% (1/18) 0% (-/20) 0% (-/15) 0% (-/20) 0% (-/18)
Atrophia 9% (1/11) 0% (-/8) 10% (1/10) 0% (-/11) 0% (-/7) 0% (-/11) 0% (-/10)
Hyperplasia 11% (1/9) 14% (1/7) 0% (-/8) 0% (-/9) 0% (-/8) 0% (-/9) 0% (-/8)
EECa next to 55% (12/22) 27% (6/21) 18% (4/22) 1 (5%) 9% (2/19) 0% (-/22) 5% (1/22)
Atrophia 55% (6/11) 9% (1/11) 27% (3/11) 1/11 (9%) 20% (2/10) 0% (-/11) 9% (1/11)
Hyperplasia 55% (6/11) 50% (5/10) 9% (1/11) 0% (-/11) 0% (-/9) 0% (-/11) 0% (-/11)
Next to 
serous
17% (1/6) 25% (1/4) 0% (-/5) 0% (-/6) 0% (-/4) 0% (-/5) 0% (-/5)
Serous 13% (1/8) 0% (-/6) 17% (1/6) 0% (-/8) 0% (-/5) 17% (1/6) 0% (-/7)
aEndometrioid endometrial carcinoma
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Mutations in benign and premalignant endometrium
The number of mutated benign and premalignant cases, as well as the genes mutated 
in these cases, are shown in Table 2. No mutations were found in the proliferative and 
atrophic endometrium cases. Of the 62 analyzed cases with endometrial hyperplasia, but 
no adjacent carcinoma, nine (15%) contained mutations, eight of which contained one 
mutation, and one contained two mutations. A mutation of the EGFR gene was found in 
one case with simple hyperplasia without atypia. Two PIK3CA mutations were found in the 
cases with complex hyperplasia without atypia. All other mutations were found in the cases 
with complex atypical hyperplasia: three KRAS mutations, two PIK3CA mutations and two 
AKT1 mutations. In comparison, mutations were slightly more common in cases with atypia 
than in cases without atypia (18% vs. 11%), and more common in complex than in simple 
hyperplasia (30% vs. 3%). When comparing the subgroups, cases with complex hyperplasia 
without atypia and complex atypical hyperplasia were mutated in 22% and 33%, respectively, 
compared to only one (5%) mutation found in simple hyperplasia without atypia, and none 
in the cases with simple atypical hyperplasia. 
Mutations in carcinomas and adjacent endometrium
The number of mutated carcinoma cases and of the adjacent endometrium, as well as the 
genes mutated in these cases, are shown in Table 3. Of the 30 analyzed carcinomas (both 
endometrioid and non-endometrioid), 14 (43%) contained mutations, 11 of which contained 
one mutation, and three contained two mutations. Of the 22 included endometrioid 
carcinomas, twelve cases had a total of 14 mutations, most of which in the KRAS and 
PIK3CA genes. Five of the six mutations in endometrioid carcinomas next to hyperplastic 
endometrium were in the KRAS gene and one in the PIK3CA gene. Endometrioid carcinomas 
next to atrophic endometrium were more heterogeneous: the six cases with mutations 
contained three PIK3CA mutations, two CTNNB1 mutations, and a KRAS, an AKT1, and an 
NRAS mutation. One of the three cases with PIK3CA mutations contained two mutations. 
Two of the cases contained two mutations: one case had a PIK3CA and a CTNNB1 mutation, 
and the other a PIK3CA and an NRAS. There was only one mutated serous carcinoma, which 
contained both a PIK3CA and a BRAF mutation.
In the 26 endometrium next to a carcinoma samples, we identified only three (12%) mutations: 
a KRAS mutation in hyperplastic endometrium next to an endometrioid carcinoma, a PIK3CA 
mutation in atrophic endometrium next to an endometrioid carcinoma, and a KRAS mutation 
in, interestingly, atrophic endometrium next to a serous carcinoma. Only the KRAS mutation 
in the hyperplastic endometrium next to an endometrioid carcinoma was identified in the 
corresponding carcinoma.
Discussion
This study analyzed the presence of mutations in the endometrium, and found no mutations 
in the included cases with benign endometrium, and only one mutation in the cases with 
simple hyperplasia. Complex hyperplasia without atypia and complex atypical hyperplasia 
appear to be important steps in endometrial carcinogenesis, as most mutations were 
found in these cases. Interestingly, KRAS mutations were very common in endometrioid 
carcinomas next to hyperplastic endometrium, but not in endometrioid carcinomas next to 
atrophic endometrium. There were only a few mutations in the endometrium adjacent to 
the carcinomas.
Mutations
AKT1. Although the PI3K/AKT pathway is frequently affected in endometrial carcinomas, 
more often than in any other cancer type analyzed by The Cancer Genome Atlas, AKT1 
mutations do not seem to play a major role.21, 22 Shoji et al. analyzed 89 endometrial 
carcinomas, and found AKT1 mutations in only two cases, both at location c.49, and in both 
cases there were no mutations in the KRAS, PIK3CA, and ERBB2 genes.23 This is comparable 
to our findings in endometrial carcinomas: we found only one AKT1 mutation, which was at 
the same position. Interestingly, we found two AKT1 mutations in complex hyperplasia as 
well, which could imply that these do play a role in endometrial carcinogenesis. However, 
the allele frequency of these mutations was low, and it is quite possible that they do not 
play a tumor driving role. This is supported by the fact that we found a much more prevalent 
KRAS mutation in one of the cases with an AKT1 mutation. 
BRAF. Although BRAF is part of the PI3K/AKT pathway as well, it does not seem to play a 
major role in endometrial carcinomas. There is one publication which analyzed BRAF exon 
11 and 15, and found mutations in 21% of the endometrial carcinomas, and in 11% of the 
complex atypical hyperplasia cases, but not in benign endometrium.24 However, all of these 
were novel mutations, and other studies have contested these findings.34, 35 BRAF mutations 
do not seem to play a major role in the samples we analyzed, but we did find one previously 
described BRAF mutation with a high allele frequency in one of the serous carcinomas. 
CTNNB1. Previous studies analyzing the CTNNB1 gene in endometrial carcinomas have found 
CTNNB1 mutations in 15-25% of the endometrioid carcinomas.25, 26 We found less CTNNB1 
mutations than previously described, but it has to be noted that analysis of CTNNB1 was not 
possible in a substantial number of cases, most likely because FFPE tissue was used for this 
study. We did not find any CTNNB1 mutations in the other subgroups, but previous studies 
have only analyzed carcinomas, and we are therefore not able to compare this finding. 
EGFR and ERBB2. Immunohistochemical expression of EGFR and Her2/Neu, activated 
by the PI3K/AKT and MAP/ERK pathways, is frequently seen in endometrial carcinomas, 
especially in serous carcinomas. EGFR mutations in endometrial carcinomas have not been 
described, whereas ERBB2 mutations are common in serous carcinomas and uncommon 
in endometrioid carcinomas.27-30 In accordance with these findings, we found only one 
EGFR mutation in the parts of the gene we sequenced, in a case with simple hyperplasia 
without atypia. Given the lack of these mutations in complex hyperplasia and endometrial 
carcinomas, it is unlikely that this gene plays a role in endometrial carcinogenesis. We 
included only a small number of serous carcinomas, which might explain why we were 
unable to find any ERBB2 mutations.
KRAS. The presence of KRAS mutations in endometrioid carcinomas has been extensively 
studied, and these were found in 9-19%.31, 32, 34 There is one previous study analyzing 
the presence of KRAS mutation in both endometrioid carcinomas (n=58) and atypical 
hyperplasia (n=22) next to the carcinomas.31 This study found KRAS mutations in 19% of the 
carcinoma, and in 5% of the hyperplasia cases. In comparison, we found KRAS mutations in 
27% of the endometrioid carcinomas, almost all of which in endometrioid carcinomas next 
to hyperplastic endometrium. We also found one KRAS mutation in the hyperplasia next to 
the carcinoma, and it was present in the adjacent carcinoma as well. In addition, we found 
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KRAS mutations in 5% of the endometrial hyperplasia cases with no adjacent carcinoma, all 
of which were complex atypical hyperplasia cases.
HRAS and NRAS. Both HRAS and NRAS play a role in the PI3K/AKT pathway as well, and 
although they have been described in other cancer types which are driven by this pathway, 
HRAS mutations have never been described in endometrial carcinomas, and NRAS mutations 
were only found in only 1.8% of the endometrial carcinomas (both endometrioid and non-
endometrioid).26, 32 This is in line with our findings: we found no HRAS mutations and NRAS 
mutations in only 5% of the endometrioid carcinomas. 
PIK3CA. Oda et al. found PIK3CA mutations in 36% of the 66 endometrial carcinomas studied, 
and in 26% of the cases PTEN was mutated as well.33 In addition, Hayes et al. analyzed both 
these genes in 29 cases with complex atypical hyperplasia and 44 cases with an endometrial 
carcinoma.12 They found PTEN mutations in 48% of the complex atypical hyperplasia cases 
and 57% of the endometrial carcinoma cases. In contrast, they found PIK3CA mutations in 
only 7% of the complex atypical hyperplasia cases, and in 39% of the endometrial carcinoma 
cases. They hypothesized that PTEN mutations are a very early event, whereas PIK3CA 
mutations, amongst others, are important for the invasive potential. This is supported by 
numerous studies showing either PTEN mutations or loss of immunohistochemical PTEN 
expression in endometrial hyperplasia.36-38
Premalignancies
Endometrioid carcinomas are assumed to originate from hyperplastic endometrium under 
the influence of unopposed estrogen expression, and many different mutations have been 
associated with this process. Especially PTEN mutations are assumed to be an early event, 
already present in a substantial number of cases with atypical hyperplasia, whereas other 
mutations, especially of the KRAS and PIK3CA genes, may play a role in the progression 
from hyperplasia into a carcinoma.12, 22, 33, 36-38 Based on several recent studies describing 
a high risk of up to 30% of progression from atypical hyperplasia into an endometrioid 
carcinoma, the WHO advises a subdivision of endometrial hyperplasia into non-atypical and 
atypical hyperplasia.8, 9, 39, 40 In contrast, the previous subdivision had four categories, and 
was based on both the architecture (simple or complex) and the absence or presence of 
atypical nuclei.6 This was based on a study by Kurman et al., which shows a progression 
risk of 1% in simple hyperplasia without atypia, 3% in complex hyperplasia without atypia, 
8% in simple atypical hyperplasia, and 29% in complex atypical hyperplasia.41 Nevertheless, 
most recent studies concluding that there is a risk of progression when atypical nuclei are 
present have pooled simple and complex atypical hyperplasia.8, 39, 40 However, combining 
these cases, and subsequently advising a hysterectomy for both diagnoses, is challenged 
by our findings that almost all mutations are found in complex hyperplasia without atypia 
and complex atypical hyperplasia, and not in simple atypical hyperplasia. The new WHO 
subdivision was also based on the fact that many of the mutations present in endometrioid 
carcinomas were already present in atypical hyperplasia.9 As previous studies have shown 
that PTEN mutations are a very early event, followed by other mutations which lead to 
malignant progression, it might very well be possible that PTEN mutations are already 
present in simple atypical hyperplasia, but progression mainly occurs as a result of other 
mutations, which we found predominantly in complex and complex atypical hyperplasia.36-38 
The traditional morphological characterization has also been challenged by studies 
suggesting that the identification of endometrioid premalignancies, which were called 
endometrial intraepithelial neoplasia (EIN), should include assessment of glandular volume, 
architectural complexity, and nuclear abnormality.42 Coexistent carcinomas and progression 
to a carcinoma were found in a substantial number of the EIN cases.43, 44 Interestingly, 
EIN was predominantly diagnosed in cases with complex hyperplasia without atypia and 
complex atypical hyperplasia.43, 44 Moreover, progression to a carcinoma was most likely to 
occur if both EIN and complex atypical hyperplasia were present.43, 44 Little is known about 
molecular characteristics of EIN, besides the fact that the combined presence of EIN and 
loss of PTEN predicts the progression risk better than the presence of EIN alone.45 
All together, these findings suggest that it may be too simplistic to consider all atypical 
hyperplasia to be the endometrioid premalignancy, and future studies should investigate 
possible improvements to the histological classification, as well as the combined value 
of histology and molecular markers in the identification of cases at risk of a coexistent 
carcinoma or progression to a carcinoma.
Carcinogenesis
It has previously been shown that endometrial hyperplasia can be very focal, and it has 
been hypothesized that only a few hyperplastic glands are required for endometrial 
carcinogenesis.46 This is further supported by the fact that next to around 20% of the 
endometrioid carcinomas the assumed precursor lesion, endometrial hyperplasia, is not 
present.16 Interestingly, in the current study we failed to find mutations present in the 
carcinomas in most of the corresponding endometrial samples, which would support that 
endometrial carcinogenesis may be a focal process. 
Furthermore, previous studies found prognostic and molecular differences between 
endometrioid carcinomas next to hyperplastic and atrophic endometrium.16, 47 In the current 
study almost all mutations found in the endometrioid carcinomas next to hyperplastic 
endometrium were in the KRAS gene, whereas endometrioid carcinomas nest to atrophic 
endometrium were in several other genes other than KRAS. It is of course unknown if these 
latter carcinomas originated from focal hyperplasic endometrium or directly from atrophic 
endometrium, but it seems likely that their carcinogenic pathway is different than that of 
endometrioid carcinomas next to hyperplastic endometrium. This is further supported by a 
recent study by Berg et al., which shows that the carcinogenesis of endometrial carcinomas 
is dependent on the body mass index (BMI), and is characterized by PTEN mutations 
and PIK3CA mutations in non-obese women, and by KRAS mutations in obese women.48 
Interestingly, a previous study has shown that the BMI of patients with an endometrioid 
carcinoma with adjacent atrophic endometrium is significantly lower than that of patients 
with an endometrioid carcinoma with adjacent hyperplastic endometrium.16 Even when 
taking into account the fact that we did not include PTEN mutations in our analyses, the 
fact that we found mutations in only 55% of the endometrioid carcinomas underlines the 
fact that carcinogenesis of these carcinomas appears to be a very heterogeneous process. 
Moreover, in light of recent studies classifying endometrial carcinomas based on their 
molecular profiles, it would be interesting to study the carcinogenesis in relation to this new 
classification into four subgroups.17, 18
The carcinogenesis of non-endometrioid carcinomas is believed to be independent 
of estrogen stimulation and these carcinomas are assumed to originate directly from 
atrophic endometrium, although a minority might in fact be dedifferentiated endometrioid 
carcinomas.2 Interestingly, there was one case which had both a BRAF and a PIK3CA mutation, 
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and was adjacent to hyperplastic endometrium. This might in fact be a dedifferentiated 
endometrioid carcinoma.2, 3
Strengths and weaknesses
This is the first study analyzing endometrial tissue with smMIPs, which has several 
advantages over other Next Generation Sequencing techniques (Eijkelenboom A. et al. (in 
press). Reliable Next Generation Sequencing of FFPE tissue using single molecule tags. J Mol 
Diagn).49 The number of false positive variants with an allele frequency >5% is significantly 
reduced in the smMIP-NextSeq500 approach, while the detection of clinically relevant 
mutations is comparable. Additionally, overestimation of the actual number of analyzed 
molecules as a result of sequence analysis of PCR duplicates is a problem when poor quality 
FFPE-derived gDNA is used. Because smMIPs have a unique molecular tag the exact number 
of analyzed input DNA molecules can be calculated, preventing overestimation. Moreover, 
this is the first study analyzing a substantial number of genes in an extensive and well 
described, and revised cohort containing benign, premalignant and malignant lesions, as 
well as endometrium next to the malignant lesions.
Unfortunately, the smMIP analysis was not successful in all cases, most likely as a result of 
DNA fragmentation caused by the use of FFPE tissue which has been archived for years. 
In addition, a smMIP probe targeting PTEN was not included in the panel. Although PTEN 
alterations undeniably play an important role in the development of endometrial carcinomas, 
this has already been extensively described in other publications highlighting its role in both 
premalignant and malignant endometrial tissue. The genes described in the current study 
have been described to play a role in a later stage of carcinogenesis, but there is little data on 
the presence of these mutations in endometrial tissue other than endometrial carcinomas. 
Conclusion
This study reinforces the heterogeneous genetic origin of endometrial carcinogenesis. On 
a molecular level, complex endometrial hyperplasia appears to be the most important 
step in this process. Endometrioid carcinogenesis seems to follow different pathways in 
the presence of hyperplastic and atrophic background endometrium. More research into 
these distinct carcinogenic changes and the role of these findings in the management of 
endometrial carcinomas is needed. Moreover, it should be studied whether non invasive 
follow-up of patients with simple atypical hyperplasia might be sufficient, possibly with 
repeated mutation analyses of the endometrial biopsies.
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Supplementary Table 1. The hotspots targeted by the smMIPs
Gene Exon Amino acids Positions RefSeq ID Ensembl ID
AKT1 03 E17 c.47-5 to c.86 NM_005163 ENST00000555528
BRAF 15 D594-K601 c.1742-5 to c.1845 NM_004333 ENST00000288602
CTNNB1 03 D32-S45 c.53 to c.146 NM_001904 ENST00000349496
EGFR
12 S492 c.1392 to c.1498+5
NM_005228 ENST00000275493
18 E709-G719 c.2062-5 to c.2184+5
19 all (G729-D761) c.2185-5 to c.2283+5
20 all (E762-K823) c.2284-5 to c.2469+5
21 L858-L861 c.2245 to c.2630
ERBB2 20 Y772 - Y781 c.2308-1 to c.2357 NM_004448 ENST00000269571
HRAS
02 G12, G13 c.17 to c.83
NM_005343 ENST00000451590
03 A59, Q61 c.128 to c.227
KRAS
02 G12, G13, c.9 to c.71
NM_004985 ENST0000031193603 A59, Q61 c.122 to c.215
04 K117, A146 c.291-5 to c.357 and c.402 to c.450+5
NRAS
02 G12, G13, c.-17-5 to c.64
NM_002524 ENST0000036953503 A59, Q61 c.161 to c.245
04 K117, A146 c.312 to c.450+5
PDGFRA
12 all (K552-L595) c.1654-5 to c.1786+5
NM_006206 ENST0000025729014 all (T632-S667) c.1892-5 to c.2002+5
18 V824-D842 c.2440-5 to c.2544
PIK3CA
10 E542-Q546 c.1558 to c.1664+5
NM_006218 ENST00000263967
21 M1043-G1049 c.3058 to c.3207+10
Supplementary Table 2. The locations, allele frequency and study groups of the mutations found 
in this study.
Location 
(allele frequency)
Study group
KRAS c.35G>T (14%) Complex atypical hyperplasia
c.35G>T (10%) Complex atypical hyperplasia
c.35G>T (64%) Complex atypical hyperplasia
c.35G>A (14%) Hyperplasia next to USC
c.35G>T (19%) Hyperplasia next to EEC
c.35G>T (29%) EEC next to atrophia
c.35G>T (12%) EEC next to hyperplasia
c.35G>T (54%) EEC next to hyperplasia
c.35G>T (25%) EEC next to hyperplasia
c.38G>T (20%) EEC next to hyperplasia
c.38G>T (10%) EEC next to hyperplasia
PIK3CA c.1624G>A (7%) Complex hyperplasia
c.3044C>T (13%) Complex hyperplasia
c.3044C>T (6%) Complex atypical hyperplasia
c.3140A>G (16%) Complex atypical hyperplasia
c.1658G>A (19%) Atrophia next to EEC
c.1634G>A (49%) EEC next to atrophia
c.3129G>A(16%) EEC next to atrophia
c.3140A>T (22%) EEC next to atrophia
c.3148G>A (44%) EEC next to atrophia
c.1616C>G (10%) EEC next to hyperplasia
c.3062A>G (22%) USC
AKT c.49C>A (7%) Complex atypical hyperplasia
c.49G>A (8%) Complex atypical hyperplasia
c.49G>A (5%) EEC next to atrophia
CTNNB1 c.94G>T (16%) EEC next to atrophia
c.100G>A (17%) EEC next to atrophia
BRAF c.1805C>A (22%) USC
EGFR c.2107C>T (60%) Simple hyperplasia
NRAS c.35G>A (22%) EEC next to atrophia
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Abstract
Background 
A minority of endometrial carcinomas present at an advanced stage with a poor prognosis, 
and should be identified to individualize treatment. Immunohistochemical markers have 
been studied, but most have not been directly linked to metastasis. This study analyzes 
the immunohistochemical profile of endometrioid endometrial carcinomas (EECs) with and 
without metastases, and corresponding metastases.
Materials and Methods 
Tissue Micro Array slides from stage I EECs, and stage III-IV EECs and corresponding 
metastases were stained and scored for expression of β-catenin, E-cadherin, ER, PR, PTEN, 
p16, MLH1, PMS2, L1CAM, p53, p21 and MIB1. Scores were compared between primary 
stage I and III-IV EECs, stage III-IV EECs and the corresponding metastases, and between 
intra-abdominal and distant metastases.
Results 
Primary tumors with distant metastases had a significantly lower ER expression than 
those without metastases or with intra-abdominal metastases. Distant metastases had a 
significantly lower PR expression than the corresponding primary tumor and intra-abdominal 
metastases. In contrast, p16 and PTEN expression was significantly higher in intra-abdominal 
metastases compared to corresponding primary tumors. 
Conclusion 
Immunohistochemistry predicts both presence and location of EEC metastases. Loss of ER 
and PR was related to distant spread, and increased expression of PTEN and p16 was related 
to intra-abdominal spread. Additional research should assess the use of these markers in 
the diagnostic workup as well as the possibility to target metastases through these markers.
Introduction
Endometrial carcinoma is the most common gynecologic malignancy in the developed world 
and its incidence is increasing.1 Endometrial carcinomas can be divided into two subtypes 
with different clinical and pathologic characteristics.1 The most common endometrioid 
endometrial carcinoma (EEC) is believed to arise from hyperplastic endometrium under the 
influence of unopposed estrogen stimulation. They often present at an early stage and have 
a good prognosis. The less common non-endometrioid carcinomas, most with serous or 
clear cell histology, arise from atrophic endometrium and have a worse prognosis. These two 
subtypes were shown to differ on a molecular level as well. EECs often have microsatellite 
instability and mutations in PTEN, PIK3CA, KRAS and CTNNB1, whereas TP53, STK15, CDKN2A 
(p16), CDH1 and ERBB2 are often mutated in non-endometrioid carcinomas.2 Recent studies 
have shown that there are more than two subgroups, based on the molecular profile, but 
these new findings have not yet been incorporated in clinical practice.3-5
Although most EECs present at an early stage with a favorable prognosis, some may already 
be advanced stage at the time of diagnosis. It is important to identify these patients in order 
to further individualize treatment, and although several immunohistochemical prognostic 
markers have been studied, only a few have been directly linked to the presence of 
metastatic lesions.6-8 Expression of the estrogen receptor (ER), progesterone receptor (PR), 
stathmin and p-mTOR was found to be different in endometrial carcinoma recurrences when 
compared to the primary tumor, and loss of ER and PR in preoperative endometrial biopsies 
was associated with the presence of lymph node metastases.9, 10 In addition, E-cadherin is 
assumed to play a role in epithelial to mesenchymal transition, a process important in tumor 
progression and metastasis.11
Although EECs can spread intra-abdominal and to a distant site (lymphogenous or 
hematogenous), it is unknown whether there is a molecular difference between these 
two.12 In ovarian carcinomas distinct molecular differences have been found in cells 
spreading to an intra-abdominal site, and lymphogenously or hematogenously to a distant 
site.13 Interestingly, it has been shown that endometrial cancer cells can be intra-abdominal 
without metastasizing.14
Understanding the mechanisms underlying metastasis of EECs is of great value in individualizing 
the treatment. This study therefore aims to compare the immunohistochemical profile of 
EECs without metastases to that of EECs with metastases, of the primary tumor to that of 
corresponding metastases, and of intra-abdominal metastases to that of distant metastases.
Materials and Methods
Patient selection
For this case-control study the nationwide network and registry of histo- and cytopathology 
in the Netherlands (PALGA) was searched for all patients surgically treated between January 
1999 and January 2010 for International Federation of Gynaecology and Obstetrics (FIGO) 
stage III or IV EEC at the Radboud university medical center and the Canisius-Wilhelmina 
Hospital in Nijmegen, and the TweeSteden and St. Elisabeth Hospital in Tilburg, the 
Netherlands.15 Subsequently, a control group of patients with stage I EEC, matched for 
tumor grade, was collected from a well-defined cohort of patients treated for endometrial 
cancer between January 1999 and January 2010 at the Radboud university medical center 
and the Canisius-Wilhelmina Hospital . 
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All histological slides of the primary carcinoma and the metastatic site were retrieved from 
the pathology archives and reviewed systematically with respect to the histological type and 
tumor grade of both the primary tumor and the metastasis. Moreover, primary tumor slides 
were reviewed with respect to depth of myometrial invasion, presence of lymphovascular 
space invasion, and the nature of the background endometrium as well. Review was 
performed in every hospital separately by an independent pathologist (JB, SB, or AW) who 
was unaware of the original pathology reports and the clinical outcome. When there was 
doubt about the diagnosis or discrepancy between the review and the original pathology 
report, the three reviewing pathologists reached consensus. 
Clinical data were recorded from patient records: age, menopausal state, body mass index 
(BMI), parity, personal medical history, treatment, stage of disease, date of recurrence of 
disease, date of death, and cause of death. 
Tissue microarray and immunohistochemistry
Representative areas of the primary carcinomas and the metastatic lesions were selected on 
haematoxylin and eosin-stained slides. These areas were combined into tissue microarrays 
(TMAs) by punching a cylinder with a diameter of 3 mm from the corresponding formalin-
fixed paraffin-embedded (FFPE) block and mounting it into a recipient paraffin block using a 
manual tissue microarray (Tissue-Tek, Quick-Ray, Sakura Finetek, USA).
Slides (4 μm) cut from the TMA blocks were immunohistochemically stained. In short, 
following antigen retrieval of deparafinized and rehydrated slides, endogenous background 
was blocked using Peroxidase Blocking Reagent (3% H2O2 in PBS) and protein was blocked 
using horse serum. After incubating with the primary antibody, a secondary antibody was 
added and visualization was performed with Vectastain and 3,3’-Diaminobenzidine (Zymed 
lab. California, USA) as substrate, and slides were counterstained with Mayer’s haematoxylin. 
Finally, slides were dehydrated and mounted. Table 1 contains an overview of the antibodies 
used in this study.
Table 1. Antibodies used for staining
Antibody Clone Vendor Retrieval Dilution Staining
β-catenin 14/Beta-catenin BDa EDTA 10’ 1:100 Membranous
E-cadherin SPM471 Thermo Scientificb EDTA 10’ 1:300 Membranous
ER SP1 Thermo Scientific EDTA 10’ 1:80 Nuclear
PR PgR636 DAKOc citrate 10’ 1:250 Nuclear
PTEN 6H2.1 DAKO EDTA 10’ 1:100 Nuclear, cytoplasmatic
p16 G175-405 BD citrate 10’ 1:20 Nuclear, cytoplasmatic
MLH1 G168-15 BD EDTA 10’ 1:50 Nuclear
PMS2 A16-4 BD EDTA 10’ 1:100 Nuclear
L1CAM UJ127 Thermo Scientific EDTA 10’ 1:100 Membranous
p53 DO-7 Thermo Scientific citrate 10’ 1:400 Nuclear
p21 CDS-60.2 Thermo Scientific citrate 10’ 1:75 Nuclear
MIB MIB-1 DAKO citrate 10’ 1:100 Nuclear
aBecton, Dickinson and Company, Franklin Lakes, New Jersey, US; bThermo Fisher Scientific Inc., Waltham, 
Massachusetts, US.;cDako , Glostrup, Denmark.
Evaluation of staining
Percentage (0 = 0%, 1 = 1-10%, 2 = 11-50% and 3 = 51-100% positive) and intensity of staining 
(0 = none, 1 = weak, 2 = moderate and 3 = strong) were scored per slide independently by 
two evaluators (YG and JB).The product of the percentage and intensity scores (range 0 to 
9) was calculated and the average of these 2 scores per case was considered to be the final 
score.9 This semiquantitative score was used unaltered for ER and PR, in accordance with the 
literature, and for β-catenin,E-cadherin, PTEN and p16 because there is no consensus which 
scoring system should be used.16 MLH1 and PMS2 were considered lost when there was 
no scoring at all, according to the international guidelines. L1CAM was considered positive 
when staining was seen in at least 10% of the malignant cells.8 Cases with a final p53 score 
≥ 4 were considered positive.6 All p21 scores below the first quartile (score 0 for the tumors 
and score 1.5 for the metastatic lesions) were considered negative.6 Finally, MIB1 staining 
was considered positive at every intensity and categorized as 1%-10%, 11%-50% and 51%-
100% cells positive. 
Statistical analysis
For statistical analysis, metastases were classified according to the hypothesized route of 
spread: intra-abdominal (tubal, ovarian, peritoneal and omental), and lymphogenous or 
hematogenous (vaginal, nodal and other organs). Clinical and pathologic parameters of the 
case and the control groups were compared using the Pearson χ2 or Fisher exact test for 
categorical variables, and the Mann-Whitney test for continuous variables. Differences in 
marker scores between the case and the control groups as well as between intra-abdominal 
and distant metastases were calculated using the Mann-Whitney test for β-catenin, 
E-cadherin, ER, PR, PTEN and p16, and Pearson χ2 or Fisher exact test for MLH1, PMS2, 
L1CAM, p53, p21 and MIB1. Differences in marker scores between the primary tumors 
and the corresponding metastases were calculated in a paired fashion using the Wilcoxon 
test for β-catenin, E-cadherin, ER, PR, PTEN, MIB1and p16, and McNemar’s test for MLH1, 
PMS2, L1CAM, p53, p21 and MIB1. P-values < 0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS version 20 (SPSS IBM, New York, NY, USA).
Results
Patients
A total of 53 patients with FIGO stage III or IV EEC were retrieved from nationwide network 
and registry of histo- and cytopathology. After review 15 cases were excluded: 10 because 
non-endometrioid histology was seen, 4 because insufficient material was available and 1 
because the metastatic site was found to be a second primary malignancy. Of the remaining 
38 patients, 5 had FIGO stage IIIA disease, 6 stage IIIB, 9 stage IIIC, 5 stage IVA and 13 stage 
IVB. Three tumors were grade 1, 16 grade 2 and 19 grade 3. The matched control group 
consisted of 37 patients with FIGO stage I EEC. Four had a grade 1 tumor, 17 grade 2 tumor 
and 16 a grade 3 tumor.  
Of the metastases, 23 were considered to be intra-abdominal: 7 peritoneal, 6 ovarian, 4 
omental, 2 tubal, 2 parametrial, 1 of the mesovarium and 1 of the uterosacral ligament. Of 
these patients, 4 had another lesion at a distant site suspected to be a metastasis, but of 
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which no tissue was available. Fifteen metastases were considered to be distant: 11 lymph 
nodes, 3 vaginal, and 1 liver metastasis.
Clinical and pathological characteristics of the included patients are shown in Table 2. There 
were no differences between patients with and without metastatic disease in terms of 
age at diagnosis, BMI and menopausal age. However, deep myometrial invasion, cervical 
involvement and lymphovascular space invasion were found significantly more often in the 
case group compared to the control group. As a result, patients in the case group were 
treated with adjuvant radio- and chemotherapy more often and were more likely to die as a 
consequence of the carcinoma, and the follow-up was therefore longer in the control group.
Table 2. Comparison of the clinical and pathologic characteristics of the case and control groups
Case group Control group pa
Number of patients 38 37
Median age (years) 65.5 (49-82) 66.0 (45-82) 0.84
Median BMI (kg/mb) 28.7 (19.4-50.8) 28.3 (18.7-41.4) 0.87
Menopausal state   0.96
   Premenopausal 5 (13%) 5 (14%)
   Postmenopausal 33 (87%) 32 (86%)
FIGO stage   
   IA  - 26 (70%)
   IB  - 11 (30%)
   II  - - 
   III 19 (50%) -
   IV 19 (50%) -
Grade   1.00
   1 3 (8%) 4 (11%)
   2 16 (42%) 17 (46%)
   3 19 (50%) 16 (43%)
Myometrial invasion  <0.01
   <1/2 7 (18%) 22 (61%)
   ≥1/2 31 (82%) 14 (39%)
Cervical involvement   <0.01
   No 28 (55%) 35 (95%)
   Endocervical 7 (18%) 2 (5%)
   Stromal 10 (26%)  
LVSI  <0.01
   No 15 (40%) 34 (92%)
   Yes 23 (61%) 3 (8%)
aP-value for the Mann-Whitney U test in case of continuous variables and the χ2 test for categorical variables.
Evaluation of staining
All immunohistochemical scores are shown in Figure 1. Primary tumors with a metastasis 
had a significantly lower ER expression compared to primary tumors without a metastasis 
(p = 0.04) This was attributable to a significantly lower ER expression (p = 0.02) in primary 
tumors with a distant metastasis compared to those without a metastasis, as there were 
no differences between primary tumors with an intra-abdominal metastasis and primary 
tumors without a metastasis. Moreover, distant metastases had a significantly lower PR 
expression than the corresponding primary tumor (p = 0.04) as well as than intra-abdominal 
metastases (p = 0.04).
Both PTEN (p = 0.02) and p16 (p < 0.01) expression was significantly increased in metastatic 
lesions compared to the corresponding primary tumor. This difference was caused by a 
significantly increased expression of PTEN (p = 0.05) and p16 (p = 0.01) in intra-abdominal 
metastases compared to the corresponding primary carcinoma. There were no significant 
differences between distant metastatic lesions and the corresponding primary tumor in 
PTEN and p16 expression, although there was a trend towards increased p16 expression in 
distant metastases compared to the corresponding primary tumor.
Other, non-significant observations were loss of β-catenin in distant metastases, loss of 
E-cadherin in all metastases, increased expression of L1CAM in distant metastases, increased 
expression of p53 in EECs with distant metastases and in all metastatic lesions, and finally 
loss of p21 in EECs with metastases, but not in the corresponding metastases. 
Discussion
In this study primary EECs with distant metastases were shown to have a significantly 
reduced immunohistochemical expression of ER compared to EECs without metastases, and 
had a significantly lower expression of PR than corresponding primary tumors as well as 
intra-abdominal metastases. In contrast, intra-abdominal metastases were found to have 
and increased expression of PTEN and p16 compared to the corresponding primary EEC. 
ER and PR in distant metastasis
In line with the previous literature, we found ER expression to be significantly lower in 
EECs with distant metastases compared to EECs confined to the uterus. Moreover, the ER 
expression was significantly lower in distant metastases than in intra-abdominal metastases. 
The carcinogenesis of EECs is thought to be directly related to estrogen and progesterone 
exposure, and binding of these hormones to their respective receptor leads to specific 
phenotypic effects.17 Estrogen promotes cell proliferation, inhibits apoptosis and modulates 
tumor suppressor function, and loss of ER and PR have been shown to be independent 
prognostic factors for survival and recurrence in many studies.2, 18 Moreover, loss of ER has 
been described in recurrences of endometrial carcinomas, and ER and PR expression in 
grade 2 and 3 EECs has been associated with an improved outcome.9, 19 Finally, it has been 
previously shown that loss of ER and PR in preoperative endometrial biopsies is related to 
lymphogenous spread.10 
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Figure 1. Immunohistochemical scores of primary EECs without metastases (control), of primary EECs with 
metastases and the corresponding metastases (case), of primary EECs with locoregional metastases and the 
corresponding metastases, and of primary EECs with distant metastases and the corresponding metastases.
PTEN and p16 in intra-abdominal metastasis
We found that expression of PTEN is significantly higher in intra-abdominal metastatic 
lesions than in the corresponding EECs. Inactivation of PTEN frequently occurs in EECs, but 
seldom in aggressive, non-endometrioid endometrial carcinomas.20, 21 
In addition, increased expression of p16 was found in intra-abdominal metastases compared 
to the corresponding primary carcinomas. Previous studies looking at p16 in EECs have shown 
conflicting results. Several studies have associated a decreased expression of p16 with a 
poor prognosis in endometrial carcinomas, whereas others found increased p16 expression 
to be associated with high FIGO stage in grade 3 EECs and to be expressed in the invasive 
front of endometrial carcinomas.22-27 A possible explanation for these conflicting data might 
be the fact that CDKN2A alterations can occur through homozygous deletion, promoter 
hypermethylation, or point mutations, all leading to different immunohistochemical 
expression patterns.24, 28, 29 Increased expression of p16 might for example reflect 
accumulation of dysfunctional proteins as is frequently observed in p53 expression.18 
The differences found in PTEN and p16 expression between intra-abdominal metastases 
and corresponding primary tumors might have been the results of tumor heterogeneity, or 
the presence of mixed histology.2 Expression of PTEN and p16 in endometrial carcinomas 
has been associated with serous histology, and expression of PTEN has been described in 
the serous component of mixed carcinomas.30, 31 Serous carcinomas have been shown to 
be prone to metastasize intra-abdominal.12 It is possible this component was missed either 
when sampling the primary tumor or when creating the TMA.
It is worth noting that many different are reported in studies assessing PTEN and p16 
expression in endometrial carcinomas. A semiquantitave staining index developed for 
research purposes was used in the current study. For the possible future use of PTEN and 
p16 expression in the management of endometrial carcinomas consensus should be reached 
about standardized scoring systems. 
Other molecular markers
Expression of E-cadherin, p53 and L1CAM, other known predictors of poor survival, was 
not significantly different between the groups.7, 8 There was a trend towards increased 
p53 expression in primary EECs with distant metastases. Moreover, metastatic lesions 
had an increased p53 expression and a decreased E-cadherin expression compared to the 
corresponding primary tumor. Complete absence of p53 staining has been associated with 
the presence of TP53 nonsense mutations and a poor prognosis.32 However, completely 
p53 negative cases did not have a high MIB1 staining index, and were distributed equally 
among all subgroups (data not shown).33, 34 They were therefore categorized as negative. 
Finally, increased expression of L1CAM was found in distant metastases compared to the 
corresponding primary EECs, primary EECs without metastatic disease and intra-abdominal 
metastases. The number of lesions might not have been sufficient to find significant 
differences for these markers. L1CAM for example is known to be expressed only in a 
minority of the EECs, and only in a few in this study.8 
Implications for the management of endometrial carcinomas
Dividing endometrial carcinomas into two subgroups has proven to be a simple and effective 
way to individualize treatment . In addition to this, many immunohistochemical markers of 
poor prognosis have been identified, which might be used in the future to characterize and 
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treat endometrial carcinomas.6-8 More recently, molecular markers of poor prognosis have 
also been identified and a new subdivision completely based on the molecular profile of 
endometrial carcinomas has even been proposed by The Cancer Genome Atlas.3-5 
The findings of the current study confirm that ER and PR are strong and useful pre- and 
postoperative markers. This study also shows that, like in ovarian carcinomas, intra-
abdominal metastases of EECs have a distinct molecular profile.13 
In this light of these findings it is interesting to compare our study to that of Soslow et 
al., which compares recurrences instead of metastases to the corresponding primary 
tumor.35 Based on both morphological and molecular comparison they conclude that 
there are only subtle differences between primary carcinomas and recurrences, which are 
possibly the result of either tumor progression or suboptimal sampling. The most notable 
immunohistochemical difference they describe is a reduced expression of PR in recurrences 
compared to the primary carcinoma. A substantial number of cases was found to have 
ambiguous or mixed histology, and peritoneal metastases in their study were related to the 
presence of serous histology. All cases with p16 over expression had serous histology.
The findings of both their study and the current study suggest that more extensive sampling 
and immunohitochemical analysis of the primary tumor is worthwhile, especially when the 
metastasis and primary tumor are immunohistochemically discordant.
Strengths and weaknesses
To our knowledge, this is the first study analyzing a large set of immunohistochemical 
markers in a cohort of EEC patients with histologically proven metastatic disease on both 
the primary tumors and the metastatic lesions. In addition, the control group was matched 
for tumor grade, avoiding possible bias in the immunohistochemical comparison between 
patients with and without metastatic disease. 
A limitation might be the fact that, in accordance with national guidelines, no routine 
lymphadenectomy was performed and only suspicious lesions were surgically removed.36 
This means the absence of metastatic disease was not histologically proven for most 
patients in the control group. However, none of these patients developed recurrent disease 
during a median follow-up period of 44 months, which makes it highly unlikely there were 
metastatic lesions at the time of the primary treatment. Although the use of TMA slides has 
been validated for most markers in this study, they might not be an accurate reflection on 
heterogenic markers. For example, a heterogeneous staining pattern of MLH1 and PMS2 has 
previously been described.37 However, two representative areas were selected per case, the 
number of cases with no MLH1 or PMS2 expression was in accordance with the literature.38, 
39 
Conclusion
This study confirms there is a strong association between loss of ER and PR from primary 
EECs and distant spread of the disease. However, it also shows expression of PTEN and p16 
in intra-abdominal metastases is comparable to that of serous carcinomas, and not to the 
corresponding primary tumor. Immunohistochemistry of metastatic lesions in addition to 
primary EECs might be of value in managing endometrial cancer and future research should 
clarify the underlying processes of tumor progression and investigate the implications of 
these immunohistochemical findings.
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Abstract
Background
Treatment of clinical early-stage endometrioid endometrial cancer (EEC) in The Netherlands 
consists of primary hysterectomy and bilateral salpingo-oophorectomy. Adjuvant 
radiotherapy is given when 2 or more of the following risk factors are present: 60 years 
or older, grade 3 histology, and 50%ormore ofmyometrial invasion.Lymphovascular space 
invasion (LVSI) is a predictor of poor prognosis and early distant spread. It is unclear whether 
adjuvant radiotherapy is sufficient in patients with LVSI-positive EEC.
Materials and Methods
Eighty-one patients treated from 1999 until 2011 for stage I LVSI positive EEC in 11 Dutch 
hospitals were included. The outcomes of patients with 0 to 1 risk factors were compared 
with those with 2 to 3 risk factors, and both were compared with the known literature.
Results
Eighteen patients presented with recurrent disease, and 12 of those recurrences had a 
distant component. Overall and distant recurrence rates were 19.2% and 11.5% in patients 
with 0 to 1 risk factors followed by observation and 25.5% and 17% in patients with 2 to 3 
risk factors who received adjuvant radiotherapy. Only 1 patient with grade 1 disease had a 
recurrence.
Conclusion
In stage I LVSI-positive EEC with 0 to 1 risk factors, observation might not be adequate. 
Moreover, despite adjuvant radiotherapy, a high overall and distant recurrence rate was 
observed in patients with 2 to 3 risk factors. The use of systemic treatment in these patients, 
with the exception of patients with grade 1 disease, should be investigated.
Introduction
Endometrial cancer is the most common gynecologic malignancy in postmenopausal 
women in developed countries. Most patients present with endometrioid endometrial 
cancer (EEC) at an early stage and have a favorable prognosis.1 Primary treatment consists 
of hysterectomy and bilateral salpingo-oophorectomy. Risk factors for recurrent disease are 
myometrial invasion ≥50%, grade 3 histology, and an age of 60 years or older.2-4 External 
beam radiotherapy (EBRT) and vaginal brachytherapy (VBT) have been shown to reduce the 
risk of locoregional recurrence when at least two of these three risk factors are present. 
However, the morbidity of VBT was significantly less than that of EBRT.5-7 Therefore, adjuvant 
treatment of patients with stage I EEC and at least two of the three risk factors consists of 
VBT in the Netherlands.8 
Despite the good prognosis of stage I EEC, factors leading to an unexpected worse outcome 
are still under investigation. Lymphovascular space invasion (LVSI) has been reported as an 
important factor in poor outcome and is associated with a reduced progression-free and 
overall survival, as well as increased lymph node metastasis.3, 9-11 Concerning the adjuvant 
treatment of patients with stage I endometrial cancer with LVSI, two studies demonstrated 
that EBRT is superior to both observation and VBT.12, 13 In contrast, other studies showed 
that VBT is equally effective to EBRT in patients with endometrial cancer and LVSI.7, 14 In the 
presence of LVSI, both lymphadenectomy and systemic treatment have been proposed.3, 15, 
16 So far, the implications of LVSI in patients with stage I EEC on either primary or adjuvant 
treatment have not been well established. If there is a strong association between LVSI and 
distant spread, adjuvant radiotherapy is expected to be of limited value in LVSI-positive EEC.3, 
17, 18 Moreover, all these studies look at centrally diagnosed LVSI, while this is commonly 
done by the primary pathologist. As the interobserver variability of LVSI is unknown, the 
exact relevance of these findings on the daily clinical practice is not known.
The aim of the current study was to examine the recurrence pattern in patients with 
stage I, LVSI-positive EEC, as diagnosed by the primary pathologist, who received adjuvant 
radiotherapy based on the presence of two or three risk factors. Furthermore, the aim was 
to evaluate whether or not the use of radiotherapy in these patients is sufficient, or if more 
aggressive therapy may be warranted.
Materials and Methods
Patients and treatment
Patients treated within the Comprehensive Cancer Center South (CCCS, a collaboration 
between nine hospitals in the Netherlands) between January 2005 and December 2011, and 
at the Radboud university medical center and the Canisius-Wilhelmina Hospital in Nijmegen, 
the Netherlands, between January 1999 and January 2009, were reviewed for inclusion. 
Only patients with surgical stage I EEC  according to the 2009 criteria of the International 
Federation of Gynecology and Obstetrics (FIGO), and documented LVSI, as indicated in the 
primary pathologist’s report, were included.4 LVSI was defined by the presence of malignant 
cells in endothelial-lined channels and was assessed on hematoxylin and eosin stained 
slides as previously described.19, 20 Patients were treated according to the Dutch guidelines.8 
In cases of clinical stage I EEC, a hysterectomy and bilateral salpingo-oophorectomy with 
sampling of suspicious nodes is advised. Based on the Post-Operative Radiation Therapy in 
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Endometrial Carcinoma (PORTEC) trials, adjuvant radiotherapy is advised in the presence 
of at least two out of three risk factors (myometrial invasion ≥50%, grade 3 histology, and 
age ≥60 years).5, 6 Observation is recommended if <2 risk factors are present. Patients with 
histological types of endometrial cancer other than endometrioid, patients who did not 
undergo a hysterectomy and bilateral salpingo-oophorectomy, and patients who received 
either neoadjuvant treatment or adjuvant chemotherapy were excluded.
Patient data were extracted from files at the hospital where the patient received treatment. 
Age, date of diagnosis, date of surgery, type of surgery, lymphadenectomy, origin and 
number of dissected lymph nodes, tumor grade, myometrial invasion, adjuvant treatment, 
date of last follow-up, date of recurrence, location of recurrence, treatment for recurrence, 
date of death, and cause of death were recorded. Vaginal recurrences and pelvic masses 
were considered local recurrences, pelvic and iliac lymph node metastases were considered 
regional recurrences, and all others were considered distant recurrences. All histological 
data were retrieved from the primary pathologist’s report and were not reviewed centrally. 
No ethical approval was needed for this observational study according to the Code of 
Conduct for the use of data in Health Research (Dutch federation of Biomedical Scientific 
Societies, www.federa.org).
Outcome
Primary outcome was defined as the recurrence rate location related to primary and 
adjuvant therapy. 
Secondary outcome was defined as the demographic and tumor characteristics of patients 
with recurrence. 
Statistical analysis
Differences between patients who had a recurrence and those who did not were assessed 
using the Student’s t-test for parametric data; the Mann-Whitney U test for non-parametric 
data; and the χ2, the Fisher exact, and the Freeman-Halton exact tests for categorical 
data. Differences were considered significant at a p-value ≤ 0.05. Patients were compared 
with respect to age, duration of follow-up, risk factors, primary treatment, and adjuvant 
treatment. The same was done when comparing patients who were followed by observation 
and those who received adjuvant treatment. Three year disease-free and overall survival 
was calculated using the Kaplan-Meier method. IBM SPSS 20.0 (SPSS IBM, New York, NY, US) 
was used for statistical analysis of the data.
Results
Patients and treatment
In total, 81 patients with stage I, LVSI-positive EEC were included in this study (51 from the 
CCCS and 30 from the two hospitals in Nijmegen). Clinical and tumor characteristics of all 
included patients, as well as patients stratified according to adjuvant therapy, are shown in 
Table 1. Out of the 81 included patients, 32 (39.5%) were followed by observation only and 
49 (60.5%) received adjuvant radiotherapy. The median time of follow-up was 48 months 
(range 5–134) for all patients and and 50 months (range 12-134) for those not deceased. 
All patients underwent a hysterectomy and bilateral salpingo-oophorectomy. Additional 
lymphadenectomy was performed in 16 patients (19.8%) and as only patients with surgical 
stage I EEC were included, all nodes were shown to be disease free. 
Table 1. Demographic and tumor characteristics of all patients combined and patients grouped by 
adjuvant treatment.
All No adjuvant 
treatment
Adjuvant 
radiotherapy p
c
Patients 81 32 49
Mean age in years 67 (sd 9.1) 66 (sd 10.5) 68 (sd 7.9) 0.25
Median months follow-up 48 (5–134) 47 (5–113) 49 (8–134) 0.34
Surgery 0.72
Laparotomy 55 (67.9%) 21 (65.6%) 34 (69.4%)
Minimally invasive 26 (32.1%) 11 (34.4%) 15 (30.6%)
Lymphadenectomy 16 (19.8) 9 (28.1%) 7 (14.3%) 0.16
Grade 0.10
1 21 (25.9%) 11 (34.4%) 10 (20.4%)
2 40 (49.4%) 17 (53.1%) 23 (46.9%)
3 20 (24.7%) 4 (12.5%) 16 (32.7%)
Myometrial invasion <0.01
<50% 22 (27.2%) 20 (62.5%) 2 (4.1%)
≥50% 59 (72.8%) 12 (37.5%) 47 (95.9%)
Age <0.01
<60 years 15 (18.5%) 11 (34.4%) 4 (8.2%)
≥60 years 66 (81.5%) 21 (65.6%) 45 (91.8%)
Risk factors <0.01
0–1 28 (34.6%) 26 (81.3%) 2 (4.1%)
2–3 53 (65.4%) 6 (18.7%) 47 (95.9%)
Adjuvant treatment
VBTa 22 (27.2%) - 22 (44.9%)
EBRTb 23 (28.4%) - 23 (46.9%)
VBT + EBRT 4 (4.9%) - 4 (8.2%)
Recurrence
Total 18 (22.2%) 5 (15.6%) 13 (26.5%) 0.29
Local 4 (4.9%) 2 (6.3%) 2 (4.1%) 0.65
Regional 5 (6.2%) - 5 (10.2%) 0.15
Distant 12 (14.8%) 3 (9.4%) 9 (18.4%) 0.35
Death of disease 9 (11.1%) 2 (6.3%) 7 (14.3%) 0.31
aVaginal brachytherapy, bExternal beam radiotherapy, cp-values for Student’s t-test for parametric data, the 
Mann-Whitney U test for non-parametric data, and the χ2, Fisher exact, and Freeman-Halton exact tests for 
categorical data
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Treatment was according to the recommended guidelines in 26/28 (92.9%) patients with 
0–1 risk factors who were followed by observation and 47/53 (88.7%) patients with 2–3 risk 
factors who received adjuvant radiotherapy. In total, 73/81 (90.1%) patients were treated 
according to the recommended guidelines. The reasons for the discrepancy between the 
actual treatment and the guidelines varied from patients or clinicians preference to the 
fact that some patients were not eligible for radiotherapy. Other than the presence of the 
three risk factors, there were no significant differences between patients being observed 
and those receiving adjuvant radiotherapy. Adjuvant radiotherapy consisted of VBT in 22 
(44.9%) patients and EBRT+/-VBT in 27 (55.1%) patients. 
Outcome
A total of 18 (22.2%) patients were diagnosed with recurrent disease. The recurrences had 
a local component in four (22.2%) patients, a regional component in five (27.8%) patients, 
and a distant component in 12 (66.7%) patients. This results in local, regional, and distant 
recurrence rates of 4.9%, 6.2%, and 14.8%, respectively. Nine patients (11.1%) died as a 
consequence of endometrial cancer, eight of whom had a distant recurrence.
Characteristics of patients with and without recurrent disease are shown in Table 2. With 
respect to the primary treatment, there was no significant difference in the recurrence rate 
among patients that underwent open surgery compared to those who underwent minimally 
invasive surgery (p = 0.92), nor between patients who underwent a lymphadenectomy (with 
negative nodes) and those who did not undergo a lymphadenectomy (p = 0.62). 
Only one of the patients with grade I EEC in this study recurred. Consequently, the number 
of patients with grade 2 or 3 disease was significantly higher in the population of patients 
who had a recurrence compared to the patients who did not.
All but one of the recurrences were found in patients who received adjuvant treatment 
according to the guidelines. The overall and the distant recurrence rate in patients with 0–1 
risk factors followed by observation (n=26) were 19.2% and 11.5%, respectively. In patients 
with 2–3 risk factors who received adjuvant radiotherapy (n=47) they were 25.5% and 17%. 
There were no differences with respect to the recurrence rate when comparing VBT to EBRT 
+/- VBT (data not shown). 
The four year disease-specific and disease-free survival rates were 87% and 77%, respectively. 
They  were 91% and 77%, respectively, for patients with 0–1 risk factors who were followed 
by observation, and 85% and 75% for those with 2–3 risk factors who received adjuvant 
radiotherapy.
Table 2. Demographic, tumor, and treatment characteristics of patients with or without recurrent 
disease.
 Recurrence No recurrence pc
Patients (% of total) 18 (22.2%) 63 (77.8%)
Mean age in years 69 (sd 9) 66 (sd 9.2) 0.30
Median months to recurrence 19 (4–63) -
Surgery 0.78
Laparotomy 13 (72.2%) 42 (66.7%)
Minimally invasive 5 (27.8%) 21 (33.3%)
Lymphadenectomy 4 (22.2%) 12 (19%) 0.75
Grade
1 1 (5.6%) 20 (31.7%) 0.03
2 12 (66.7%) 28 (44.4%)
3 5 (27.8%) 15 (23.8%)
Myometrial invasion 1.00
<50% 5 (27.8%) 17 (27%)
≥50% 13 (72.2%) 46 (73%)
Age 1.00
<60 years 3 (16.7%) 12 (19%)
≥60 years 15 (83.3%) 51 (81%)
Risk factors 1.00
0–1 6 (33.3%) 22 (34.9%)
2–3 12 (66.7%) 41 (65.1%)
Adjuvant treatment
Observation 5 (27.8%) 27 (42.9%) 0.29
Radiotherapy 13 (72.2%) 36 (57.1%)
VBTa 9 (50%) 13 (20.6%) 0.71
EBRTb+/-VBT 4 (22.2%) 23 (36.5%)
aVaginal brachytherapy, bExternal beam radiotherapy, cp-values for Student’s t-test for parametric data, the 
Mann-Whitney U test for non-parametric data, and the χ2, Fisher exact, and Freeman-Halton exact tests for 
categorical data
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Discussion
In this retrospective study of 81 patients with stage I, LVSI-positive EEC, a recurrence rate of 
22.2% was observed. The majority of these recurrences had a distant component, especially 
in patients with 2–3 risk factors. In the presence of 0–1 risk factors and after observation 
the recurrence rate was 19.2%, while it was 25.5% in patients with 2–3 risk factors, despite 
adjuvant radiotherapy. Only one of the patients with grade 1 histology had recurrent disease. 
The current practice of treating patients with two or three risk factors with adjuvant 
radiotherapy is based on data from multiple large studies. In the PORTEC I trial, 714 patients 
with stage I endometrial cancer with 0–3 risk factors were randomly assigned to observation 
or EBRT.5 Keys et al. performed a comparable study in patients with FIGO 1988 stage Ib, Ic, 
and IIa endometrial cancer who underwent a lymphadenectomy.12, 21 These studies showed 
that, in patients that did not receive adjuvant radiotherapy, the overall recurrence rate was 
15.3–16.7%, and the distant recurrence rate was 5.6–6.4%. In patients that received EBRT, 
these rates were 6.8–9.9% and 5.3–6.8%, respectively. Both studies showed that adjuvant 
EBRT reduced locoregional recurrence in stage I EEC patients with two or three risk factors. 
Subsequently, EBRT was replaced by VBT in The Netherlands, since the PORTEC II trial 
showed that this was equally effective in preventing locoregional recurrence, but with a 
significantly reduced morbidity.6
When comparing these results to the current study, it must be noted that in the current 
study patients were not randomized, but treated according to the presence of risk factors, 
which leads to a selection bias. Our data show that observation might not be sufficient 
when LVSI is present next to 0–1 risk factors, as they had a much higher recurrence rate than 
patients with comparable risk factors and treatment who were not selected based on the 
presence of LVSI, as assessed by the primary pathologist. Moreover, the overall (25.5%) and 
distant (17%) recurrence rate in patients with LVSI-positive EEC next to 2–3 risk factors who 
received adjuvant radiotherapy were much higher than those of patients with comparable 
risk factors and treatment who were not selected based on the presence of LVSI, as assessed 
by the primary pathologist.5, 12, 14 In our study, all patients who died of endometrial cancer 
had recurrent disease and all but one had a distant component. A group of patients that did 
exceptionally well were those with grade 1 EEC. Even in the presence of the other two risk 
factors, only one of these patients recurred.
It is hypothesized that patients with stage I, LVSI-positive EEC and two or three risk factors 
may have a high risk of distant recurrence, which would not be reduced by any form of 
adjuvant radiotherapy.18 Compared to recurrence rates in studies of patients with stage I 
endometrial cancer who were not selected based on the presence of LVSI, our results show 
that LVSI in stage I EEC appears to be a predictor of distant recurrence. 
Several studies have shown LVSI to be an independent predictor of poor prognosis and an 
indication of early distant spread in patients with stage I EEC.3, 9, 22, 23 While these studies 
all had central pathology review done, the current study included patients who had LVSI 
according to the primary pathologist. Interestingly, the findings of these studies are in line 
with our findings in the clinical practice setting. It is therefore worthwhile to investigate the 
role of adjuvant treatment in patients with LVSI and 0–1 risk factors and adjuvant systemic 
treatment in with LVSI and 2–3 risk factors, which has previously been proposed.15, 16 An 
exception may be made for patients with grade 1 disease and two risk factors, who seem to 
have an excellent prognosis with radiotherapy alone. 
The strength of this study is the inclusion of a large number (n = 81) of a very specific group 
of patients with stage I, LVSI-positive EEC. Most other studies include either a small number 
of patients with stage I, LVSI-positive EEC or include other histological types and higher-
stage disease. Only in the study by Simpkins et al. was a large group of patients with LVSI-
positive, early-stage endometrial cancer included.24 Moreover, none of the studies looked 
specifically at the impact of LVSI on the treatment of stage I EEC based on the number of 
present risk factors. 
The statistical power of our study is limited by the low event rate and the lack of a LVSI-
negative control group. Moreover, there has been a selection bias because only patients 
with 2–3 risk factors were to receive adjuvant radiotherapy and very few of these patients 
were followed by observation alone, which is no surprise given the proven value of adjuvant 
radiotherapy in preventing locoregional recurrence. However, this selection bias does not 
interfere with the research questions. 
Finally, the fact that there was no central pathology review might be seen as a shortcoming 
which reduces the relevance of this study. However, while all previous studies had central 
review and a very detailed description of the LVSI present, this is not in line with clinical 
practice. With this study we wanted to demonstrate that the presence of LVSI, when 
assessed in daily practice, is of prognostic relevance. Criteria for the presence of LVSI were 
used by the primary pathologist in accordance with the known literature.19, 20 This means 
there was no systematic assessment of for example retraction artifacts, pseudoinvasion, 
artificial vascular involvement and immunohistochemically stained slides. The impact of 
these aspects on our findings is unknown. But as it was shown that even LVSI diagnosed by 
the primary pathologist has prognostic importance in stage I EEC, the need to include these 
aspects in the assessment of the primary pathologist should be studied.  
In conclusion, when LVSI is present in stage I EEC patients with 0–1 risk factors, adjuvant 
radiotherapy might prove to be beneficial. Moreover, in patients with LVSI and 2–3 risk factors 
a substantial overall and distant recurrence rate is observed, despite adjuvant radiotherapy. 
The use of systemic treatment in these patients should be investigated, possibly with the 
exception of patients with two risk factors and grade 1 disease, who showed a favorable 
outcome.
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Abstract
Background
Myometrial invasion (MI) as a percentage (%MI), categorized into <50% or ≥50%, is an 
important predictor of prognosis in endometrial carcinoma. Recent studies suggest that 
tumor free distance (TFD) to serosa and the absolute depth of invasion (DOI) might be 
stronger predictors of prognosis. Although reproducibility is important in clinical practice 
for patient prognostication and treatment, reproducibility of these methods for the 
measurement of MI is largely unknown.
Materials and Methods
One or two slides from 50 patients with FIGO stage I endometrioid endometrial carcinoma 
were viewed by seven gynecological pathologists, who were requested to measure %MI, 
TFD and DOI. We categorized %MI as <50% (including no MI) or ≥50%, TFD as ≤1.75mm 
or >1.75mm (including no MI), ≤7mm or >7mm (including no MI), and ≤10mm or >10mm 
(including no MI) and DOI as <4mm (including no MI) or ≥4mm. Light’s kappa for multi-rater 
agreement was calculated. 
Results
The %MI, TFD and DOI could be measured in 88%, 83% and 79% of cases, respectively. 
Kappa was 0.75 for %MI, 0.77, 0.73 and 0.69 respectively for TFD with cut-offs of 1.75mm, 
7mm and 10mm, and 0.59 for DOI. 
Conclusion 
Pathologists reach substantial agreement when measuring %MI and TFD, and moderate 
agreement when measuring DOI. The %MI can be measured in more cases than TFD and 
DOI. This supports the use of %MI in daily clinical practice, but future studies should compare 
%MI and TFD more extensively, including inter-observer variability.
Introduction
Endometrial carcinoma is the most common gynecological malignancy in developed 
countries, and its incidence is increasing.1, 2 Primary treatment of endometrial carcinoma 
consists predominantly of hysterectomy and bilateral salpingo-oophorectomy. Additional 
staging is typically undertaken for non-endometrioid and high grade endometrioid 
carcinomas, and when tumor stage is advanced. Most patients are diagnosed with FIGO 
stage I disease and low grade (grade 1 or 2) endometrioid histology and have a good 
prognosis.2 After primary surgery, the decision to administer adjuvant radiotherapy to 
prevent locoregional recurrences relies on the presence of predictors of poor outcome, such 
as high tumor grade, lymphovascular space invasion, deep myometrial invasion (MI) and 
patient age >60 years.2
Traditionally, the percentage of myometrial invasion (%MI), categorized as < 50% or ≥50%, 
is one of the parameters used in the determination of the need for adjuvant radiotherapy.3-5 
However, more recently, two other methods of measuring MI been proposed: tumor-free 
distance to serosa (TFD, the distance in millimeters between the deepest point of invasion 
and the serosa) and absolute depth of invasion (DOI, the distance in millimeters between 
the endometrial/myometrial junction and the deepest point of MI). A study comparing TFD 
and DOI and another study comparing %MI, TFD and DOI concluded that TFD is superior in 
predicting disease extension as well as outcome.6, 7 Two comparable studies, on the other 
hand, have shown that DOI is superior in predicting nodal involvement, recurrent disease, and 
disease related mortality.8, 9 One study comparing TFD and DOI concluded that DOI is a stronger 
predictor of outcome, but TFD is easier to measure, but kappa statistics were not reported.10
If measurement of TFD or DOI is superior to that of %MI, it might improve identification of 
high risk patients and individualization of adjuvant treatment. However, reproducibility of 
these measurements is important to support their prognostic value in daily clinical practice. 
Because all previous studies were single-center studies and measurements were performed 
by a limited number of pathologists, reproducibility of TFD and DOI is currently unknown. 
Some studies have reported on reproducibility of %MI, but only one study included kappa 
statistics with a kappa value of 0.83.11 The aim of our study was to assess inter-pathologist 
reproducibility of %MI, TFD and DOI.
Materials and Methods
Included cases
Slides from patients treated for stage I endometrioid endometrial carcinoma at the Radboud 
university medical center (Radboudumc), Nijmegen, the Netherlands, between January 
1999 and December 2009 were reviewed by a gynecological pathologist (JB). 
All pathologists collaborating in the European Network for Individualized Treatment of 
Endometrial Cancer (ENITEC) were invited to participate in this study, and seven expressed 
their interest. The sample size calculation was based on previous studies assessing 
reproducibility of the %MI measurement, as the kappa for TFD and DOI measurements 
is unknown.11-14 Based on a kappa of 0.8 for %MI, we calculated that 50 cases should be 
included in order to have 90% assurance that the two-sided 95% confidence interval would 
be no more than 0.1.11, 15
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Myometrial invasion measurement
All cases were assessed independently by seven expert gynecological pathologists who work 
in large referral centers (AW, KV, CB, SG, BD, WGM and GT), using the same set of slides. 
Scoring was performed according to the instructions shown in Figure 1.
Figure 1. Scoring instructions.
For every case the presence of MI had to be determined. In cases with MI, the three 
different methods for MI, as shown in Figure 2, needed to be scored: %MI (not measurable, 
<50% or ≥50%), TFD (not measurable or the number of millimeters from the deepest point 
of invasion to the serosa) and DOI (not measurable or the number of millimeters from the 
endometrial/myometrial junction to the deepest point of invasion). Moreover, a perception 
of the difficulty of each measurement (easy, moderate or difficult) had to be reported by 
each pathologist. There was also an option to provide comments after every measurement.
Statistical analysis
For statistical analysis, %MI was categorized as <50% (including no invasion) or ≥50%. 
Reproducibility of TFD was calculated for all three previously reported cut-off values: 
≤1.75mm or >1.75mm (including no invasion), ≤7mm or >7mm (including no invasion), and 
≤10mm or >10mm (including no invasion).6, 7, 9, 10 Only one earlier study described a cut-off 
for DOI, which was categorized as <4mm (including no invasion) or ≥4mm.9 
Light’s Kappa for multi-rater agreement was calculated for categorized %MI, TFD and DOI 
scores, bootstrapped (1000 runs) and 95% confidence intervals were calculated. Missing 
scores were excluded in a pairwise fashion. Kappa was categorized into slight (0.01-0.20), 
fair (0.21-0.40), moderate (0.41-0.60) substantial (0.61-0.80) or almost perfect (0.81-0.99) 
agreement.16 R statistical software was used to perform the calculations.17
Figure 2. Drawing of the different measuring methods in an endometrial carcinoma with <50% myometrial invasion. 
The dotted lines show the position of the endometrial/myometrial junction (EMJ), and the line where the tumor 
would invade half of the myometrium (50% MI). The arrows show the Absolute Depth of Invasion (A) and Tumor 
Free Distance (B) measurements.
Results
Myometrial invasion measurement
The results of the measurements are shown in Table 1. As there were 50 cases, measured 
by seven pathologists, a total of 350 measurements were possible per method. In 95% 
of the 350 measurements the pathologists were able to assess whether or not there was 
MI, ranging from 82% to 100% of the 50 measurements per pathologist. For the %MI, 
TFD and DOI measurements this was 88% (64-98%), 83% (78-88%) and 79% (24-100%), 
respectively. For the presence of MI and the measurement of TFD the median number of 
measurements per case available to calculate Light’s multi-rater kappa, was 7, for the %MI 
measurement this was 6.5 and for the DOI measurement 6. Almost all cases had two or 
more measurements per method, allowing calculation of a kappa value. In four cases, it was 
impossible to calculate the kappa value for the TFD measurement, because no or only one 
measurement was performed.
The pathologists reported MI in 76% of the measurements with a kappa of 0.63, and ≥50% 
myometrial invasion in 28% of the measurements with a kappa of 0.75. The median TFD 
was 7mm (range 0.8 to 19mm). TFD was ≤1.75mm in 6%, ≤7mm in 38% and ≤10mm in 53% 
of the measurements, with kappa values of 0.77, 0.73, and 0.69, respectively. Median DOI 
was 5mm (range 0.1mm to 25mm), and ≥4mm in 43% of the measurements, with a kappa of 
0.59. Examples of cases with good or poor reproducibility are shown in Figure 3.
Difficulties in measuring myometrial invasion
Table 2 shows how the pathologists rated the difficulty of the three measurements relative 
to the percentage of cases measured. For the %MI the number of measurements performed 
with a reported difficulty was 211, for TFD this was 201 and for DOI 189. The measurements 
were perceived to be easy in 54% for %MI, 72% for TFD and 24% for DOI; they were moderate 
in 30% for %MI, in 21% for TFD and in 43% for DOI and difficult in 16% for %MI, in 7% for TFD 
and in 33% for DOI. For all three measurements the kappa value of the perceived difficulty 
was smaller than 0.1.
3MI
⃝ <5Y3
⃝ ≥5Y3
⃝ Easy
⃝Moderate
⃝ Diﬃcult ⃝ Not measurable
1
Depth of Invasion
……………………………mm
⃝ Easy
⃝Moderate
⃝ Diﬃcult ⃝ Not measurable
⃝
No MI
Tumor Free Distance
……………………………mm
⃝ Easy
⃝Moderate
⃝ Diﬃcult ⃝ Not measurable
-R Iden�fy the right slideOs4
3R Score 3MIk DOI and TFD
4R Indicate how diﬃcult
the scoring was
5R Check when you were
not able to perform this
measurement
6R Room for notes
2R Check when you think
there is no myometrial
invasionR You can skip 365
A
B
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Table 1. Characteristics and reproducibility of myometrial invasion measurements
Number of cases 50
Measurements possible per method 350
Is there myometrial invasion?
Measurable 331 (95%)
Range 82-100%
Median measurements per case 7
Range 3-7
No 79 (24%)
Yes 252 (76%)
Kappa (95% confidence interval) 0.63 (0.5-0.78)
Percentage of myometrial invasion
Measurable 307 (88%)
Range 64-98%
Median measurements per case 6.5
Range 3-7
<50% 220 (72%)
≥50% 87 (28%)
Kappa (95% confidence interval) 0.75 (0.60-0.87)
Tumor free distance
Measurable 291 (83%)
Range 78-88%
Median measurements per case 7
Range 0-7
Median tumor free distance 7mm
Range 0.8-19mm
>1.75mm 273 (94%)
≤1.75mm 18 (6%)
Kappa (95% confidence interval) 0.77 (0.60-0.90)
>7mm 181 (62%)
≤7mm 110 (38%)
Kappa (95% confidence interval) 0.73 (0.60-0.85)
>10mm 137 (47%)
≤10mm 154 (53%)
Kappa (95% confidence interval) 0.69 (0.54-0.79)
Depth of invasion
Measurable 275 (79%)
Range 24-100%
Median measurements per case 6
Range 2-7
Median depth of invasion 5mm
Range 0.1-25mm
<4mm 156 (57%)
≥4mm 119 (43%)
Kappa (95% confidence interval) 0.59 (0.41-0.76)
Table 2. Difficulty of the myometrial invasion measurements of cases with myometrial invasion
%MI TFD DOI
Percentage measurable 88% 83% 79%
Number of measurements with MI and 
known difficulty 211 201 189
Percentage difficulty (range)
Easy 54% (21-77) 72% (59-93) 24% (0-39)
Moderate 30% (23-54) 21% (4-50) 43% (28-68)
Hard 16% (0-29) 7% (0-23) 33% (24-64)
Figure 3. Several examples of slides scored in this study. Slides A and B were scored with little agreement 
concerning the DOI, and it was commented that it was hard to distinguish the endometrial/myometrial 
junction. Slides C and D on the other hand were scored with perfect agreement for all measurements.
Table 1. Characteristics and reproducibility of myometrial invasion measurements (continued)
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Discussion
This study shows that gynecological pathologists reach substantial agreement when 
measuring %MI and TFD and moderate agreement when measuring DOI. Pathologists found 
measuring DOI more difficult than measuring %MI and TFD.
Myometrial invasion measurement
It is widely accepted that high tumor grade, non-endometrioid histology, lymphovascular 
space invasion, and deep myometrial invasion are predictors of poor prognosis in endometrial 
carcinoma and important parameters to decide on individualized treatment.2 Although 
many studies reported on reproducibility of tumor grading and histological typing, reports 
on reproducibility of assessment of MI and lymphovascular space invasion is limited.18-21 One 
study reported a kappa value of 0.83 for two pathologists measuring myometrial invasion in 
177 cases of endometrial cancer.11 Other studies determined the percentage of agreement 
between pathologists when measuring MI, but without calculating the kappa value. Ali 
et al. reported a discrepancy between the original %MI and the specialist reviewer %MI 
measurement in 12% of endometrial cancer cases.14 Jacques et al. reported discrepancies 
between MI measured by the pathologist who reported the case and a reviewing pathologist 
in 31.5% of cases.12 In that study, MI was categorized as not present, less than one third, and 
equal to or more than one third and discrepancies most commonly resulted in upstaging 
from no to less than one third MI. A comparable study by Chafe et al. described differences 
between the original pathology report and a review in 34% of 226 cases, but the percentage 
of cases with discrepancies in the categorization of %MI was not separately mentioned.13 
Lindauer et al. assessed the prognostic value of the TFD measurement in 153 cases, but the 
reproducibility between two pathologists was only determined in five cases.6
We show that gynecological pathologists reach substantial agreement with respect to the 
presence of MI and the measurement of %MI and TFD, and moderate agreement with 
respect to the measurement of DOI.16 Interestingly, for both %MI and TFD reproducibility 
was better than for assessment of the presence of MI. This is in line with the studies of 
Jacques et al. and Ali et al., who found most discrepancies between cases with no MI and 
cases with superficial MI.12, 14 Because the revised 2009 FIGO staging system does not 
differentiate between no MI and superficial MI, this finding does not affect staging and has 
been shown to be of no clinical significance.22. 
In comparing agreement between pathologists with respect to %MI, TFD and DOI 
measurements, the best agreement was reached when measuring TFD with a cut-off of 
1.75mm. This was closely followed by the %MI measurement, and TFD with cut-offs of 7 
and 10mm. The most relevant cut-off for TFD needs to be determined, but the differences 
in reproducibility are small and probably without clinical importance, as are the differences 
between the reproducibility of the %MI and TFD measurements. 
Measuring MI is more difficult in the presence of an irregular endometrial/myometrial 
junction, of a polypoid tumor or of adenomyosis, and also when the pattern of MI is 
unusual, such as diffusely infiltrative, or microcystic, elongated and fragmented (MELF).12, 
23-26 Because these are not yet regularly reported in daily clinical practice, this was beyond 
the scope of our study. However, it would be interesting to analyze the effect of different 
invasion patterns on the reproducibility of MI measurements. 
Difficulties in measuring myometrial invasion
Pathologists found measurement of DOI more difficult than that of %MI and TFD, which is 
reflected in the lower average reproducibility of these measurements. However, perception 
of difficulty per case varied widely between pathologists, as reflected in a low kappa value.
Comments of the participating pathologists indicated that sampling and sectioning of the 
endometrium and myometrium varies between institutions. Nonetheless, moderate to 
substantial agreement was obtained. However, further standardization of the guidelines 
might decrease inter-observer variability of these three measurements, which might improve 
their prognostic value. Possible improvements might be 1) standardization of the method to 
open the uterus as well as the location and direction in which the tissue samples are taken 
relative to the tumor, the myometrium, and the serosa, 2) photographic documentation of 
the specimen and 3) standardization of identification of the deepest point of invasion and 
the definition of the endometrial/myometrial junction. 
Strengths and weaknesses of this study
This is the largest study assessing inter-pathologist reproducibility of MI measurement and 
the first assessing the reproducibility of the TFD and DOI measurement. Although the 95% 
confidence intervals of the kappa values were slightly wider than expected, in part due 
to the fact that not all measurements were performed, they remained acceptable. For a 
study on reproducibility in daily practice, our use of slides from daily practice rather than 
cases optimized for measurability makes the results relevant for daily practice. A limitation 
is that these slides were from one institution, while significant differences exist between 
institutions regarding sectioning and measuring procedures. Standardization of guidelines 
might further improve inter-observer reproducibility. 
Conclusions
We show that gynecological pathologists reach substantial agreement when measuring %MI 
and TFD, but only moderate agreement when measuring DOI. Measurement of %MI and 
TFD was perceived to be easier than DOI measurement and %MI was the measure most 
often successful. This supports use of %MI but also of TFD. These two parameters merit 
further study, always by at least two pathologists as this will provide insight in inter-observer 
variability. Guidelines for gross examination, sectioning, and measuring of MI should be 
standardized to improve the inter-observer variability and improve on prognostic value.
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Abstract
Background
Identification of aggressive endometrioid endometrial carcinomas (EEC) and non-
endometrioid carcinomas (NEEC) is essential to improve outcome. L1 cell adhesion 
molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known 
about L1CAM expression in advanced-stage EECs, and NEECs. This study analyzes L1CAM 
expression in a clinically representative cohort of endometrial carcinomas.
Materials and Methods
The expression of L1CAM was immunohistochemically determined in 1199 endometrial 
carcinomas, treated at one of the European Network for Individualized Treatment of 
Endometrial Cancer (ENITEC) centers. Staining was considered positive when >10% of the 
tumor cells expressed L1CAM. The association between L1CAM expression and several 
clincopathological characteristics and disease outcome was calculated.
Results
In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced-stage 
EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced 
stage, nodal involvement, high tumor grade, non-endometrioid histology, lymphovascular 
space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, 
but not in the NEECs.
Conclusion
The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. 
It is strongly associated with non-endometrioid histology and distant spread, and could 
improve the postoperative selection of high-risk endometrial carcinomas. The value of 
L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should 
be studied.
Introduction
Endometrial carcinoma is the most common gynecological malignancy in developed 
countries.1 These carcinomas can be histologically classified as either endometrioid 
endometrial carcinomas (EECs) or non-endometrioid endometrial carcinomas (NEECs).2, 
3 In general, EECs have a favorable prognosis, and are characterized by expression of the 
estrogen en progesterone receptors, microsatellite instability and PTEN, KRAS, PIK3CA, 
and CTNNB1 mutations. The most common NEECs have serous or clear cell histology, 
and a worse prognosis. They are characterized by TP53 mutations, and PTEN and PIK3CA 
mutations, respectively. Less common carcinomas with non-endometrioid histology are 
those with undifferentiated histology, characterized by microsatellite instability, those with 
mucinous histology, with a prognosis and molecular characterization similar to EECs, and 
the carcinosarcomas. However, a substantial number of endometrial carcinomas do not fit 
within this dualistic model, and have mixed histology or hybrid molecular and histological 
characteristics, which makes the diagnosis challenging.2 After primary surgery, adjuvant 
treatment is recommended based on the presence of predictors of poor outcome, most 
importantly FIGO stage. Additionally, the prognosis is related to histological type, tumor 
grade, myometrial invasion, lymphovascular space invasion (LVSI), and the age of the patient.4 
More recently a new subdivision into four subgroups, based on the molecular profile, was 
proposed by The Cancer Genome Atlas Research network.5 However, these data have not 
been incorporated in clinical practice yet. In addition, several immunohistochemical markers 
have been shown to be associated with poor outcome. Expression of the transmembrane 
L1 cell adhesion molecule (L1CAM) seems to be one of the most powerful ones described 
to date. The L1CAM plays an important role in neurogenesis, but has been associated with 
poor outcome in various cancer types.6-14 Two large studies have shown a strong association 
between L1CAM expression in stage I EEC and poor disease outcome.15, 16 However, there was 
a wide variation both in the percentage of cases expressing L1CAM, and in the strength of the 
association between L1CAM and disease outcome found by these studies. More recently, 
several smaller studies have highlighted the association between L1CAM expression and 
poor disease outcome in advanced-stage EECs, and NEECs, as well as a strong association 
between L1CAM expression and non-endometrioid histology.17-19 However, these studies 
have limited clinical applicability because neither of these studies analyzed the subgroups 
separately, and the number of included advanced-stage EECs and NEECs is still limited. In 
addition, Dellinger et al. used mRNA L1CAM expression with a different cut-off than the 
other studies, which limits the comparability. 
The aim of the current study is therefore to analyze the value of immunohistochemical 
L1CAM expression in a large, clinically representative cohort of endometrial carcinomas, 
including substantial numbers of all histological types and FIGO stages.
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Materials and Methods
Patients
This study was performed within the European Network for Individualized Treatment of 
Endometrial Cancer (ENITEC), a European Society of Gynecological Oncology (ESGO) 
consortium aiming to improve and individualize treatment of women with uterine cancers 
by sharing expertise. All ENITEC members were invited to participate in this study and to 
include patients treated for stage I EEC (a maximum of 150 cases per center), stage II-IV 
EEC, or NEEC. Cases with any non-endometrioid component were included in the NEEC 
group, except for the mucinous carcinomas, that were included in the EEC groups as their 
characteristics and prognosis are similar to that of endometrioid carcinomas.3 Only cases 
diagnosed by an expert gynecological pathologist, with complete data on treatment and 
pathology, and at least 36 months of follow-up were included. Clinical and pathological 
data were recorded from the patient files into a database, including patient age, date of 
diagnosis, surgical treatment (including lymphadenectomy and omentectomy), tumor 
histology and grade, myometrial invasion, cervical invasion, LVSI, FIGO stage, adjuvant 
treatment (including radiotherapy, chemotherapy and chemoradiation), residual disease, 
recurrent disease, and death. 
Tissue and staining
One representative slide was selected per case. Blank 4µm sections, cut from the corresponding 
formalin fixed, paraffin embedded tissue blocks, on Superfrost slides were sent to the 
Radboud university medical center. A hematoxylin and eosin and an immunohistochemically 
stained L1CAM slide were made for every case. Immunohistochemical staining was 
performed in semiautomatic staining devices using an optimized version of the previously 
described staining protocol.20 In short, after EDTA antigen retrieval and blocking of 
endogenous peroxidase with hydrogen peroxide, slides were incubated with 1:100 diluted 
L1CAM antibody (purified anti-CD171 (L1) antibody clone 14.10, Biolegend, San Diego, CA, 
US). They were subsequently incubated with PowerVision+ Poly-HRP and visualized with 
PowerVision DAB substrate solution (Leica Biosystems, Buffalo Grove, IL, US). Finally, the 
slides were counterstained with hematoxylin, dehydrated, and mounted. Staining of the 
nerves was used as internal positive control.
Scoring
All slides were scored twice, by independent pathologists. First by N. Visser or K. van de 
Vijver, and subsequently by M. Santacana, P. Bronsert or J. Bulten. They were blinded for 
clinical and pathological data, as well as each other’s scores. They were asked to score the 
number of stained tumor cells as 0%, 1-10% 11-50% or 51-100%, and cases were considered 
to express L1CAM when one or both pathologists considered >10% of the tumor cells to 
be stained, in accordance with the previously described cutoff.15, 16, 18 Cohen’s Kappa was 
calculated for L1CAM expression as a dichotomous variable (either ≤10% or >10%). In 
case of large discrepancies (i.e. if one pathologist scored 0% and the other 11-100%, or if 
one pathologist scored 1-10% and the other 51-100%) the slides were reviewed by a third 
pathologist who did not score the slide initially (either N. Visser or J. Bulten). 
Statistical analysis
Clinicopathological differences between L1CAM positive and negative cases were compared 
using the χ2 and Fisher exact tests for categorical and the Mann-Whitney U-test for 
continuous variables, and corresponding p-values are shown in Tables 1-4. 
The association between L1CAM expression and other known risk factors expressed as an 
odds ratio (OR) and corresponding 95% confidence interval (95% CI), was calculated using 
univariate logistic regression analysis. These risk factors were deep myometrial invasion, 
patient age over 60 years, LVSI, non-endometrioid (except mucinous) histology, advanced 
FIGO stage, and nodal involvement.
Kaplan-Meier curves of 10-year disease-free and overall survival were generated for the 
stage I EEC, stage II-IV EEC, and NEEC subgroups. The corresponding hazard ratio (HR) and 
95% CI was calculated using Cox regression analysis. For stage I EECs a multivariate analysis 
was performed including covariates which were significantly associated with outcome in the 
univariate analysis. Sample size calculation accounted only for multivariate Cox regression 
analysis of the stage I EECs.
Statistical differences were considered significant at a two-sided p-value ≤0.05. SPSS version 
22 (SPSS IBM, New York, NY, US) statistical software was used to perform the statistical 
analyses.
Ethical approval
The study was approved by the institutional review board (IRB) of all participating centers.
Results
L1CAM in endometrial carcinomas
There were 1199 cases included from ten European centers, including 935 stage I EECs, 
160 stage II-IV EECs and 104 NEECs. L1CAM was expressed in 200 (17%) cases, and was 
scored with a κ of 0.82. Table 1 shows demographic and tumor characteristics of all cases 
and a comparison between the L1CAM-negative and -positive cases. These two groups 
were significantly different concerning demographics, treatment, tumor characteristics and 
disease outcome. 
In univariate regression analysis, L1CAM expression was significantly associated with 
advanced stage (OR 5.1, 95% CI 3.5-7.3), nodal involvement (OR 5.0, 95% CI 3.2-7.7), and 
non-endometrioid histology (OR 24.0, 95% CI 14.8-38.8).
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Table 1. Comparison of the clinical and pathologic characteristics and disease outcome of all 
included carcinomas with respect to the L1CAM expression.
All L1CAM- L1CAM+ pc
Number of patients 1199 999 (83%) 200 (17%)
Median age (years) 64 (range 31-93) 63 (range 31-93) 69 (range 39-93) <0.01
Median follow-upa (months) 62 (range 0-229) 64 (1-229) 50 (range 0-185) <0.01
Treatment
Lymphadenectomy 795 (66%) 645 (65%) 150 (75%) <0.01
Radiotherapy 563 (47%) 467 (47%) 96 (48%) 0.86
Chemotherapy 123 (10%) 72 (7%) 51 (26%) <0.01
FIGO stage
I 965 (80%) 849 (85%) 116 (58%) <0.01
II 74 (6%) 58 (6%) 16 (8%)
III 125 (10%) 76 (8%) 49 (25%)
IV 35 (3%) 16 (2%) 19 (10%)
Histology
Endometrioid 1095 (91%) 973 (97%) 122 (61%) <0.01
Non-endometrioid 104 (9%) 26 (3%) 78 (39%)
Grade
1 467 (39%) 441 (44%) 26 (13%) <0.01
2 474 (40%) 417 (42%) 57 (29%)
3 258 (22%) 141 (14%) 117 (59%)
Myometrial invasion
<1/2 746 (62%) 656 (66%) 90 (45%) <0.01
≥1/2 453 (38%) 343 (34%) 110 (55%)
LVSIb
No 813 (83%) 723 (88%) 90 (60%) <0.01
Yes 162 (17%) 101 (12%) 61 (40%)
Unknown 224 175 49
Outcome
Residual disease 40 (3%) 15 (2%) 25 (12.5%) <0.01
Recurrence 158 (13%) 100 (10%) 58 (33%) <0.01
Locoregional 76 (7%) 57 (6%) 19 (11%) 0.02
Distant 98 (8%) 53 (5%) 45 (26%) <0.01
Deceased 171 (14%) 104 (10%) 67 (34%) <0.01
Endometrial carcinoma 99 (8%) 48 (5%) 51 (26%) <0.01
aMedian follow-up including deceased patients bLymphovascular space invasion, cp-value for the Mann-
Whitney U test for continuous variables, and Chi square test for categorical variables
L1CAM in stage I endometrioid endometrial carcinomas
Patient and tumor characteristics of all stage I EEC cases (n = 935, including four mucinous 
carcinomas) with respect to L1CAM expression are shown in Table 2. L1CAM was expressed 
in 93 (10%) cases. These patients were older, had a higher tumor grade and LVSI, and more 
often presented with distant recurrence and disease-related mortality. 
In univariate regression analysis, L1CAM expression was significantly associated with grade 
3 histology (OR 4.1, 95% CI 2.5-6.8) and LVSI (OR 2.9, 95% CI 1.5-5.6), but not with deep 
myometrial invasion.
Table 2. Comparison of the clinical and pathologic characteristics as well as disease outcome of 
stage I endometrioid endometrial carcinomas with respect to L1CAM expression.
All L1CAM- L1CAM+ pc
Number of patients 935 842 (90%) 93 (10%)
Median age (years) 63 (range 32-93) 63 (range 32-91) 67 (range 39-93) <0.01
Median follow-upa (months) 64 (range 1-210) 65 (range 1-210) 55 (range 6-185) <0.01
Treatment
Lymphadenectomy 586 (63%) 519 (62%) 67 (72%) 0.05
Radiotherapy 400 (43%) 359 (43%) 41 (44%) 0.79
VBT 206 (22%) 189 (23%) 17 (18%)
EBRT+/-VBT 190 (20%) 166 (20%) 24 (26%)
Chemotherapy 36 (4%) 31 (4%) 5 (5%) 0.42
Grade <0.01
1 442 (47%) 418 (50%) 24 (26%)
2 389 (42%) 348 (41%) 41 (44%)
3 104 (11%) 76 (9%) 28 (30%)
Myometrial invasion 0.15
<1/2 664 (71%) 604 (72%) 60 (65%)
≥1/2 271 (29%) 238 (28%) 33 (36%)
LVSIb <0.01
No 703 (91%) 645 (92%) 58 (81%)
Yes 67 (9%) 53 (8%) 14 (19%)
Unknown 165 144 21
Outcome
Recurrence 85 (9%) 66 (8%) 19 (20%) <0.01
Locoregional 48 (5%) 41 (5%) 7 (8%) 0.27
Distant 42 (5%) 29 (3%) 13 (14%) <0.01
Deceased 88 (9%) 69 (8%) 19 (20%) <0.01
Endometrial carcinoma 37 (4%) 26 (3%) 11 (12%) <0.01
aMedian follow-up including deceased patients bLymphovascular space invasion, cp-value for the Mann-
Whitney U test for continuous variables, and Chi square test for categorical variables
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L1CAM in advanced-stage endometrioid endometrial carcinomas
Patient and tumor characteristics of all advanced-stage EEC cases (n = 160, including five mucinous 
carcinomas) with respect to L1CAM expression are shown in Table 3. L1CAM expression was 
present in 28 (18%) cases. These cases had a higher tumor grade, a more advanced FIGO stage, 
and more often presented with distant recurrence and disease-related mortality. 
In univariate regression analysis, L1CAM expression was significantly associated with the 
presence of nodal disease (OR 4.1, 95% CI 1.5-11.5) and LVSI (OR 3.0, 95% CI 1.1-8.0).
Table 3. Comparison of the clinical and pathologic characteristics as well as disease outcome of 
advanced stage endometrioid endometrial carcinoma cases with respect to L1CAM expression.
All L1CAM- L1CAM+ pc
Number of patients 160 131 (82%) 29 (18%)
Median age (years) 64 (range 37-93) 64 (range 37-93) 68 (range 47-84) 0.40
Median follow-upa (months) 55 (range 1-227) 58 (range 3-227) 37 (range 1-106) <0.01
Treatment
Lymphadenectomy 122 (76%) 103 (79%) 19 (65%) 0.13
Radiotherapy 112 (80%) 95 (73%) 17 (59%) 0.14
Chemotherapy 41 (26%) 31 (24%) 10 (36%) 0.23
Chemoradiotherapy 7 (5%) 6 (5%) 1 (4%) 1.00
FIGO stage
II 59 (37%) 54 (41%) 5 (18%) 0.02
III 83 (52%) 62 (47%) 21 (72%) 0.02
IV 18 (12%) 15 (12%) 3 (11%) 1.00
Grade 0.20
1 25 (16%) 23 (18%) 2 (7%)
2 82 (51%) 68 (52%) 14 (48%)
3 53 (33%) 40 (31%) 13 (45%)
Myometrial invasion 0.11
<1/2 43 (27%) 39 (30%) 4 (14%)
≥1/2 117 (73%) 92 (70%) 25 (86%)
LVSIb 0.052
No 67 (54%) 60 (58%) 7 (32%)
Yes 58 (46%) 43 (42%) 15 (68%)
Unknown 35 28 7
Outcome
Residual disease 19 (12%) 13 (10%) 6 (21%) 0.12
Recurrence 41 (26%) 28 (24%) 13 (57%) <0.01
Locoregional 15 (9%) 12 (10%) 3 (13%) 0.71
Distant 31 (19%) 20 (17%) 11 (48%) <0.01
Deceased 38 (24%) 25 (19%) 13 (45%) <0.01
Endometrial carcinoma 26 (16%) 16 (12%) 10 (35%) <0.01
aMedian follow-up including deceased patients bLymphovascular space invasion, cp-value for the Mann-
Whitney U test for continuous variables, and Chi square test for categorical variables
Table 4. Comparison of the clinical and pathologic characteristics as well as disease outcome of the 
non-endometrioid carcinoma cases with respect to L1CAM expression.
All L1CAM- L1CAM+ pc
Number of patients 104 26 (25%) 78 (75%)
Median age (years) 69 (range 31-88) 64 (range 31-83) 70 (range 49-88) <0.01
Median follow-upa (months) 46 (range 0-229) 52 (range 2-229) 45 (range 0-129) 0.15
Treatment
Lymphadenectomy 87 (84%) 23 (89%) 64 (82%) 0.56
Radiotherapy 51 (49%) 13 (50%) 38 (49%) 0.91
Chemotherapy 46 (44%) 10 (39%) 36 (46%) 0.50
FIGO stage
I 30 (39%) 7 (27%) 23 (30%) 0.73
II 15 (14%) 4 (15%) 11 (14%) 1.00
III 42 (40%) 14 (54%) 28 (36%) 0.11
IV 17 (16%) 1 (4%) 16 (21%) 0.06
Histology
Pure NEEC 76 (73%) 17 (65%) 59 (76%) 0.32
Mixed EEC/NEEC 28 (27%) 9 (35%) 19 (24%)
Primary NEEC component
Serous 61 (59%) 14 (54%) 47 (60%) 0.57
Clear Cell 22 (21%) 4 (15%) 18 (23%) 0.58
Carcinosarcoma 14 (14%) 5 (19%) 9 (12%) 0.33
Undifferentiated 7 (7%) 3 (12%) 4 (5%) 0.36
Myometrial invasion 0.13
<1/2 39 (38%) 13 (50%) 26 (33%)
≥1/2 65 (63%) 13 (50%) 52 (67%)
LVSIb <0.01
No 43 (54%) 18 (78%) 25 (44%)
Yes 37 (46%) 5 (22%) 32 (56%)
Unknown 24 3 21
Outcome
Residual disease 21 (20%) 2 (8%) 19 (24%) 0.09
Recurrence 32 (39%) 6 (25%) 26 (44%) 0.14
Locoregional 13 (16%) 4 (17%) 9 (15%) 1.00
Distant 25 (30%) 4 (17%) 21 (36%) 0.12
Deceased 45 (43%) 10 (39%) 35 (45%) 0.57
Endometrial carcinoma 36 (35%) 6 (23%) 30 (39%) 0.23
aMedian follow-up including deceased patients bLymphovascular space invasion, cp-value for the Mann-
Whitney U test for continuous variables, and Chi square test for categorical variables
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L1CAM in non-endometrioid carcinomas
Patient and tumor characteristics of all NEEC cases (n = 104) with respect to L1CAM expression 
are shown in Table 4. L1CAM expression was present in 78 (75%) cases, and varied between 
the subgroups: 77% of the serous carcinomas, 82% of the clear cell carcinomas, 64% of the 
carcinosarcomas, and 57% of the undifferentiated carcinomas expressed L1CAM. Patients 
with L1CAM expression were older, more often had LVSI, and more often presented with 
distant recurrences and disease related mortality.
In univariate regression analysis, L1CAM expression was significantly associated with the 
presence of LVSI (OR 4.6, 95% CI 1.5-14.1).
L1CAM expression and survival
The 10-year disease-free and overall survival Kaplan-Meier plots are shown in Figure 1. 
Corresponding HRs are shown in Table 5.
Multivariate analysis of the stage I EEC cases showed that expression of L1CAM is a strong 
and independent predictor of both reduced disease-free survival and overall survival, along 
with several known prognostic markers. Patient age >60 was the strongest predictor of 
reduced overall survival, but not of reduced disease specific survival (data not shown).
L1CAM expression and the presence of LVSI in advanced-stage EEC cases were significantly 
associated with reduced disease-free, and overall survival in univariate analysis. Grade 3 
histology and deep myometrial invasion predicted a reduced overall survival as well, but the 
myometrial invasion HR had a very wide CI.
Analysis of the NEEC cases showed that L1CAM expression is not associated with reduced 
disease-free and overall survival. Patient age >60 and advanced FIGO stage were associated 
with reduced disease-free survival, and the presence of LVSI and advanced FIGO stage were 
associated with reduced overall survival.
Figure 1. Kaplan-Meier plots of the 10-year disease-free and overall survival of the stage I endometrioid, 
advanced-stage endometrioid, and non-endometrioid cases, with respect to L1CAM expression.
Table 5. Results of the Cox regression analysis, depicting the association between several risk 
factors and outcome. The table shows Hazard Ratio’s and corresponding 95% Confidence Intervals. 
Bold Hazard Ratio’s are significantly associated with the respective outcome variable. For the 
stage I EEC subgroup, additional multivariate Cox regression analysis was performed, including 
covariates which were significantly associated with outcome in the univariate analysis. 
Stage I EEC Stage II-IV EEC NEEC
Univariate Multivariate Univariate Univariate
HRa (95%CIb) HR (95%CI) HR (95%CI) HR (95%CI)
DF
Sc
L1CAM+ 3.1 (1.9-5.1) 2.3 (1.3-4.1) 3.9 (2.0-7.7) 2.0 (0.8-4.8)
Grade 3 2.7 (1.6-4.4) 2.0 (1.1-3.5) 1.3 (0.7-2.5) -
MI>50% 1.5 (1.0-2.3) - 1.8 (0.8-4.0) 1.1 (0.6-2.7)
Age>60 2.0 (1.2-3.3) 2.0 (1.1-3.4) 1.3 (0.7-2.6) 4.2 (1.0-17.7)
LVSI 2.9 (1.6-5.1) 2.3 (1.3-4.1) 3.1 (1.5-6.7) 1.8 (0.8-4.1)
FIGO 3/4 - - 1.6 (0.8-3.2) 2.6 (1.3-5.4)
OS
d
L1CAM+ 3.1 (1.9-5.2) 2.4 (1.4-4.2) 3.7 (1.9-7.3) 1.6 (0.8-3.3)
Grade 3 2.8 (1.7-4.6) 2.1 (1.1-3.6) 2.7 (1.4-5.1) -
MI>50% 1.3 (0.8-2.0) - 7.7 (1.9-32.0) 1.4 (0.8-2.7)
Age>60 2.8 (1.6-4.8) 2.9 (1.6-5.3) 2.0 (0.9-4.2) 1.7 (0.7-4.1)
LVSI 2.4 (1.3-4.4) 1.9 (1.0-3.4) 3.0 (1.4-6.2) 2.3 (1.1-4.7)
FIGO 3/4 - - 1.6 (0.8-3.4) 3.7 (1.8-7.5)
aHazard Ratio, b95% Confidence Interval, cDisease-free Survival, dOverall Survival
Discussion
This large, well-documented series of 1199 endometrial carcinomas shows a strong 
association between L1CAM expression and poor outcome in stage I EECs and advanced-
stage EECs, but not in NEECs. Moreover, L1CAM expression was shown to be associated 
with the presence of nodal disease, grade 3 histology, LVSI, distant disease recurrences, but 
especially with non-endometrioid histology. 
Prognostic value of L1CAM expression in stage I endometrioid carcinomas
Two large studies have described the prognostic value of L1CAM expression in stage I EECs. 
Zeimet et al. found L1CAM expression in 17% of the cases, with HRs of 16.33 for recurrence 
and 15.01 for death.15 The PORTEC group found L1CAM expression in 7%, with HRs of 2.55 
for pelvic recurrence, 3.48 for distant recurrence, and 2.05 for death.16 In comparison, we 
found L1CAM expression in 10% of the stage I EECs, with HRs of 2.3 for recurrences, 2.8 for 
distant recurrences, and 2.4 for death. 
The number of lymphadenectomies performed in our study was slightly higher than in the 
Zeimet study. The PORTEC study does not mention the exact number of lymphadenectomies, 
but it is described that routine lymphadenectomies were not performed, and only suspicious 
nodes were removed. Patients in our study received radiotherapy, especially external beam 
radiotherapy, more often than patients in the Zeimet study, but less often than those in 
the PORTEC study. Patients in the PORTEC study more often had a low grade tumor and 
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deep myometrial invasion, which was related to the inclusion criteria of the study. LVSI was 
present in a large number of carcinomas in the Zeimet study compared to both our study 
and the PORTEC study. 
It was hypothesized that a lower number of included grade 1 cases might explain the higher 
number of L1CAM positive cases in the Zeimet study.16 Although we show a strong association 
between L1CAM expression and grade 3 histology, our study included even fewer grade 1 
cases, which makes it unlikely this explains the difference in L1CAM expression. As we show 
a strong association between the presence of L1CAM expression and LVSI it is possible that 
the high prevalence of LVSI in the Zeimet study is responsible for the high number of L1CAM 
positive cases, and the exceptionally strong association between L1CAM expression and 
poor outcome they describe.
Several smaller studies included stage I EECs in addition to advanced-stage EECs and NEECs. 
Unfortunately, both Van Gool et al. and Geels et al. did not analyze the value of L1CAM 
expression specifically in the stage I EECs, making it impossible to compare our findings to 
these studies.17, 18 Interestingly, Dellinger et al. included a sizeable amount of stage I EECs 
and analyzed the association between mRNA expression of L1CAM and prognosis, but 
were not able to validate the strong prognostic value of L1CAM expression.19 This might be 
explained by the fact that they considered all cases with an mRNA L1CAM expression above 
the median to be positive, which resulted in a much higher proportion of L1CAM positive 
cases in their study compared with other L1CAM studies.
Prognostic value of L1CAM expression in advanced-stage endometrioid carcinomas and 
non-endometrioid carcinomas
Several previous studies described the prognostic value of L1CAM expression in advanced-
stage EECs and NEECs. Fogel et al. described L1CAM expression in all of the ten included 
FIGO stage III and IV cases, but the histology was not mentioned, and three previous studies 
described L1CAM expression in 73% of the 15, 58% of the 12, and 55% of the 20 included 
NEEC cases.7, 15, 16 We found L1CAM expression in 75% of the 104 NEEC cases.
Three studies included both advanced-stage EECs and NEECs and described the association 
between L1CAM expression and clinicopathological variables, as well as between L1CAM 
expression and outcome.17-19 Geels et al. found an association between L1CAM expression 
and high tumor grade and LVSI, Dellinger et al. between L1CAM expression and advanced 
FIGO stage, non-endometrioid histology, high tumor grade, deep myometrial invasion, 
and nodal spread, and Van Gool et al. between L1CAM expression and non-endometrioid 
histology and high tumor grade, but not FIGO stage, depth of myometrial invasion, and LVSI. 
In comparison, we found an association between L1CAM expression and advanced FIGO 
stage, non-endometrioid histology, high tumor grade, LVSI, and nodal spread. We found 
these associations in all three subgroups, but unfortunately neither of these studies analyzed 
the association between L1CAM and clinicopathological variables within the subgroups.
 In addition, neither of these studies analyzed the disease-free and overall survival separately 
in the advanced-stage EECs and NEECs. Our subgroup analyses have shown that there is 
indeed a strong association between L1CAM expression and poor outcome in the advanced-
stage EECs, but not in the NEECs, possibly because the presence of non-endometrioid 
histology itself is a strong marker of poor prognosis, and the majority were L1CAM positive. 
The fact that previous studies have combined the advanced-stage EECs and the NEECs in 
the high risk carcinoma group might therefore have influenced their results, and additional 
studies are required to validate the prognostic value of L1CAM expression separately in the 
advanced-stage EECs and the NEECs. 
This study shows that there is a very strong association between L1CAM expression and the 
presence of non-endometrioid histology. Up until now, p53 expression has been used to 
identify NEECs, and whereas p53 is frequently expressed in serous carcinomas, it does not 
play an important role in other NEECs.3 Previous studies reported p53 expression in 62-67% 
of all NEECs, whereas we found L1CAM expression in 75% of the NEECs, including 77% of the 
serous and 82% of the clear cell carcinomas.17, 21 Based on these findings L1CAM expression 
appears to be the most powerful marker to identify NEECs described to date.  
Interestingly, Van Gool et al. did not find an association between L1CAM expression with a 
cut-off of 10% and poor outcome in their cohort of high-risk carcinomas, including high-risk 
stage I EECs, but did find this association when using a cut-off of 50%.17 We however did find 
an association between L1CAM expression with a cut-off of 10% and poor outcome in the 
advanced-stage EECs and NEECs, and preliminary analyses did not show a major advantage 
of using a higher cut-off (data not shown). Using one cut-off in all subgroups would be 
preferable, because having to determine the tumor histology, tumor grade, and the depth 
of myometrial invasion before choosing the L1CAM cut-off would greatly limit the clinical 
applicability. 
It has to be noted that mixed carcinomas were included in the NEEC group of our study, and 
pure non-endometrioid histology was more common in the L1CAM positive cases. There 
is a possibility that mixed cases with a large endometrioid component were considered 
L1CAM negative in our study, even though L1CAM was expressed in over 10% of the non-
endometrioid component. Although the presence of non-endometrioid histology itself is 
a marker of poor prognosis, it is interesting to see that those with L1CAM expression have 
an even worse prognosis, which is in agreement with previous findings in serous ovarian 
carcinomas. 
Relationship between these findings and the function of L1CAM
The L1CAM was shown to have several extracellular and intracellular functions in cancer, 
both in an intact and cleaved form, as it has an influence on cell migration, cell survival, 
angiogenesis and tumor progression.22-28 It is known that epithelial-mesenchymal transition 
(EMT) plays an important role in endometrial cancer invasion and metastasis.29 Several 
studies suggest that L1CAM expression induces an EMT-like transition that increases 
the metastatic potential, without altering the invasive capabilities. Comparable to EMT, 
expression of L1CAM was shown to be TGFβ and Slug dependent.30, 31 Moreover, several 
studies have shown that intracellular L1CAM signaling activates NF-κB, which was shown 
to be essential for EMT and metastasis of breast cancer.32-34 In colorectal cancer cell lines, 
L1CAM expression was shown to increase cell motility and liver metastasis, without changes 
in expression of epithelial or mesenchymal markers. Introduction of major EMT regulators 
changed expression of epithelial and mesenchymal markers, but did not increase the 
metastatic potential.35 Many clinical studies have shown that there is a strong association 
between L1CAM expression and metastasis in various cancer types.8-14 The current study 
shows a comparable association between L1CAM expression and advanced stage, lymph 
node involvement, and metastasis in both EECs and NEECs. Interestingly, there was no strong 
association between L1CAM expression and myometrial and cervical invasion, and although 
it was not scored separately in our study, the pathologists did not notice a clear localization 
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of L1CAM at the invasive front of the carcinomas. These findings are in accordance with the 
hypothesis that L1CAM induces EMT-like changes, but only plays a role in metastasis, and 
not invasion. 
However, several previous studies analyzing the association between L1CAM expression and 
clinicopathological variables present conflicting results concerning whether or not there 
is an association between L1CAM expression and the presence of LVSI, deep myometrial 
invasion, and cervical invasion.15-19 Future studies focusing on the function of L1CAM will 
likely provide more insight in the possible association between L1CAM and these processes 
of invasion and metastasis. 
Future perspectives
Accumulating data associating L1CAM expression in stage I EECs with a poor outcome 
should have treatment implications. Moreover, this study shows that L1CAM expression 
in advanced-stage EECs is associated with poor outcome as well, and there was a trend 
towards more residual disease after treatment, which is in line with L1CAM expression 
in ovarian carcinoma, which has been associated with restricted tumor resectability.13 
Although this would seem to support the use of chemotherapy, L1CAM expression in 
other cancer types has been shown to be associated with chemotherapy resistance.13, 26, 27 
Given the fact that a substantial number of advanced-stage EECs, and the majority of the 
NEECs are L1CAM positive, and a growing number of these carcinomas are treated with 
chemotherapy, studying the issue of resistance of L1CAM-positive tumors to chemotherapy 
has a high priority. In addition, the use of anti-L1CAM treatment might be an interesting 
future option.36 
This study also found a strong association between L1CAM expression and the presence 
of other markers of poor prognosis, most notably non-endometrioid histology, grade 3 
histology, and nodal disease. Once it is established that L1CAM expression in preoperative 
biopsies is in accordance with final pathology, incorporation into currently used preoperative 
prediction models might improve the selection of patients requiring a lymphadenectomy, and 
help pathologists to identify high-risk carcinomas, especially those with non-endometrioid 
histology.
In light of the recently proposed subdivision of endometrial carcinomas into four subgroups 
based on the molecular profile, it would be interesting to analyze the L1CAM expression 
in these four groups.5 The studies of both Dellinger et al. and Van Gool et al. looked at 
L1CAM expression in the mRNA data from the TGCA database, but unfortunately they 
did not describe the expression of L1CAM relative to the four proposed subgroups.17, 19 If 
either L1CAM expression or the proposed genetic subdivision are to be used in the future 
management of endometrial carcinomas, it is imperative to know how these markers are 
related to each other.
Strengths and weaknesses
This is the largest study to date including all endometrial carcinoma types. Complete surgical 
staging was performed in the majority of cases, limiting the risk of under diagnosis, and a 
minimal follow-up of 36 months was required, limiting the risk of missing disease recurrences 
and deaths. As this was a retrospective study, there has been no standardized treatment 
protocol, and there is the risk for selection bias. There was no centralized pathology review 
in this study, but all slides were from large referral hospitals with dedicated gynecological 
pathologists. This makes the results of this study applicable to daily practice in such hospitals.
Conclusion
In conclusion, this study shows the prognostic value of L1CAM expression in stage I EECs and 
advanced-stage EECs, but not in NEECs. L1CAM expression was associated with the presence 
of nodal disease, non-endometrioid histology, grade 3 histology, LVSI, and with a high risk 
of distant disease recurrence. Implementation of L1CAM expression in clinical practice 
could improve the postoperative selection of high-risk carcinomas. Both the value of L1CAM 
expression in the preoperative selection of high-risk carcinomas and the consequences of 
L1CAM expression on the use of and response to chemotherapy should be studied. 
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Abstract
Background 
Endometrial carcinoma mortality is mainly caused by recurrent disease, and the value of 
various immunohistochemical markers in predicting recurrences has been studied. Loss of 
the estrogen (ER) and progesterone receptor (PR), and expression of L1CAM are promising 
markers, but their combined value has not been studied yet. 
Materials and Methods
Expression of ER, PR and L1CAM was immunohistochemically determined in 293 endometrial 
carcinomas from 11 collaborating ENITEC centers. ER, PR, or L1CAM staining was considered 
positive or negative when expressed by >10% or ≤10% of the tumor cells, respectively. The 
association between these markers and clinicopathological markers, and their combined 
value in predicting survival were calculated. 
Results
Expression of ER and PR was lost in 19% and 28% of the cases, respectively, and L1CAM 
was expressed in 18%. All three markers were associated with advanced stage, high grade, 
non-endometrioid histology, lymphovascular space invasion (LVSI), and reduced disease-
free survival. Only advanced stage, loss of PR, and lymphovascular space invasion were 
independently associated with reduced disease-free survival in multivariate analysis. A 
prognostic model including these three markers was superior to models including only 
histological or immunohistochemical markers.
Conclusion
Loss of ER and PR, and expression of L1CAM are associated with high risk characteristics. 
For predicting recurrences, loss of PR appears to be more important than loss of ER or 
expression of L1CAM. A prognostic model including stage, PR expression, and LVSI instead 
of the traditional model including histological markers could improve the identification of 
high risk carcinomas. 
Introduction
Endometrial carcinoma is the most common gynecological malignancy in developed 
countries, and its incidence is increasing.1 These carcinomas are traditionally divided into 
endometrioid, and non-endometrioid endometrial carcinomas, based on their histology.1, 2 
Endometrioid carcinomas are assumed to arise from hyperplastic endometrium under the 
influence of unopposed estrogen stimulation, and generally have a favorable prognosis.1 
Non-endometrioid carcinomas on the other hand are assumed to arise from atrophic 
endometrium less dependent of estrogen stimulation, and have a worse outcome.1 
Primary treatment for endometrial carcinomas consists of a hysterectomy and bilateral 
salpingo-oophorectomy, and additionally a lymphadenectomy in high grade endometrioid, 
and non-endometrioid carcinomas. Adjuvant treatment is recommended based on FIGO 
stage, histological type, tumor grade, myometrial invasion, lymphovascular space invasion 
(LVSI), and the age of the patient.1 
Despite these recommendations, 15-20% of the carcinomas which are assumed to be low 
risk will recur, whereas 50% of the assumed high risk carcinomas will not.3 As the majority 
of the disease related mortality is caused by distant recurrences, additional markers are 
needed to identify cases at risk, and subsequently individualize the treatment.4, 5 Well 
studied markers that might be of value in improving the identification of high risk cases 
are immunohistochemical loss of the estrogen receptor (ER) and progesterone receptor 
(PR), and expression of the L1 cell adhesion molecule (L1CAM). Expression of ER and PR 
is common in the estrogen dependent endometrioid carcinomas, whereas loss of ER and 
PR, and expression of L1CAM are more common in the non-endometrioid carcinomas.1, 3, 
6-13 Loss of ER and PR, and expression of L1CAM have been associated with more aggressive 
disease, both in endometrioid and non-endometrioid carcinomas.3, 6-13 
However, although all three markers have been shown to be strong predictors of poor 
outcome, we only have limited knowledge about their combined value, which makes 
it difficult to translate these findings into daily clinical practice.12, 14 The aim of this study 
therefore is to analyze the relationship between these three markers, and to analyze the 
combined value of ER, PR and L1CAM in predicting recurrent disease.
Materials and Methods
Patients
Data and tissue were already collected for a study analyzing the value of L1CAM expression 
in endometrial carcinomas, which included endometrial carcinomas from 11 collaborating 
European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centers.13 
Cases with any non-endometrioid component were categorized as non-endometrioid. Only 
cases diagnosed by an expert gynecological pathologist, with complete data on treatment 
and pathological examination, and at least 36 months of follow-up were included. Clinical 
and pathological data were recorded from the patient files into a database. From the 1199 
cases included in the previous study, 300 were randomly selected using SPSS version 22 
(SPSS IBM, New York, NY, U.S.) statistical software.
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Tissue and staining
Blank 4µm formalin fixed, paraffin embedded sections on Superfrost slides, corresponding 
to previously stained sections, were immunohistochemically stained for expression of ER 
and PR. After EDTA antigen retrieval and blocking of endogenous peroxidase with hydrogen 
peroxide, slides were incubated for one hour with either anti-ER (SP1 RM-9101-S, Thermo 
Scientific, Waltham, MA, US) or anti-PR (PgR636, Dako, Glostrup, Denmark) diluted 1:80 or 
1:500, respectively, in Normal Antibody Diluent (Immunologic, Duiven, the Netherlands). They 
were subsequently incubated with PowerVision+ Poly-HRP and visualized with PowerVision 
DAB substrate solution (Leica Biosystems, Buffalo Grove, IL, US). Finally, the slides were 
counterstained with hematoxylin, dehydrated, and mounted. L1CAM staining was performed 
for a previous study using a 1:100 diluted L1CAM antibody (purified anti-CD171 (L1) antibody 
clone 14.10, Biolegend, San Diego, CA, US), and the protocol described above.13
Scoring
L1CAM expression was scored for a previous study.13 In brief, it was considered to be present 
when expression was seen in more than 10% of the tumor cells, regardless of histological 
type and disease stage.13 All ER and PR slides were scored twice for this study, first by LP and 
subsequently by either NV or KV. All were blinded for clinical and pathological data and each 
other’s scores. ER and PR were considered lost when expression was seen in less than 10% 
of the tumor cells. In case of disagreement, the final score was determined by JB, who was 
blinded for clinical and pathological data as well as the previous scores. 
Statistical analysis
Cohen’s kappa value was calculated to assess the interobserver variability of scoring ER and 
PR expression.
Clinical and pathological differences between cases with and without ER, PR, and L1CAM 
expression were calculated using the χ2 and Fisher’s exact tests for categorical, and the 
Mann-Whitney U test continuous variables. 
The association between ER, PR, and L1CAM expression and other known risk factors was 
calculated using univariate logistic regression analysis, expressed as odds ratios (OR) and 
95% confidence intervals (95%CI). Correlation between ER, PR, and L1CAM expression was 
calculated as well.
Using Cox regression analysis, the association between several risk factors, including ER, PR 
and L1CAM expression, and reduced 10-year disease-free survival was calculated, expressed 
as Hazard Ratios (HR) and 95%CI. A multivariate analysis was performed including covariates 
which were significantly associated with reduced disease-free survival in the univariate 
analysis. Different combinations of markers were compared. These combinations were:
1. Traditional histological: advanced FIGO stage or at least two of the following markers: 
LVSI, deep myometrial invasion, and high grade (including non-endometrioid histology).
2. Immunohistochemical: at least two of the three included immunohistochemical markers.
3. Combined classical and immunohistochemical markers: at least two of the seven 
histological and immunohistochemical markers included in this study.
4. Cox regression: at least two of the three markers independently associated with recurrent 
disease in the multivariate Cox regression analysis (advanced FIGO stage, loss of PR, and 
LVSI).
Sensitivity, specificity, positive predictive value, and negative predictive value of these 
combinations were calculated. 
Statistical differences were considered significant at a two-sided p-value ≤0.05. SPSS version 
22 (SPSS IBM, New York, NY, U.S.) statistical software was used to perform the statistical 
analyses.
Results
After immunohistochemically staining for ER and PR, 7 of the 300 cases were excluded 
because those slides did not contain endometrial carcinoma tissue. The kappa values of ER 
and PR scoring were 0.74 and 0.80, respectively, and revision was necessary in 26 (9%) and 
24 (8%) cases, respectively.
Clinical and pathological details of the remaining 293 cases, including 236 stage I 
endometrioid, 34 advanced stage endometrioid, and 23 non-endometrioid carcinomas, are 
shown in Table 1. This table also shows the characteristics of the subgroups with ER or PR 
loss, and L1CAM expression. Loss of ER and PR, and expression of L1CAM were found in 55 
(19%), 82 (28%), and 53 (18%), respectively. As shown in Table 1, cases with loss of ER or 
PR, and cases with L1CAM expression significantly more often had advanced stage disease, 
high grade endometrioid disease, non-endometrioid histology, and LVSI. Cases with loss 
of PR and cases with L1CAM expression also had deep myometrial invasion more often. 
Additionally, residual disease after surgery, recurrent disease, overall mortality, and disease 
related mortality, were more common in the cases with loss of ER and PR, and those with 
expression of L1CAM. Only locoregional recurrences were more common in cases with ER 
loss, whereas distant recurrences were more common in cases with L1CAM expression. 
Both locoregional and distant recurrences were more common in cases with loss of PR.
Regression analysis (Table 2) shows statistically significant associations between these three 
immunohistochemical markers and clinicopathological markers of poor prognosis. There 
was a particularly strong association between L1CAM expression and non-endometrioid 
histology (OR 24.2, 95%CI 5.5-20.9). Statistically significant associations between expression 
of the markers were also found, with correlation coefficients for ER/PR, ER/L1CAM, and PR/
L1CAM of 0.60, -0.27, and -0.46, respectively.
Table 2. Associations between loss of ER, loss of PR, and L1CAM expression with several clinical 
and pathological characteristics, expressed as Odds Ratios and 95% confidence intervals. Significant 
associations are bold. 
ER- PR- L1CAM+
FIGO stage 3 or 4 3.8 (1.7-8.3) 3.2 (1.5-6.8) 3.4 (1.5-7.5)
Non-endometrioid histology 5.8 (2.4 (14.0) 15.6 (5.1-47.6) 24.2 (8.4-69.2)
High gradea 6.2 (3.3-11.8) 8.2 (4.4-15.2) 10.7 (5.5-20.9)
Lymphovascular space invasion 3.6 (1.8-7.5) 3.7 (1.9-7.2) 4.9 (2.4-10.1)
Myometrial invasion ≥1/2 1.4 (0.8-2.7) 2.0 (1.2-3.3) 2.6 (1.4-4.7)
aBoth high grade endometrioid and non-endometrioid carcinomas
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Results from the Cox regression analysis are shown in Figure 1. All included markers, except 
age > 60 years, were associated with reduced 10-year disease-free survival in the univariate 
analysis. In the subsequent multi variate analysis, only advanced stage disease, loss of PR, 
and the presence of LVSI, were signifi cantly associated with reduced 10-year disease-free 
survival. 
Figure 1. Cox regression analysis, which shows the associati on between several risk factors and reduced disease-
free survival. The Hazard Rati o (HR) and corresponding 95% Confi dence Interval (95%CI) of the univariate analysis 
are depicted by the dott ed lines and the normal text. All risk factors signifi cantly associated with reduced disease-
free survival in univariate analysis were included in a multi variate Cox regression analysis, depicted by the 
uninterrupted lines and the bold text.
Additi onally, we explored the presence of the histological and immunohistochemical 
markers (ranked based on the HRs in Figure 1) in the individual recurrences in this study, 
including 18 locoregional, and 14 distant recurrences. As shown, recurrent case number 
1-5, including two distant recurrences, were not identi fi ed by any of the markers. The value 
of various combinati ons of histological and/or immunohistochemical markers in predicti ng 
recurrences was also explored, as depicted in Figure 2 and Table 3. The traditi onal histological
model was able to identi fy 14 recurrences, including 11 with a distant component, but also 
considered 38 cases that did not develop a recurrence to be at risk. When only the three 
immunohistochemical markers were used, 16 recurrences were identi fi ed, including 8 distant 
recurrences, but 38 cases that did not develop a recurrence were considered to be at risk. 
When histological and immunological markers were combined, 22 recurrences, including 
12 distant recurrences, were identi fi ed, but 73 cases which did not develop a recurrence 
were also considered to be at risk. Finally, when using the three markers identi fi ed by Cox 
regression analysis, 14 recurrences were identi fi ed, including 11 distant recurrences, and 15 
cases which did not develop a recurrence were considered to be at risk. 
Figure 2. The marker profi les of the 32 recurrences included in this study. On the left  side, the presence (red) or 
absence (green) of the risk factors which were signifi cantly associated with reduced disease-free survival in the 
univariate Cox regression analysis is shown, ordered based on the Hazard Rati o’s. The column labeled Distant 
shows whether the recurrence had a distant component (black) or only a locoregional one. On the right side of the 
fi gure it is shown if the recurrence was predicted (red) or not (green) by several marker combinati ons explored in 
this study. 
Table 3. Characteristi cs of various possible prognosti c models.
Sensiti vity Specifi city PPVa NPVb
1. Histological 44% 85% 27% 92%
2. IHC 50% 85% 30% 93%
3. Combined 69% 71% 15% 95%
4. Cox regression 44% 94% 48% 93%
aPositi ve predicti ve value, bNegati ve predicti ve value
Table 3 shows the test characteristi cs (sensiti vity, specifi city, positi ve predicti ve value, 
and negati ve predicti ve value) which were calculated based on the numbers above. 
Compared to the histological markers, the immunohistochemical markers had an equal 
specifi city, and a superior sensiti vity and positi ve predicti ve value. When all histological 
and immunohistochemical markers were combined, the sensiti vity increased, at the cost 
of a decreased specifi city and positi ve predicti ve value. Finally, the model using the three 
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markers which were significantly associated with reduced disease-free survival in the Cox 
regression analysis had a sensitivity equal to that of the traditional histological markers, and 
a much higher specificity and positive predictive value than any of the other combinations. 
The negative predictive value of all four combinations was almost the same.
Discussion
This study of a clinically representative cohort of 293 endometrial carcinomas shows that 
loss of ER, loss of PR, and expression of L1CAM are associated with clinicopathological 
markers of poor prognosis. Advanced FIGO stage, loss of PR, and LVSI were associated with 
recurrent disease in multivariate Cox regression analysis. When used to predict recurrences, 
the three significant markers from the Cox regression analysis were superior to using only 
histological or immunohistochemical markers.
Expression of ER, PR, and L1CAM separately 
ER and PR play an important role in the development of endometrial carcinomas, and 
loss of these markers is a characteristic of tumor progression.1, 6, 15 Consequently, many 
studies have shown that loss of these receptors is associated with a reduced disease-free 
and overall survival, as summarized in a recent meta-analysis.7 In our study, loss of ER and 
PR were associated with advanced stage disease, non-endometrioid histology, high tumor 
grade, and LVSI. Even though there are slight variations in the associations and the strength 
of the associations found by previous studies, they are generally in line with our findings, 
indicating that loss of these markers is associated with markers of poor prognosis like non-
endometrioid or high grade histology, advanced stage, lymph node metastasis, and LVSI.16-22
As expected, L1CAM expression was associated with advanced stage, non-endometrioid 
histology, high grade endometrioid histology, and LVSI.8-11, 13, 23, 24 However, in contrast to 
previous studies, we did not find an independent association between L1CAM expression 
and reduced disease-free survival. The percentage of recurrences, especially those with a 
distant component, was lower in the randomly selected cohort compared to the original 
one.13 Although this might be an explanation for the fact that L1CAM, which is assumed to be 
a strong marker of distant spread, was not associated with recurrent disease, the percentage 
of (distant) recurrences is comparable to that of two other studies which did find L1CAM 
expression to be of prognostic value.8-11, 13, 23, 24 Moreover, we found an association between 
L1CAM expression and reduced disease-free survival in univariate analysis, indicating that 
the other markers included in the multivariate regression are superior.
 
Combined value of ER, PR, and L1CAM expression
Our study is one of the very few which have studied the combined value of these three 
markers. We found that there is a strong association between expression of ER and PR, 
but the associations between expression of ER and PR and L1CAM were only moderate 
and weak, respectively. A previous study analyzed the correlation between expression of 
these three markers in endometrial carcinomas, but not their combined prognostic value.12 
Contrary to our findings, loss of ER and PR was observed in all L1CAM positive cases included 
in that study. This might be explained by the fact that this study did not use a cut-off value 
for L1CAM expression, but also included tumor foci with loss or ER and PR, and L1CAM 
expression. For our study, we did not perform such an in-depth analysis, but rather used the 
clinically relevant cut-off of 10%.
Interestingly, although all three markers were associated with reduced disease-free survival 
in univariate Cox regression analysis in our study, only loss of PR was an independent 
predictor of reduced disease-free survival. This is in line with multiple previous studies 
which have analyzed the additional value of ER and PR immunohistochemistry, and 
concluded that loss of PR was the most important sign of tumor progression.16, 18-20 The 
strong prognostic value of loss of PR might be explained by the fact that progesterone is 
a strong tumor suppressor, and by the fact that loss of PR has been shown to play a role 
in epithelial to mesenchymal transition (EMT), the process which is assumed to increase 
invasive and migratory capacities of cancer cells, and therefore assumed to be a driver of 
cancer progression.6, 15, 25, 26 Progesterone lowers the levels of multiple molecules involved in 
EMT, as well as the activity of the Wnt/β-catenin pathway, which plays an important role in 
EMT.26 Interestingly, the expression of PR was shown to be lower in metastatic endometrial 
carcinoma lesions compared to the corresponding primary tumor, which suggests that loss 
of PR plays a role in EMT.19, 27 Expression of L1CAM has also been related to both distant 
spread and EMT.12, 28-31 However, these studies show that expression of L1CAM is dependent 
on TGFβ signaling, and Wnt/β-catenin activity, both of which are inhibited by progesterone.6, 
15, 25, 26 This suggests that loss of PR precedes L1CAM expression, and might be a possible 
explanation for the fact that L1CAM expression is not an independent predictor in our study.
To our knowledge, only one other prognostic study included all three markers.14 That study 
analyzed the expression of these (and other) markers in relation to molecularly defined 
endometrial carcinoma subgroups, as proposed by The Cancer Genome Atlas research 
network.14, 32 These four distinct subgroups are the ultramutated and copy-number low 
groups, containing mainly endometrioid carcinomas with an intermediate prognosis, the 
copy-number high group, containing non-endometrioid and high grade endometrioid 
carcinomas with an unfavorable prognosis, and the hypermutated group, containing high 
grade endometrioid carcinomas with, unexpectedly, an excellent prognosis.32 Loss of ER and 
PR, and expression of L1CAM were mainly found in the copy-number high and hypermutated 
groups, and were associated with high grade disease, deep myometrial invasion, and 
LVSI.14 All three markers were shown to be associated with reduced survival in univariate 
regression analyses. Unfortunately, it was not further analyzed whether these markers were 
independent prognostic markers.
Future perspectives
Recurrences are an important cause of endometrial carcinoma related mortality, but so 
far we are not able to reliably predict disease recurrences based on the currently used 
histological prognostic model.3-5 Many immunohistochemical and genetic additions to 
the currently used predictive model have been proposed, but none of these have been 
translated to daily clinical practice.3, 5, 32 The current study is the first to study the combined 
value of immunohistochemical expression of ER, PR and L1CAM, three very promising 
prognostic markers. Interestingly, only loss of PR was shown to be an independent predictor 
of reduced disease-free survival, along with advanced FIGO stage and LVSI When combined 
into a prognostic model, these three markers were superior to the traditional histological 
model. The value of this new prognostic model should be validated. However, this study also 
highlights the fact that, even when adding ER, PR, and L1CAM expression, we are still unable 
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to predict a substantial number of recurrences, while we consider a substantial number 
of cases which will not develop a recurrence to be at risk. Future studies are warranted to 
clarify whether these recurrences can be predicted with other markers.3, 14, 32 
At the moment, the extent of surgery is based on the histological classification of small 
amounts of preoperatively obtained tumor tissue.1 Histological markers like myometrial 
invasion and LVSI, which play an important role in the postoperative prognostic model, 
cannot be reliably determined in endometrial biopsies. However, we found a strong 
association between loss of ER and PR, and expression of L1CAM, and the presence of 
histological markers of poor prognosis. Moreover, a prognostic model including only these 
three easily reproducible, immunohistochemical markers was shown to be superior to the 
traditional model (Table 3). The combined value of these markers in preoperative biopsies 
might therefore be valuable in the early identification of high risk carcinomas, and should 
be studied. Furthermore, all three markers have previously been implied to play a role in 
EMT, which might explain their prognostic value.6, 15 More studies are needed to understand 
this process and the markers involved, because this will help us understand the mechanism 
between expression or loss of these markers, and poor prognosis. Finally, treatment 
aimed specifically at these markers might be of value in personalizing the management of 
endometrial carcinomas.25, 33
Strengths and weaknesses
This is the first study analyzing the combined value of histological markers, and combined 
immunohistochemical expression of ER, PR and L1CAM in a clinically representative, well 
described cohort of endometrial carcinomas.13 Complete surgical staging was performed 
in the majority of cases, reducing the risk of incorrectly diagnosed early stage carcinomas, 
and a minimal follow-up of 36 months was required, reducing the risk of missing disease 
recurrences. Given the low event rate, the results of the (Cox) regression analyses should 
be interpreted with caution. However, because this is the first study to include all of these 
markers, and most previous studies including only ER and PR were smaller, these findings 
are still a strong indicator which can be used to design future (prospective) studies. As this 
was a retrospective study, there has been no standardized treatment protocol, and there is 
the risk for selection bias. There was no centralized pathology review in this study, but all 
slides were from large referral hospitals with dedicated gynecological pathologists. 
Conclusion
Immunohistochemical loss of ER and PR, and expression of L1CAM were shown to be easily 
reproducible markers, which were associated with other markers of poor outcome. Out 
of these three markers, only loss of PR was an independent predictor of reduced disease-
free survival. A prognostic model including the FIGO stage, PR expression, and LVSI, was 
shown to be superior to the currently used model including only histological markers, and 
this model should be validated. However, additional markers are needed to selectively 
predict all recurrences. Moreover, the value of these markers in the preoperative diagnosis 
of endometrial carcinomas, as well as the treatment consequences of expression of these 
markers, should be further studied.
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 “When people thought the earth was flat, they were wrong. 
When people thought the earth was spherical, they were wrong. 
But if you think that thinking the earth is spherical is just as wrong 
as thinking the earth is flat, then your view is wronger than both 
of them put together.”1
Categorizing endometrial carcinomas
Following surgical treatment of endometrial carcinomas, guidelines for the management of 
endometrial carcinomas recommend adjuvant radiotherapy based on tumor histology and 
differentiation grade, depth of myometrial invasion, and presence of lymphovascular space 
invasion.2, 3 However, despite management based on the presence of these markers, 15-20% 
of the carcinomas which are considered to be low risk, and 50% of the carcinomas which are 
considered to be high risk will still recur.4, 5 Moreover, radiotherapy is aimed at preventing 
locoregional recurrences, and does not reduce disease related mortality, which is caused by 
distant spread.2-20 It is therefore important to improve the identification of carcinomas at 
risk of distant recurrent disease. In this thesis we explored the predictive value of molecular 
markers, as well as possible improvements to the currently used histological markers.
Previously, low grade endometrioid carcinomas adjacent to atrophic endometrium were 
shown to have a worse prognosis than those adjacent to hyperplastic endometrium.21 In 
Chapter 2 and 3 we show that the endometrioid carcinomas adjacent to atrophic endometrium 
are characterized by the absence of KRAS mutations, and immunohistochemical loss of 
E-cadherin. Loss of the estrogen receptor (ER) and progesterone receptor (PR) were associated 
with distant disease spread in Chapter 4. Furthermore, we have shown that expression of 
the L1 cell adhesion molecule (L1CAM), and loss of ER and PR are strong and independent 
prognostic markers in clinically representative cohorts of endometrial carcinomas (Chapter 
7 and 8). In Chapter 5 we show that the recurrence rate of stage I endometrioid carcinomas 
is very high if lymphovascular space invasion is present.6, 7, 22 Most of these recurrences had a 
distant component, which consequently resulted in disease related mortality in the majority 
of those cases.2, 3, 6-17 In order to prevent distant recurrences, it should be studied whether 
systemic therapy is indicated in the presence of lymphovascular space invasion.2, 3, 6-17 
Despite the fact that many other publications have also shown that lymphovascular space 
invasion, L1CAM expression, and loss of ER and PR are mainly associated with distant 
recurrences, lymphovascular space invasion is only used as a marker in recommended 
adjuvant radiotherapy, and immunohistochemical markers are only used to support the 
histological findings.23-35 This thesis illustrates that translating new findings to daily clinical 
practice is challenging. Based on the findings in Chapter 7, and several other studies which have 
analyzed the additional value of L1CAM expression alone, L1CAM immunohistochemistry 
should be incorporated in daily clinical practice, since it was shown to be a stronger predictor 
of poor outcome than several currently used prognostic markers.27-31 However, by adding 
just two biomarkers, as demonstrated in Chapter 8, it already becomes more complex, and 
loss of PR appears to be an more important than L1CAM expression. However, this study 
included only three new markers, whereas many more biomarkers which could be of value 
in daily clinical practice have been described.5 Implementing biomarkers in daily clinical 
practice is a challenge in all fields of medicine: although around 150.000 biomarkers been 
described in literature, less than 100 are currently used.36 
The question, then, is how these large numbers of promising biomarkers can be incorporated 
in a prognostic model, and translated to daily clinical practice.4, 5, 19, 23-33, 37-39 Although there 
have been some studies relating multiple (bio)markers to each other, these included a limited 
number of (bio)markers, and were performed in single institutions.38, 39 In order to reliably 
validate large numbers of biomarkers a very large number of samples and patient data, 
collected and handled in a standardized fashion, is required.36, 40 As illustrated by the findings 
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in Chapter 6, there are at the moment major differences in the collection and handling of 
tissue. The centralized validation of markers in a large cohort of data and tissue collected in 
a standardized way by all centers involved in biomarker research might therefore be of great 
value in translational research. Subsequently, these centers could also work together in 
designing prospective studies which test new markers or different management strategies 
of endometrial carcinomas. Currently, several studies with significant overlap have been 
initiated, complicating not only the inclusion, but the applicability of their findings to daily 
clinical practice as well.
The second question is whether we need a completely new prognostic model, like for 
example the completely genomic categorization of endometrial carcinomas as proposed by 
The Cancer Genome Atlas research network.37 However, this focus disregards the fact that 
the markers which are currently used in the guidelines are not wrong, but rather incomplete. 
Both this thesis and many of the previous biomarker studies show a strong association 
between these new markers and the currently used prognostic markers, indicating that both 
are expressions of the same underlying processes. Instead of trying to develop new models, 
we should keep improving the model with new findings, as  demonstrated or proposed by 
several studies.19, 38, 39, 41 
Profiling endometrial carcinomas
Even after improvement, prognostic models will be limited to categorizing endometrial 
carcinomas. The question is whether these categories are a good reflection of the intricate 
processes that cause endometrial carcinomas to progress, which is assumed to be driven by 
endothelial-mesenchymal transition (EMT).42-44 
Figure 1. The molecular regulation of endothelial to mesenchymal transition (EMT).
As shown in Figure 1, this complex process which results in an invasive and metastatic 
phenotype, is driven by multiple pathways.43, 44 Interestingly, many findings presented in 
the current thesis can be explained by our knowledge of EMT. In Chapter 2 and 3 we show 
that endometrioid carcinomas adjacent to atrophic endometrium, which have a worse 
prognosis than those adjacent to hyperplastic endometrium, are characterized by loss of 
E-cadherin and mutations in the PI3K/Akt and Wnt pathways. These pathways both play an 
important role in EMT, and in the subsequent loss of E-cadherin, one of the most important 
characteristics of EMT, which causes endometrial carcinoma cells to become more 
invasive.43 Loss of E-cadherin has been previously associated with lymph node metastasis, 
deep myometrial invasion, and advanced disease stage.45-48 We also observed (Chapter 4 
and 8) that loss of ER and PR is associated with lymphogenous and hematogenous spread, 
and subsequently with worse disease outcome. Loss of ER and PR have also been shown to 
be a characteristics of EMT.43 L1CAM expression, which was associated with advanced stage, 
lymph node involvement, and metastasis (Chapter 7 and 8), has also been associated with 
EMT.49-53 Finally, lymphovascular space invasion, which was shown to be a strong prognostic 
marker in Chapter 5, 7, and 8, is likely caused by EMT.43
Our current knowledge of EMT might also give explanations between some of the 
associations found in this thesis. We found, for example, a strong associations between 
L1CAM expression and loss of ER and PR, which were previously shown to be characteristics 
of EMT, and the presence of lymphovascular space invasion, which was previously shown 
to be a result of EMT.43, 44 It has been previously shown that progesterone, which is a 
strong tumor suppressor, lowers the activity of the Wnt/β-catenin pathway, and inhibits 
transforming growth factor beta (TGF-β) signaling.54, 55 Other studies have shown that Wnt/
β-catenin activity and TGF-β signaling play an important role in L1CAM expression.49-53
However, this process  is not yet completely understood. For example, L1CAM expression 
only appears to play a role in increasing the metastatic properties of endometrial carcinoma 
cells, whereas EMT also plays a role in increasing the invasive properties.56 Moreover, in 
Chapter 4 we show that increased expression of PTEN and p16 is associated with intra-
abdominal spread of endometrial carcinomas. These markers do not play a significant role in 
EMT, and EMT therefore does not appear to be responsible for intra-abdominal metastasis.43 
Understanding the role of EMT in individual carcinomas is complicated by the question 
whether the process depicted in Figure 9.1 applies to all endometrial carcinomas, as it has 
previously been hypothesized that in every individual carcinoma there is only one active 
tumor-driving pathway.57 Moreover, endometrial carcinomas can have mixed histology and 
mixed molecular profiles, and small, more aggressive parts of the carcinoma might in fact be 
completely responsible for progression and metastasis. 58-60 
The influence of the micro- and macroenvironment on tumor progression is also not very 
well understood.61 It was, for example, shown that PIK3CA mutations were more common in 
endometrioid carcinomas if the patient had a low body mass index.62 Interestingly, in Chapter 
2 and 3 we show that these mutations are more common in endometrioid carcinomas with 
adjacent atrophic endometrium. Patients with these carcinomas had a lower body mass 
index, and a worse prognosis than patients  with an endometrioid carcinoma adjacent 
hyperplastic endometrium.21 Endometrial hyperplasia is assumed to be caused by high 
estrogen levels, which are often related to a high body mass index, illustrating the possibility 
that differences between patients could have molecular effects in their carcinomas.63 
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Identification of endometrial carcinoma progression, which causes the majority of the 
disease mortality, will require a thorough understanding of EMT.3, 9, 10, 18-20, 64 Complete profiling 
of all macroscopical, microscopical, and molecular characteristics of individual cases, but 
especially understanding the combined role of these markers in disease progression and 
recurrence, might make it possible to reliably predict the prognosis of individual carcinomas. 
Moreover, this approach could also lead to truly personalized management of endometrial 
carcinomas, as these mechanisms might be targeted using anti-L1CAM, progesterone, or 
even treatment specifically aimed at metastases.54, 65-68 
Conclusion
Scientific theories, including prognostic models for endometrial carcinomas, should not be 
considered to be wrong, but rather incomplete.1 Endometrial carcinoma research has been 
a quest for finding molecular markers which are superior to the currently used histological 
ones. However, these histological characteristics are often closely linked to the molecular 
characteristics, and have proven to be very useful in the management of endometrial 
carcinomas. The real challenge therefore is not the discovery of superior models, but 
rather the continuous improvement of the currently used model. Ultimately, the prognostic 
models should become profiles which include macroscopic, microscopic, and molecular 
aspects of individual cases. These profiles will no longer be restricted to categorizing cases 
into prognostic groups, but will be a complete reflection of the mechanisms that are at 
play within the carcinoma. Based on understanding these mechanisms, it will be possible to 
accurately predict the behavior of individual tumors. Especially predicting and preventing 
(possibly by targeted therapy of these mechanisms) distant spread should be studied, as this 
is the most important cause of endometrial carcinoma mortality.
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Summary
Endometrial carcinoma is the most common gynecological malignancy in the developed 
world, and it’s incidence is increasing. As described in Chapter 1, these carcinomas are 
traditionally classified as either endometrioid or non-endometrioid, based on the tumor 
histology. Endometrioid carcinomas are assumed to arise from hyperplastic endometrium 
under the influence of unopposed estrogen stimulation, and generally have a favorable 
prognosis. Non-endometrioid carcinomas on the other hand are assumed to arise from 
atrophic endometrium, and have a worse outcome. However, this dualistic model appears 
to be a simplification of the molecular mechanisms which drive the carcinogenesis and 
progression of endometrial carcinomas. In addition, prognostic models used in the 
management of endometrial carcinomas are mainly based on histological criteria, and their 
predictive value could be improved by reevaluating the currently used histological markers, 
and by adding new (bio)markers.
Although endometrioid carcinomas are assumed to arise from hyperplastic endometrium, 
in 20% only atrophic endometrium is found adjacent to these carcinomas, which is 
associated with a worse prognosis. Because this does not fit within the dualistic histological 
model, we explored possible molecular differences between these carcinomas, and non-
endometrioid carcinomas in Chapter 2. As expected, endometrioid carcinomas were shown 
to be characterized by expression of the estrogen receptor (ER) and progesterone receptor 
(PR), and in some cases loss of MLH1 and PMS2, whereas non-endometrioid carcinomas are 
characterized by expression of L1CAM and p53, and loss of E-cadherin. However, compared to 
the endometrioid carcinomas with adjacent hyperplastic endometrium, those with adjacent 
atrophic endometrium had reduced E-cadherin expression, and less KRAS mutations. To 
further explore these differences, the genetic profiles of benign an hyperplastic endometrium, 
endometrial carcinomas, and endometrium adjacent to carcinomas were studied in Chapter 
3. This chapter confirms that KRAS mutations are prevalent in endometrioid carcinomas 
with adjacent hyperplastic endometrium, whereas those adjacent to atrophic endometrium 
were characterized by PIK3CA and CTNNB1 mutations. Although both simple and complex 
hyperplasia with nuclear atypia are considered to be premalignancies of endometrioid 
carcinomas, we found most mutations in complex hyperplasia. The clinical application of 
molecular markers in identifying endometrial carcinogenesis has yet to be studied.
We also studied the molecular background of endometrial carcinoma progression. In Chapter 
4, we explored the immunohistochemical profiles of primary endometrial carcinomas 
without metastases, with either intra-abdominal, lymphogenous, or hematogenous 
metastases, and of the corresponding metastases. Loss of ER and PR were shown to be 
associated with lymphogenous and hematogenous spread of endometrial carcinomas. In 
contrast, increased expression of PTEN and p16 was found in intra-abdominal metastases. 
Trends we observed were loss of E-cadherin, and increased expression of L1CAM in the 
metastases. This not only supports the role of these markers in endometrial carcinoma 
metastasis, but also the hypothesis that different markers play a role in different types of 
spread. These markers might be of value for the identification of endometrial carcinomas at 
risk of metastasizing. 
In Chapter 5 and 6 we further explored the role of the traditional histological markers in 
predicting the prognosis. The recurrence rate of early stage endometrioid carcinomas was 
shown to be high if lymphovascular space invasion was present (Chapter 5). Most of these 
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recurrences had a distant component, and were the cause of disease related mortality. 
Yet, at the moment, the presence of lymphovascular space invasion only plays a role in 
advising radiotherapy to prevent locoregional recurrences. The depth of myometrial 
invasion is another histological marker which plays an important role in the guidelines for 
the management of endometrial carcinomas. However, the interobserver variability of this 
marker is unknown, and was therefore studied for several methods of measuring the depth 
of myometrial invasion (Chapter 6). It was shown that the pathologists reach substantial 
agreement when measuring the percentage of invasion, and when measuring the distance 
between the deepest point of invasion and the serosa. They reached moderate agreement 
when measuring the distance between the endometrial/myometrial junction and the 
deepest point of invasion. Moreover, it was shown that there are differences between 
centers in the handling of the hysterectomy specimen, and the sampling and sectioning of 
the endometrium and myometrium. The value of these findings in improving the currently 
used histological markers should be studied. 
In Chapter 7 of this thesis the value of immunohistochemical L1CAM expression in a clinically 
representative cohort of endometrial carcinomas is studied. We found a strong association 
between L1CAM expression and advanced stage, nodal disease, non-endometrioid histology, 
high tumor grade, lymphovascular space invasion, and distant recurrences. Especially the 
association between L1CAM expression and non-endometrioid histology was very strong. 
We showed that expression of L1CAM was a very strong predictor of poor outcome in 
both early and advanced stage endometrioid carcinomas, but not in the non-endometrioid 
carcinomas. Subsequently, the combined value of expression of L1CAM, and loss of ER 
and PR was studied in Chapter 8. The value of various combinations of histological and/
or immunohistochemical markers in predicting recurrent disease was explored. The three 
easily reproducible immunohistochemical markers were shown to have a slightly higher 
sensitivity than the currently used histological model, and a similar specificity. However, a 
combination of advanced stage, LVSI, and loss of PR had the same sensitivity as the currently 
used histological model, and a much higher specificity. Future studies should further validate 
which is the best combination for daily clinical practice, but adding one or more of these 
easily reproducible immunohistochemical markers to the currently used histological model 
appears to be valuable. 
Chapter 9 discusses these findings in relation to previous publications, as well as the future 
direction of endometrial carcinoma research. At the moment, none of the new markers 
discussed in this thesis, as well as in other publications have been incorporated in prognostic 
models used in daily clinical practice. Implementing these markers might be facilitated by 
aiming to improve the currently used model instead of only trying to discover new markers 
of models. Improving the model might be facilitated by validating all new markers in a 
cohort which has been centrally collected by all centers involved in endometrial carcinoma 
research. Moreover, many of the markers discussed in this thesis have previously been 
associated with endothelial-mesenchymal transition (EMT), which appears to play a crucial 
role in endometrial carcinoma progression. Future research should further explore the 
mechanisms which cause progression, and the markers involved. If we can combine the 
knowledge about EMT with a growing database of centrally validated (bio)markers, we 
might in time be able to truly predict the prognosis of individual carcinomas, based on their 
unique marker profiles.   
Samenvatting
Het endometriumcarcinoom is de meest voorkomende gynaecologische maligniteit in 
ontwikkelde landen, en de incidentie neemt toe. In Hoofdstuk 1 wordt besproken dat 
deze carcinomen onderverdeeld worden in de endometrioide en non-endometrioide 
carcinomen, afhankelijk van de histologie. Het wordt aangenomen dat endometrioide 
carcinomen, gestimuleerd door oestrogeen, hun oorsprong vinden in hyperplastisch 
endometrium, en over het algemeen een goede prognose hebben. Non-endometrioide 
carcinomen, daarentegen, vinden hun oorsprong in atrofisch endometrium, en hebben 
een slechtere prognose. Deze onderverdeling lijkt echter een versimpeling te zijn van de 
moleculaire mechanismen die verantwoordelijk zijn voor het ontstaan en de progressie 
van endometriumcarcinomen. Ook de prognostische modellen die gebruikt worden in de 
behandeling van endometriumcarcinoman maken voornamelijk gebruik van een beperkte 
set histologische criteria. De waarde van deze modellen zou verbeterd kunnen worden door 
de histologische markers die nu gebruikt worden te verbeteren, en er nieuwe (bio)markers 
aan toe te voegen.
Hoewel aangenomen wordt dat endometrioide endometriumcarcinomen voortkomen 
uit hyperplastisch endometrium, wordt er in ongeveer 20% van de gevallen alleen 
atrofisch endometrium gevonden naast endometrioide carcinomen, die dan een slechtere 
prognose blijken te hebben. Omdat dit niet past binnen het dualistische model hebben 
we in Hoofdstuk 2 de moleculaire kenmerken van endometrioide carcinomen naast 
hyperplastisch endometrium, endometrioide carcinomen naast atrofisch endometrium, en 
non-endometrioide carcinomen onderzocht. Zoals verwacht vonden we in de endometrioide 
carcinomen expressie van ER en PR, en in sommige casus verlies van MLH1 en PMS2, en in 
de non-endometrioide carcinomen expressie van L1CAM en p53, en verlies van E-cadherine. 
Daarnaast vonden we dat de endometrioide carcinomen naast atrofisch endometrium, 
vergeleken met die naast hyperplastisch endometrium, gekenmerkt werden door verlies 
van E-cadherine, en de afwezigheid van KRAS mutaties. Om meer licht te werpen op deze 
verschillen, hebben we in Hoofdstuk 3 de genetische profielen van benigne en hyperplastisch 
endometrium, endometriumcarcinomen, en endometrium naast endometriumcarcinomen 
onderzocht. De bevindingen in dit hoofdstuk bevestigen dat KRAS mutaties veel voorkomen 
in endometrioide carcinomen naast hyperplastisch endometrium, terwijl PIK3CA en 
CTNNB1 mutaties juist vaker voorkomen in endometrioide carcinomen naast atrofisch 
endometrium. Hoewel aangenomen wordt dat zowel simpele als complexe hyperplasie 
met nucleaire atypie voorstadia zijn van endometrioide endometriumcarcinomen, vonden 
we de meeste mutaties in complexe hyperplasie. Het moet nog onderzocht worden hoe 
moleculaire markers toegepast kunnen worden in het identificeren van het ontstaan van 
endometriumcarcinomen.
Daarnaast hebben we gekeken naar de moleculaire achtergrond van progressie van 
endometriumcarcinomen. In Hoofdstuk 4 onderzochten we de immunohistochemische 
profielen van primaire endometriumcarcinomen zonder metastasen, met intra-abdominale 
metastasen, met lymfogene of hematogene metatasen, en van de corresponderende 
metastasen. Verlies van ER en PR waren geassocieerd met lymfogene en hematogene 
metastasering, terwijl verlies van PTEN en p16 vooral gevonden werd in intra-abdominale 
metastasen. Daarnaast vonden we verlies van E-cadherine en expressie van L1CAM in de 
metastasen, maar dit was niet significant. Deze bevindingen laten niet alleen zien dat deze 
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markers een rol spelen in het metastaseren van endometriumcarcinomen, maar ook dat 
verschillende markers een rol spelen in verschillende soorten metastasering.
In Hoofdstuk 5 en 6 hebben we de rol van enkele traditionele histologische markers in 
het voorspellen van de prognose verder onderzocht. De recidiefkans van vroeg stadium 
endometrioide carcinomen was hoog als er invasie van de lymfe- en/of bloedvaten 
gevonden werd (Hoofdstuk 5). De meeste van deze recidieven bevonden zich op afstand, en 
deze veroorzaakten een aanzienlijk deel van de ziekte gerelateerde sterfte. Op het moment 
speelt de aanwezigheid van invasie van de lymfe- en/of bloedvaten echter alleen een rol 
in het al dan niet toepassen van adjuvante radiotherapie om locoregionale recidieven te 
voorkomen. Myometriuminvasie is een andere belangrijke marker in de richtlijnen voor de 
behandeling van endometriumcarcinomen. Het is echter onbekend in hoeverre pathologen 
overeenstemming bereiken bij het meten van deze marker. In Hoofdstuk 6 hebben we dit 
daarom onderzocht voor verschillende methoden om myometriuminvasie  te meten. Ze 
bereikten in grote mate overeenstemming bij het meten van het percentage invasie, en bij 
het meten van de afstand tussen het diepste punt van invasie en de serosa, en gemiddelde 
overeenstemming bij het meten van de afstand tussen de endometrium/myometrium 
overgang en het diepste punt van invasie. Daarnaast bleken er verschillen te bestaan tussen 
verschillende centra met betrekking tot het verwerken van het hysterecomtiepreparaat, 
en het maken van coupes van het endometrium en myometrium. De waarde van deze 
bevindingen in het verbeteren van de histologische markers die momenteel in het 
prognostische model gebruikt worden moet onderzocht worden.
In Hoofdstuk 7 van dit proefschrift onderzochten we de waarde van immunohistochemische 
expressie van L1CAM in een klinisch representatief cohort endometriumcarcinomen. 
Er bleken sterke associaties te zijn tussen L1CAM expressie en gevorderd stadium, 
lymfekliermetastasen, non-endometrioide histologie, hoge tumorgraad, invasie van de 
lymfe- en/of bloedvaten, en recidieven op afstand. De associatie tussen L1CAM expressie en 
non-endometrioide histologie in het bijzonder was zeer sterk. L1CAM expressie voorspelde 
een slechte prognose in zowel de vroege en gevorderde endometrioid carcinomen, maar niet 
in de non-endometrioide carcinomen. In Hoofdstuk 8 hebben we vervolgens onderzocht wat 
de gecombineerde toegevoegde waarde was van L1CAM expressie, en verlies van ER en PR. 
De waarde van verschillende combinaties van histologische en/of immunohistochemische 
markers werd verkend. De drie immunohistochemische markers hadden een hogere 
sensitiviteit het voorspellen van recidieven dan het traditionele histologische model, en 
een gelijkwaardiger specificiteit. Een combinatie van een gevorderd stadium, invasie van 
de lymfe- of bloedvaten, en verlies van PR, daarentegen, had een veel hogere specificiteit 
en een gelijkwaardige sensitiviteit. Het moet onderzocht worden welke combinatie het 
beste toegepast kan worden in de dagelijkse klinische praktijk, maar het lijkt erop dat het 
waardevol is om een of meerdere van deze gemakkelijk te bepalen immunohistochemische 
markers aan het model toe te voegen.
De bevindingen in dit proefschrift worden in Hoofdstuk 9 gerelateerd aan de literatuur, en 
de toekomst van het onderzoek naar endometriumcarcinomen wordt besproken. Op dit 
moment worden de markers die in dit proefschrift besproken worden, noch de vele markers 
die in de literatuur beschreven worden gebruikt in de dagelijkse klinische praktijk. Het 
vertalen van deze bevindingen zou verbeterd kunnen worden als het onderzoek meer gericht 
is op het verbeteren van het bestaande model, in plaats van op het ontdekken van nieuwe 
markers en modellen. Het verbeteren van het bestaande model kan vergemakkelijkt worden 
door de toegevoegde waarde van nieuwe markers te onderzoeken in een centraal cohort, 
verzameld door alle centra die betrokken zijn in onderzoek naar het endometriumcarcinoom. 
Daarnaast blijken zeer veel van de markers die in dit proefschrift beschreven zijn een rol te 
spelen in endotheliale-mesenchymale transitie (EMT), het proces dat verantwoordelijk is 
voor de progressie van endomentriumcarcinomen. Toekomstige studies zouden dit proces, 
en de markers die daarin een rol spelen verder moeten ophelderen. Door kennis over EMT 
te combineren met een steeds completere database van centraal gevalideerde (bio)markers 
kunnen we wellicht in de toekomst de prognose van individuele carcinomen zeer gericht 
voorspellen op basis van het unieke profiel van dat carcinoom.
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